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7-Oxysterols constitute the major component (40%) of oxidized low-density 
lipoprotein (oxLDL). They arise in the body via auto-oxidation of cholesterol and are 
known to induce endothelial dysfunction, oxidative stress and apoptosis in the 
vascular wall, prior to development of atherosclerosis. A novel pathway has been 
described for hepatic inter-conversion of 7-ketocholesterol (7-KC) and 7-hydroxy-
cholesterol (7OHC) by the enzyme 11-hydroxysteroid dehydrogenase type-1 
(11HSD1), better known for metabolizing glucocorticoids. Inhibition of 11HSD1 
is atheroprotective and the potential underlying mechanism for this may involve 
altered metabolism and actions of glucocorticoids. However, alterations in the 
metabolism of 7-oxysterols may also play an important role in this atheroprotective 
effect. 
 
The work described here addresses the hypotheses that (i) 7-oxysterols are substrates 
for murine 11HSD1; (ii) inhibition of 11HSD1 may abolish cellular metabolism of 
7-oxysterols; (iii) this route of metabolism may modulate the actions of 7-oxysterols 
and glucocorticoids on murine vascular physiology. 
 
Murine 11HSD1 inter-converted 7-oxysterols (Km=327.6±98µM, 
Vmax=0.01±0.001pmol/µg/min) but the regulation of reaction direction is different 
from that for glucocorticoids. Predominant dehydrogenation of 7OHC to 7-KC was 
quantified in several models (recombinant protein, cultured cells stably transfected 
with 11HSD1), in which predominant reduction of glucocorticoids was measured. 
Furthermore, in murine hepatic microsomes, dehydrogenation of 7OHC occurred 
exclusively. In aortic rings in culture, however, both reduction and dehydrogenation 
of 7-oxysterols were evident. 7-Oxysterols and glucocorticoid substrates competed 
for metabolism by 11HSD1, with 7OHC inhibiting dehydrogenation of 
glucocorticoids (Ki=908±53nM). 
 




The circulating concentrations of 7-oxysterols in the plasma of C57Bl6 and 
11HSD1-/- mice were in the µM range (0.02 – 0.13µM). The disruption of 
11HSD1 has resulted in increased ratios of 7-KC and 7OHC over total plasma 
cholesterol levels (*p<0.05). This finding suggested that 11HSD1 is involved in 
metabolizing and determining the plasma levels of 7-KC and 7OHC.  
 
To assess the consequences of these alterations for vascular function, studies were 
undertaken in aortic rings. Prolonged incubation with 7-oxysterols (20-25 µM) 
showed a tendency to attenuate noradrenaline-mediated contractions of C57Bl6 
aortae, but had no effect on contractions in response to 5-hydroxytryptamine or KCl. 
Similarly, endothelium-dependent and -independent relaxations of murine aortae 
were unaltered after exposure to 7-oxysterols. 
 
Thus in the mouse, 11HSD1 may influence the balance of circulating and cellular  
7-oxysterols which may have consequential effects on glucocorticoid action. 
Although this work suggests that concentrations present in murine tissues are 
unlikely to cause vascular dysfunction, they may influence further cellular events as 
yet undescribed. Under pathological conditions where high concentrations of  
7-oxysterols occur, 11HSD1 may influence the extracellular-transport and delivery 
of 7-KC and 7OHC to the plaque. This work therefore proposes that inhibition of 
metabolism of 7-oxysterols by 11HSD1 inhibitors, may contribute to the 
atheroprotective effects of these drugs. 
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Chapter 1. Introduction 






Dyslipidaemia is a component of the “Metabolic Syndrome” and is strongly 
associated with an increased risk of atherosclerosis, type 2 diabetes, obesity and fatty 
liver disease (Beaven and Tontonoz, 2006; Paterson et al., 2004). In all of these 
conditions, excess cholesterol alters the plasma lipid profile, which further influences 
cholesterol storage and clearance by the body. Excess steroid hormones 
(glucocorticoids, GCs) can also contribute to the development of these diseases and 
has been linked with increased cardiovascular events (Hadoke et al., 2009; Walker, 
2007). Although many groups have suggested a link between increased 
glucocorticoid concentrations in tissues, particularly adipose, and the metabolic 
syndrome, the contribution of these steroids is not fully understood (Andrew et al., 
1998; Livingstone et al., 2000; Morton et al., 2005; Tomlinson et al., 2004b). Tissue-
specific increases in their levels are believed to be due to the actions of an enzyme, 
which reactivates intracellular glucocorticoid levels, 11-hydroxysteroid 
dehydrogenase type 1 (11HSD1). Indeed pharmacological inhibition of this enzyme 
is beneficial in reducing cardiovascular risk factors (lowering weight and glucose 
levels) and also in ameliorating cardiovascular disease (reduced atheroma) 
(Hermanowski-Vosatka et al., 2005). This enzyme can metabolise substrates other 
than glucocorticoids, and this thesis will explore its role in regulating the 
concentrations and actions of 7-oxysterols. 
1.2. 11-Hydroxysteroid Dehydrogenases 
Various short chain alcohol dehydrogenases (SCADs) have been identified, 
constituting a large evolutionarily-conserved family of enzymes (Oppermann et al., 
2003). This class includes mammalian enzymes (expressed in placenta, liver and 
other tissues) such as 15-hydroxyprostaglandin, 17-hydroxysteroid and 11-
hydroxysteroid dehydrogenases. Only about 20% homology exists between the 
molecular sequences of various dehydrogenases. Alignment of different SCAD 
enzymes reveals similarities between particular regions that are due to common 




sequences which are known to be of special functional/structural importance (Filling 
et al., 2002). Most known SCAD enzymes are NADH or NADPH-dependent 
oxidoreductases with distinct patterns of expression in tissues. Their generally 
accepted mechanism of catalysis is through conversion of the keto (=O) group on an 
individual molecule into a hydroxyl (-OH) group. 
1.2.1. 11-Hydroxysteroid Dehydrogenase Type 1 And Type 2: 
Biochemical And Physiological Characteristics 
11-Hydroxysteroid dehydrogenases (11HSDs) are microsomal enzymes that 
belong to the group of short chain alcohol dehydrogenases (Edwards et al., 1988). 
Intracellular glucocorticoid levels are regulated by the actions of two isoforms of this 
enzyme: 11-hydroxysteroid deydrogenase type 1 (11HSD1) and 11-hydroxy-
steroid deydrogenase type 2 (11HSD2). These two isozymes of 11HSD share 
about 20% sequence identities (Draper and Stewart, 2005). 
 
11HSD1 regenerates active glucocorticoid (cortisol (F) in human and corticosterone 
(B) in rodents) from inactive precursors (cortisone (E) in humans and 11-
dehydrocorticosterone (A) in rodents; (Seckl and Walker, 2001)). The 11HSD2 
enzyme catalyzes the opposing dehydrogenation reaction (converting active 
glucocorticoids into their inactive forms; Figure 1.2 – 1) thus preventing 
inappropriate access of glucocorticoids to mineralocorticoid receptors (Stewart and 
Krozowski, 1999). These reactions occur in a tissue-specific manner with 11HSD1 
expressed predominantly in glucocorticoid target tissues (liver, lung, adipose tissue, 
gonads and brain; (Krozowski et al., 1990)). The main 11HSD2 expressing tissues 
are kidneys and placenta, but it is also expressed in gut, colon and blood vessels 
(Agarwal et al., 1990). 11HSD1 has a broader tissue expression than 11HSD2, and 
its expression and activity are regulated by numerous complex mechanisms, 
including regulation by glucocorticoids themselves (Lanz et al., 2001, Alikhani-
Koopaei et al., 2004, Heiniger, 2003). 








Figure 1.2-1 Reactions catalyzed by 11HSDs. 
Glucocorticoid inter-conversion by 11-hydroxysteroid dehydrogenases (11HSDs). In intact 
cells 11HSD type 1 (11HSD1) predominantly catalyzes reduction of 11-
dehydrocorticosterone (A) to corticosterone (B); activation reaction. 11HSD type 2 
(11HSD2) catalyzes the dehydrogenation of corticosterone (B) to 11-dehydrocorticosterone 
(A); inactivation reaction. The inactivation reaction catalyzed by 11HSD2 utilizes NAD+ as a 
cofactor, whereas the activation reaction catalyzed by 11HSD1 utilizes NADPH. The 
NADPH is supplied by hexose-6-phosphate dehydrogenase (H6PDH), which converts 
glucose-6-phosphate (G6P) to 6-phospho-gluconolactone (6PG=O) thus generating NADPH 
for use by 11HSD1. 




11HSD1 has a low affinity (Km in the µM range) for both cortisol and 
corticosterone. It is an NADP(H)-dependent enzyme, that is a predominant reductase 
in vivo, catalyzing reduction of inactive A to active B (Jamieson et al., 2000). In 
vitro in disrupted cell and tissue preparations 11HSD1 acts as a bi-directional 
enzyme, catalyzing both reductase and dehydrogenase reactions. There are, however, 
a few studies reporting that 11HSD1 may act as a dehydrogenase in intact cell 
preparations, depending both on cell type and differentiation status In Leydig and 
neuronal cells in vitro, both reaction directions have been reported (Rajan et al., 
1996), whereas in human omental adipose stromal cells, 11HSD1 switches from 
dehydrogenase to reductase upon cell differentiation into adipocytes (Bujalska et al., 
2002; Gao et al., 1997). The directionality of this enzyme in the cell is influenced by 
cofactor availability. Reductase activity is driven by the generation of NADPH by an 
associate enzyme, hexose-6-phosphate dehydrogenase (H6PDH), within the 
endoplasmic reticulum (section 1.2.1.1). The N-terminal of 11HSD1 anchors the 
enzyme to the membrane of the ER, while its active site faces into the lumen of the 
ER. This luminal orientation of 11HSD1 is important for its reductase activity and 
is reliant upon microsomal supply of NADPH within the lumen (see Figure 1.2 – 2). 
In contrast, 11HSD2 is a unidirectional NAD-dependent dehydrogenase with high 
affinity (nM range) for cortisone (Arnold et al., 2003). 
 
Although glucocorticoids are the principal substrates investigated in relation to 
11HSD enzymes, more recently cholesterol-derived sterols (7-oxysterols) (Hult et 
al., 2004) and neurosteroids (e.g. 7-DHEA) (Nashev et al., 2007), have been 
identified as substrates for 11HSD1. This thesis investigates the role of 11HSD1 in 
metabolism of these alternative substrates. 










Figure 1.2-2 Luminal orientation of 11HSD1 in the endoplasmic reticulum.  
11-Hydroxysteroid dehydrogenase type-1 (11HSD1) is located on the luminal side of 
endoplasmic reticulum (ER) and its N-terminus is embedded into the membrane of the ER. 
The system comprising the glucose-6-phosphate (G6P) transporter (orange) and hexose-6-
phosphate dehydrogenase (H6PDH) is crucial for transport of G6P to the H6PDH enzyme. 
G6P binds to the H6PDH to form 6-phospho-gluconolactone (G6P=O) resulting in generation 
of NADPH inside the lumen of the ER. The NADPH thus produced is utilized by 11HSD1 
for the reduction of 11-dehydrocorticosterone to corticosterone. 




1.2.1.1. Mechanism Of 11βHSD1 Reaction 
The C-terminal part of 11HSD1 contains the active site motif with a tetrad 
comprising the following amino acids: Asn, Ser, Tyr and Lys, catalytically essential 
for chemical reaction. Previously the triad of Ser – Tyr – Lys residues was 
considered, but more recent evidence by Filling et al., have demonstrated a critical 
involvement of Asn residue in this process. The catalytic mechanism of 11HSD1 in 
the active site requires interaction of the substrate with a resident cofactor 
(NADP+/NADPH) and with the tyrosine (Tyr183) and serine (Ser170) residues of the 
protein. This mechanism of 11HSD1 reaction is also known as acid-base catalysis 
where substrate binding to the enzyme can be described according to a following 
mechanism of interaction (using Cleland-style notation for bi-substrate reaction, 





Tyr residue is highly conserved in the family and is acting as a catalytic base in the 
deprotonation process. Ser stabilizes the substrate in the initial orientation and in the 
transition state. The protonated Lys forms hydrogen bonds with the ribose moiety of 
NADP+ and lowers the pKa of Tyr-OH to facilitate proton transfer (Filling et al., 
2002). The presence of a conserved Asn residue is crucial in order to form a proton 
relay between the 2’OH of the nicotinamide ring and a conserved active site water 
molecule. The direct hydride transfer from the C4 position of NADP(H) to the 
carbon of the C11 ketone of the steroid (or C7 of 7-oxysterols) is facilitated by a 
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1.2.1.2. Hexose-6-Phosphate Dehydrogenase (H6PDH) Confers 
Predominant Reductase Activity Of 11HSD1 
Hexose-6-phosphate dehydrogenase (H6PDH) utilizes glucose-6-phosphate as a 
substrate to provide the reduced cofactor NADPH (Stegeman and Klotz, 1979) for 
the 11HSD1 reaction inside the endoplasmic reticulum (ER) (Hewitt et al., 2005). 
The reductase activity of 11HSD1 can be stimulated in rat liver microsomes by 
addition of the substrate for H6PDH (Banhegyi et al., 2004). Perhaps most 
convincingly, mice with deletion in H6PDH (H6PDH-/-) cannot reduce 11-
dehydrocorticosterone but show increased dehydrogenation of corticosterone 
(Lavery et al., 2006). All of these studies indicate the reliance of 11HSD1 on 
H6PDH-mediated generation of NADPH for its reductase function. Further 
expression analyses of H6PDH showed that this enzyme is present in a wide variety 
of tissues, but the greatest concentrations were in 11HSD1 target tissues such as 
liver, kidney, and Leydig cells (although not as much was present in the brain 
(Gomez-Sanchez et al., 2008)). This evidence also indicates tissue-specific 
regulation of glucocorticoid reactivation by 11HSD1. It is now widely understood 
that an uncoupled redox-system exists between H6PDH and 11HSD1 (Atanasov et 
al., 2004; Piccirella et al., 2006). Therefore, reduction of 11-dehydrocorticosterone is 
glucose-6-phosphate dependent, whereas oxidation of glucose-6-phosphate oxidation 
is dependent on the presence of 11-dehydrocorticosterone. There is recent in vivo 
evidence to show that the system comprising the glucose-6-phosphate transporter, 
H6PDH and 11HSD1 is active in rat epididymal fat tissue, showing the importance 
of all three components for modulating local glucocorticoid activation (Marcolongo 
et al., 2007). 
.  
It is assumed that perhaps dependence of 11HSD1-metabolism on the generation of 
NADPH and co-operative action of H6PDH with 11HSD1 is also important in the 
metabolism of 7-KC (as has been shown for 7-DHEA, a neurosteroid (Nashev et al., 
2007)). Therefore, an increase in 11HSD1 activity by reduction of 7-KC is 
anticipated upon in vitro co-expression of H6PDH with 11HSD1. However, this has 
not been conclusively demonstrated for 7-oxysterol substrates. This may be may be 




relevant for understanding the physiological role of 11HSD1 in metabolising 
alternative substrates. 
1.2.2. 11HSD1 Expression In The Vasculature 
As mentioned previously, it is well recognized that exposure to chronic 
glucocorticoid excess leads to metabolic disorders such as: diabetes, insulin 
resistance, obesity, glucose intolerance, dyslipidaemia and hypertension (Walker, 
2007). Considerable evidence suggests that GCs can directly influence vascular 
function and structure; actions which may contribute to development of 
cardiovascular disease. Both glucocorticoid (GR) and mineralocorticoid (MR) 
receptors are expressed in vascular tissue (Brem et al., 1999) and corticosterone can 
be an agonist for both (and exerts rapid signalling effects) in VSMCs (Molnar et al., 
2008). The downstream effects of activation of these receptors is associated with 
cardiovascular risk factors (hypertension) and alteration in the vascular response to 
injury (Hadoke et al., 2006). A recent study suggested that corticosterone can 
activate MR in the VSMC and trigger the phosphorylation of proteins key to cell 
proliferation and differentiation (Molnar et al., 2008). In aortic rings ex vivo, 
corticosterone has repeatedly been shown to enhance agonist-mediated contraction 
(Brem et al., 1997; Ullian, 1999; Ullian et al., 1996) and inhibit endothelium-
dependent relaxation (Brem et al., 1997; Ullian, 1999). This is not, however, without 
controversy as previous studies have reported contradictory findings for alterations 
of vascular function after exposure to glucocorticoids (Christy et al., 2003; Molnar et 
al., 2008). The mechanism(s) involved remain unclear but recent work has 
demonstrated both the presence of GC response elements in the endothelial nitric 
oxide synthase (eNOS) promoter region and glucocorticoid-mediated inhibition of 
eNOS expression (Liu et al., 2008). 
 
Studies of glucocorticoid metabolism in vascular tissue have demonstrated the 
presence of both 11HSD1 and 11HSD2 in vascular cells (Brem et al., 1995; 
Hatakeyama et al., 2001). Although controversy still exists concerning the exact 
localisation and direction of the activity of these enzymes, 11HSD1 in the mouse 
aorta is expressed in VSMC (Walker et al., 1991) and perhaps endothelial cells 




(Christy, 2003; Hatakeyama et al., 2001) whereas 11HSD2 is localized to 
endothelial cells only (Cai et al., 2001; Christy et al., 2003; Morris et al., 2003). An 
11HSD1-mediated increase in the local GC concentrations, leads to an activation of 
GR and MR (Seckl and Walker, 2001). This has significant implications for vascular 
homeostasis. Within the arterial wall 11HSD1 influences GC-mediated changes in 
vascular contractility and structure (Hadoke et al., 2006) and amplifies the 
angiostatic actions of GCs (Small et al., 2005). 11HSD2 on the other hand, prevents 
glucocorticoids from inhibiting endothelium-dependent vasodilation (Hadoke et al., 
2001). Pharmacological inhibition of 11HSD1 dehydrogenase activity is associated 
with an enhanced response to vasoconstrictors, whereas inhibition of the reductase 
reaction produces attenuated constriction (Morris et al., 2003). 
1.2.3. Metabolism of Glucocorticoids By 11HSD1 In The Vascular 
Wall: Influence On Atherogenesis 
During the development of atherosclerotic lesions the arterial wall undergoes 
considerable structural remodelling (Figure 1.2 – 4) leading to a complex 
environment involving monocyte accumulation, macrophage formation from 
differentiated monocytes and the uptake of oxidized lipids and cholesterol by 
macrophages to form foam cells. Increasing evidence suggests that 11HSD1 
activity may influence the processes underlying lesion development. For instance, 
the expression of 11HSD1 in VSMC is up-regulated by pro-inflammatory 
cytokines, suggesting a mechanism for suppression of inflammation in the vessel by 
local generation of GCs (Cai et al., 2001; Dover et al.,, 2006). Furthermore, 
generation of GCs within macrophages may contribute to the regulation of 
inflammatory responses in these cells and inhibition of VSMC proliferation in the 
vessel wall (Chapman et al., 2006). This suggests that local generation of GCs within 
the arterial wall may inhibit lipid accumulation and lesion formation. This has only 
been reported using exogenous GC administration (Asai et al., 1993; Tauchi et al., 
2001). 




It should also be noted, however, that beneficial effects of glucocorticoid generation 
on vascular health (such as the anti-inflammatory role of enhanced glucocorticoid 
generation by 11HSD1), contrasts with recent demonstrations that 11HSD1 
inhibitors prevent atherosclerosis (Hadoke et al., 2009; Hadoke et al., 2008; 
Hermanowski-Vosatka et al., 2005). One explanation is that the beneficial effects of 








Figure 1.2-3 Schematic diagram of the Arterial Wall - Healthy Artery versus an 
Aherosclerotic Artery.   
The composition of a healthy artery wall (in cross-section) is compared with that of an 
atherosclerotic artery. The latter illustrates the accumulation of a pool of lipid forming the 
core of an atherosclerotic plaque (adapted from (Freeman, 2005)). Chronic hyperlipidaemia/ 
atherosclerosis leads to damage of the endothelium by the action of oxidized lipids present 
in the plasma or from the lipid pool (containing oxysterols). Atheroprotective effects of 
11HSD1 inhibitors are associated with reduced cholesterol and oxidized lipid accumulation 
within the aortic plaque. 




The role of glucocorticoids in the pathogenesis of metabolic and cardiovascular 
disease has prompted the suggestion that 11HSD1 would be a valuable therapeutic 
target (Walker, 2007; Wamil and Seckl, 2007). Adding to the considerable body of 
evidence showing benefits of inhibition of 11HSD1, development of these 
inhibitors may also ameliorate risk factors associated with cardiovascular diseases, 
such as type 2 diabetes (Hale and Wang, 2008). Certainly this is consistent with the 
demonstration that pharmacological inhibition of 11HSD1 reduced cholesterol 
accumulation (and, by implication, lesion development) in an Apolipoprotein E 
knockout (ApoE-/-) mouse model of atherosclerosis (Hermanowski-Vosatka et al., 
2005). It is not clear, however, how inhibition of 11HSD1 reduced atherosclerosis 
in these mice, although it was suggested that the reduction in aortic lipid 
accumulation could not be attributed solely to the mild reduction in circulating lipid 
concentrations. In a different study using low density lipoprotein (LDL) receptor 
knockout (LDLR-/-) mice, subcutaneous injection of carbenoxolone (an 11HSD1 
inhibitor, although non-selective) inhibited lesion development only in obese 
atherosclerotic animals (Nuotio-Antar et al., 2007). Whether these effects of 
11HSD1 inhibition on lesion development are related to their inter-conversion of 
glucocorticoids, or is more to do with changes in metabolism of alternative substrates 
(such as 7-oxysterols), remains to be determined. 
1.3. Oxysterols – Active Metabolites Of Cholesterol 
The challenge of exploring cholesterol homeostasis was tackled by Goldstein and 
Brown following their description of xanthoma formation (abnormal lipid 
accumulation under the skin (Brown and Goldstein, 1974; Goldstein et al., 1974)). 
Whilst cells in patients with this condition can produce low-density lipoprotein, it 
accumulates in the plasma and is, ultimately, stored under the skin (due to a 
dysfunction of the LDL receptor). The risk of a myocardial infarction at the age of 
six and the absence of constitutive activity of 3-hydroxy 3-methylglutaryl-coenzyme 
A reductase (HMG-CoA reductase) in these patients, were later attributed to a 
disease known as homozygous familial hypercholesterolemia (FH) (for recent 
overview see Goldstein and Brown, (2009)). This discovery of dysfunctional LDL 




receptor activity leading to vascular disease provided a novel ground for future 
research on atherogenesis and its treatment. 
 
Cholesterol is the most important regulator of lipid organization in the cell 
membrane bilayer, is a vital precursor for bile acid synthesis and is the main 
precursor for synthesis both of glucocorticoids (Figure 1.3 – 1) and of oxysterols 
(Figure 1.3-2). Consequently, mammals have developed complex mechanisms for 
maintaining cholesterol concentrations within the body, with metabolism to 
oxysterols occurring predominantly in the liver. (Goldstein and Brown, 2009; Jessup 
and Kritharides, 2008; Maxfield and Tabas, 2005). Cholesterol is carried in the blood 
in different lipoprotein particles, and mainly in high-density lipoprotein (HDL; so-
called “good” cholesterol) and LDL (“bad”-cholesterol). Regulation of cholesterol 
levels within cells is controlled by lipoproteins and reverse cholesterol transport 
(Ohashi et al., 2005). The exogenous supply of cholesterol to cells and tissues is 
maintained by LDL, whereas HDL removes excess cholesterol from the cells. 
However, over-abundance of cholesterol, in association with elevation of LDL, can 
increase the risk of atherosclerosis (Libby, 2002a), in which excess cholesterol 
accumulates within cells such as macrophages within the vessel wall. Increased 
cholesterol can be toxic for cells and a number of strategies have evolved to export 
cholesterol or store it in its esterified form. HDL cholesterol exports cholesterol from 
the liver and foam cells back into the blood. This process is altered in the 
pathogenesis of atherosclerosis in which HDL levels are decreased, whereas LDL 
levels are elevated (Gaut and Heinecke, 2001). 
 
Reverse cholesterol transport is a pathway through which cholesterol is transported 
back to the liver from the peripheral organs (such as blood vessels). This represents a 
common excretion pathway, which also promotes cholesterol efflux and, thus, 
prevents atherosclerosis (Ohashi et al., 2005). Clearance from tissue is mediated by 






Figure 1.3-1 Biosynthesis of glucocorticoids from cholesterol within the 
adrenal cortex. 
Biosynthesis of steroids starts from cholesterol and is catalyzed by many cytochrome P450 
enzymes as labeled. The major active glucocorticoid in rodents is corticosterone since, 
unlike humans, rodents lack adrenal 17-hydroxylase. 







Figure 1.3-2 Biosynthesis of oxysterols from cholesterol. 
Biosynthesis of oxysterols starts from cholesterol and is catalyzed by many cytochrome 
P450 (CYP) enzymes, as labelled, and cholesterol 25-hydroxylase (Ch25h; which is a non-
cytochrome P450 enzyme). Truncated structures of the oxysterols are shown, emphasizing 
the additional oxygenation. ROS, reactive oxygen species. Figure adapted from (Brown and 
Jessup, 2009). 




members of the ATP-Binding Cassette (ABC)-transporter family: transporter A1 
(ABCA1) and transporter G1 (ABCG1). Both of these transporters use the energy of 
ATP hydrolysis to facilitate cholesterol efflux from macrophages into 
Apolipoprotein AI and/or HDL (Baldan et al., 2008). Much current research to treat 
atherosclerosis focuses on stimulating cholesterol efflux pathways from macrophages 
to HDL, with several mechanisms already described, including: ABC-mediated 
efflux; efflux through ApoE secretion; and SR-BI-mediated efflux (Tall et al., 2008). 
Although it is not certain, it is also believed that these mechanisms provide a 
mechanism for clearing 7-oxysterols (and other hydroxy cholesterols, such as 27-
hydroxycholesterol, 27-OHC) from the body. 
1.3.1. Formation And Biological Sources Of Oxysterols 
Circulating LDL particles contain lipids other than cholesterol: for  
example, oxysterols form their major (60%) component. Oxysterols are oxygenated 
derivatives of cholesterol or by-products of the cholesterol biosynthetic pathway 
(Figure 1.3 – 2). They are 27-carbon molecules generated either by enzyme-
catalyzed or non-enzymatic mechanisms. The most important oxysterols are 
generated by cholesterol hydroxylases, located in mitochondria or endoplasmic 
reticulum and belonging to the cytochrome P450 family (Luoma, 2007; Russell, 
2000). Oxysterols fall into two main categories: 
 
1) Species oxygenated on the sterol ring, mainly at the C7-position (e.g.,  
7/-hydroperoxycholesterol (7OOHC), 7-ketocholesterol (7-KC) and 7/-
hydroyxcholesterol (7OHC)). These compounds form the focus of the work 
described in this thesis 
 
2) Species oxygenated on the side-chain (e.g., 24S-hydroxycholesterol (24S-OHC), 
25-hydroxycholesterol (25-OHC) and 27-OHC). 




Generally, ring-oxygenated sterols tend to be formed non-enzymatically, whereas 
side-chain oxygenated sterols tend to be of an enzymatic origin. However, some ring 
oxysterols, previously defined as auto-oxidation products, are also formed via 
enzymatic means, as recently reported (Gill et al., 2008; Hult et al., 2004). Although 
oxysterols are less than 0.1 % of the total cholesterol in the body, they are major 
components of oxLDL (~60 %) and are, hence, highly abundant in the plasma and 
vessel wall (Brown and Jessup, 1999; Dzeletovic et al., 1995a). 
 
7-Oxygenated sterols, namely 7-keto- (7-KC), 7-hydroxy- (7OH) and 7-hydroxy-
(7OHC) cholesterol can also be formed non-enzymatically by direct radical attack 
on the cholesterol C7 position by reactive oxygen species (ROS) such as the 
hydroxyl radical. Formation of a carbon-centred radical at the C7 position produces a 
long-lived and reactive form, which can further lead to generation of the cholesterol 
peroxyl radical (COO•, Figure 1.3 – 3). Further abstraction of hydrogen from a 
second lipid molecule results in relatively stable hydroperoxy cholesterols  
(7-/7-OOHC). 
 
Biologically active oxysterols may also be generated by enzymatic routes, most 
pertinently for this thesis (see section 1.4) through metabolism by 11HSD1  
(see Figure 1.3 – 3). 








Figure 1.3-3 The reaction mechanism leading to the production of 7-oxygen-
ated cholesterol derivatives. 
Cholesterol oxidation on position C7 is initiated by a radical attack forming a delocalized 
three-carbon allylic radical, which reacts with oxygen (O2) to produce the epimeric products 
7- and 7-hydroperoxy-cholesterol. This species can decompose to hydroxy and keto 
analogues, 7-hydroxycholesterol (7OHC), 7-hydroxycholesterol (7OHC) and 7-
ketocholesterol (7-KC). Human and rodent 11-hydroxysteroid dehydrogenase type 1 
(11HSD1) interconvert 7OHC and 7-KC, whereas hamster 11HSD1 reduces 7-KC to 
7OHC and/or 7OHC. 




1.3.2. Targeted Actions Of 7-Oxysterols 
Oxysterols have multiple, often poorly-understood biological effects (summarized in 
Table 1 - 1; (Bjorkhem and Diczfalusy, 2002; Schroepfer, 2000)). Some key 
biological actions of 7-oxysterols are described further: 
1.3.2.1. Apoptosis And Necrosis 
Apoptosis (programmed cell death) is a fundamental biological process that is highly 
regulated and controlled by the cell. It was first described by Kerr and colleagues 
(Kerr et al., 1972) and involves two pathways: extrinsic (involving death receptors 
(Fas)) and intrinsic (involving mitochondria). Apoptotic cells are recognized for non-
inflammatory clearance by phagocytes (e.g. macrophages) and this process has 
implications for all stages of atherogenesis and plaque rupture (Kavurma et al., 
2005). 7-Oxysterols may induce death in various cell types by these mechanisms 
(including those found in the vascular wall). Indeed, both apoptosis and necrosis 
have been attributed to exposure to either, or a combination of, 7-KC or 7OHC 
(Lizard et al., 1999). The proposed mechanism(s) through which oxLDL and the 
oxysterol component of oxLDL cause cell death was described recently (Panini and 
Sinensky, 2001). An elevation in intracellular calcium levels is an early signal 
transduction event that leads to apoptosis via extrinsic and intrinsic pathways. In 
particular, 7-KC-induced apoptosis involves calcium-dependant activation of pro-
apoptotic and survival pathways (Berthier et al., 2005) by increasing the influx of 
calcium into, for example, endothelial cells (Zhou et al., 2000). 7-KC-induced 
apoptosis of vascular smooth muscle cells is not caspase-dependent but occurs as a 
result of a mitochondrial conformational change rather than swelling and rupture of 
the outer membrane (Seye et al., 2004). In contrast, 7OHC-induced apoptosis is 
thought to occur via activating Fas ligand (FasL) leading to stimulation of the Fas 
receptor (FasR) (Lordan et al., 2008). The process of apoptosis induced by 7-KC or 
7OHC in the vascular environment can be reversed by the addition of an 
antioxidant such as lycopene (Palozza et al., 2009), which also prevents 7-KC-
induced oxidative stress. 




Table 1-1 Major biological functions of oxysterols. 





Cellular sterol efflux 
(Gelissen et al., 1996; 
Huang et al., 2001; 
Jessup and 
Kritharides, 2008) 
Cytotoxic and pro-apoptotic effects (e.g. 7-ketocholesterol 
induces cell apoptosis) 
(Asano et al., 2007; 
Vejux et al., 2007) 
Pro-inflammatory signals (e.g. 7-hydroxycholesterol can 
induce secretion of interleukin IL-1 in vascular endothelial 
cells) 
(Lemaire-Ewing et al., 
2005; Rosklint et al., 
2002) 
Regulation of lipid metabolism via liver-X-receptor (LXR) and 
Insig (a sterol response element binding protein) – (e.g. some 
oxysterols bind to LXRs; LXR can regulate actions of 
glucocorticoids and is a potential target for drug treatment of 
diabetes) 
(Brown et al., 2002; 
Fu et al., 2001; 
Kalaany and 
Mangelsdorf, 2006) 
Modulation of estrogen receptor (ER) function – (e.g. 27-
hydroxycholesterol binds to and activates ER, instead of 
estrogen) 
(Umetani et al., 2007) 
(DuSell et al., 2008) 
Regulation of lipid metabolism, vesicle transport and 
signalling via OSBP (oxysterol-binding protein) and ORPs 
(OSBP-related proteins) 
(Suchanek et al., 
2007) (Yan et al., 
2008) 
Activators of Hedgehog signalling, cell differentiation (e.g. 
oxysterols stimulate hedgehog pathway activity via indirect 
activation of Smoothened, thus regulating developmental 
processes; and can increase formation of medulloblastoma). 
(Corcoran and Scott, 
2006; Dwyer et al., 
2007) 
 
Oxysterols are synthesized from cholesterol, as their major precursor, by the actions of 
Cytochrome P450s and exert numerous biological functions (Olkkonen and Hynynen, 2009). 
BIOLOGICAL FUNCTION OF OXYSTEROLS References: 




1.3.2.2. Actions via Nuclear Receptors And Regulation Of 
Cholesterol Efflux And Fat Metabolism 
Nuclear receptors (NRs) integrate metabolic pathways, including those involved with 
cholesterol homeostasis (www.nursa.org), and are transcription factors (TF). They 
bind to a target gene region and the transcriptional outcome depends on their 
assembly with associated co-activators and co-repressors. NRs target a network of 
genes in response to extracellular stimuli, and often respond to small hydrophobic 
ligands such as oxysterols (Hult et al., 2004). Nuclear hormone receptors are thought 
to aid maintenance of allostasis (i.e. energy supply and lipid composition), which 
was defined by Sterling and Eyer (2002) as an adaptive process for effectively 
maintaining cell stability and balance. NRs have a conserved structure comprising a 
DNA-binding domain (DBD) and a ligand-binding domain (LBD). The ligands for 
nuclear hormone receptors are often lipophilic hormones. 
 
Some nuclear hormone receptor agonists are promising drugs as they: can promote 
cholesterol efflux; can increase HDL levels; have anti-inflammatory activity and can 
reduce progression of atherosclerosis in mice (Joseph and Tontonoz, 2003; Kalaany 
and Mangelsdorf, 2006). Many oxysterols have been shown to activate various 
nuclear receptors. Most recently 27-OHC has been named an endogenous selective 
modulator of estrogen receptor  (SERM) via alteration of ER structure and cofactor 
recruitment (DuSell et al., 2008). 
 
The liver X receptor (LXR)-pathway is recognized as a potential target for 
therapeutic intervention in human cardiovascular disease, since synthetic LXR 
agonists inhibit the development of atherosclerosis in murine models (Tontonoz and 
Mangelsdorf, 2003). LXRs are small orphan receptors, critical for the control of lipid 
homeostasis in vertebrates, expression of various genes involved in the efflux, 
transport and excretion of cholesterol. LXR (NR1H3, From the Nuclear Receptors 
Nomenclature Committee, (1999)), but not LXR (NR1H2), is mainly important in 
cholesterol homeostasis in the liver. LXR, similar to LXR, is involved in the 
regulation of cholesterol metabolism in peripheral tissues (Alberti et al., 2001). 




Recent studies have identified several oxysterols, in particular 24(S)-, 25-
epoxycholesterol, and 24(S)-hydroxycholesterol (Lehmann et al., 1997), as natural 
ligands for LXR receptor. 7OHC can stimulate LXR-dependent transcription, 
although to a lesser extent than 22(R)-hydroxycholesterol (Janowski et al., 1999).  
7-KC behaves as a very weak agonist for the LXR family, and upon activation of 
LXR-mediated transcription by the synthetic non-steroidal ligand T0901317 7-KC 
acted also as a partial agonist (Crestani et al., 2004). More recently, 7-KC and 
7OHC have been ruled out as agonists for this receptor since they failed to activate 
LXR in mature adipocytes, or to display intrinsic activation of the glucocorticoid 
receptor (Wamil et al., 2008). 
 
7-KC, a physiological stimulus, has (with a number of xenobiotics) been proposed to 
modulate activation of the aryl hydrocarbon receptor (AhR) (Savouret et al., 2001).  
The ligands for this receptor have been implicated in the development of 
cardiovascular diseases due to their oxidative and atherogenic properties to activate 
or mediate activity of AhR in the vascular endothelium (Crawford et al., 1997; Dabir 
et al., 2008). Although it is not an agonist for this receptor, 7-KC could 
competitively bind to the AhR and function as an AhR antagonist, but other 7-
oxysterols do not exert this characteristic action (Crawford et al., 1997). 
 
1.3.3. The Pathophysiological Role Of 7-Oxysterols 
Plasma levels of both 7OHC and 7-KC have been proposed as biomarkers for a 
number of conditions, including: cancer, oxidative stress and inflammation in 
diabetes (Linseisen et al., 2002). Jessup and Brown reported increased circulating 
concentrations of 7-oxysterols in patients with atherosclerosis (Brown and Jessup, 
1999, 2009; Jessup and Brown, 2005) and these compounds possess a number of 
functions that have linked them with the pathogenesis of cardiovascular disease. 
These include their: pro-oxidative, pro-inflammatory (Rosklint et al., 2002), pro-
coagulant (Aupeix et al., 1996) and pro-apoptotic properties (Berthier et al., 2005; 
Prunet et al., 2006) allied with their ability to induce both oxidative stress in the cells 
of vascular wall and (Olkkonen and Lehto, 2004) cell death in atherosclerosis 




(Akishima et al., 2005). The 7-hydroxyperoxides and 7-oxysterols are major 
components (up to 40%) of LDL particles. Furthermore, high concentrations of 7-
oxysterols (>100-fold higher than in plasma) are found in human atherosclerotic 
plaques (Bjorkhem et al., 1994; Zieden et al., 1999). In particular, 7-KC is a major 7-
oxysterol found in atherosclerotic plaques (Brown et al., 1997; Suarna et al., 1995), 
and many reviews (Berliner and Heinecke, 1996; Bjorkhem and Diczfalusy, 2002; 
Brown and Jessup, 2009; Lukyanenko and Lukyanenko, 2009; Olkkonen and Lehto, 
2005) have discussed the role of 7-KC and 7OHC in atherosclerosis due to both 
their high abundance in atherosclerotic plaques and their ability to trigger pro-
apoptotic events. 
 
More recently oxysterols have been identified as major regulators of cholesterol 
metabolism (Wang et al., 2008). They can also modulate activity of the estrogen 
receptor and recruitment of its cofactor (DuSell et al., 2008). Oxysterols are potent 
membrane destabilizing agents, as they are able to displace cholesterol from its 
major sites (within cell membranes, next to phospholipids; (Siggins et al., 2006)). 
Cholesterol is (chemically) less susceptible to oxidative attack than the 
polyunsaturated fatty acyl moieties present in phospholipids. This is illustrated by the 
more extensive oxidation of fatty acyl groups compared with cholesterol in isolated 
LDL (Noguchi et al., 1998). Oxidized lipids can, however, cross the cell membrane 
easily and equilibrate with lipoproteins at a much faster rate than cholesterol 
(Massey, 2006). Along with the biological effects described (above), oxysterols can 
inhibit or stimulate important enzymes in cholesterol homeostasis and exert 
mutagenic effects. For example, oxidized cholesterol can prevent synthesis of 
enzymes linked to sterol metabolism, at an mRNA level. One such example is the 
inhibition of HMG-CoA reductase (the rate-limiting enzyme in cholesterol 
synthesis), thereby leading to reduced endogenous cholesterol synthesis (Schmidt et 
al., 2006). Oxysterols also have cytotoxic and apoptotic effects on the (endothelial 
and smooth muscle) cells of the vascular wall (Lizard et al., 1999), and (along with 
oxLDL) are susceptible to incorporation by macrophages, leading to foam cell 
formation (Hayden et al., 2002). 




In terms of atheroma, formation of oxysterols is considered a way of eliminating 
excess cholesterol via inhibition of its synthesis (by HMG-CoA). As the work by 
Terasaka et al., (2007), elegantly demonstrated, ATB-binding cassette transporters 
may aid export of 7-oxysterols from macrophages. In particular, over-expression of 
the ABCG1 transporter promotes cellular efflux of 7-KC and 7OHC to HDL 
acceptor particles. This could favour prevention of atherosclerotic plaque formation 
and suggests a metabolic benefit of increased local 7-oxysterols as opposed to 
cholesterol. 
1.3.3.1. The Endothelium Is A Target For 7-Oxysterols 
Although the formation of oxysterols aids clearance of excess cholesterol via 
formation of bile acids, there is increasing evidence that 7-oxysterols impair the 
function of vascular endothelial and smooth muscle cells. The precise mechanism(s) 
involved, however, are not completely understood. A better understanding of these 
actions should clarify the processes underlying 7-oxysterol-mediated impairment of 
endothelium-dependent vasorelaxation (Deckert et al., 1997). One potential 
mechanism may involve 7-oxysterol-mediated cell death as both 7-
hydroxycholesterol and 7-ketocholesterol have been shown to reduce cell adhesion 
and increase permeability to propidium iodide in endothelial cells, smooth muscle 
cells and fibroblasts (Lizard et al., 1999). Furthermore, 7-oxysterols may also induce 
apoptosis via a nitric oxide (NO)-dependent pathway (Panini and Sinensky, 2001). 
This is consistent with the demonstration that increased dietary oxysterols are toxic 
to the endothelium and smooth muscle cells in vivo, through the release of  
cytochrome C (although this toxicity was counterbalanced by increased endothelium-
dependent dilatation (Meynier et al., 2005)). These results suggest that detrimental 
effects of 7-oxysterols on endothelial cell function may contribute to the 
development of cardiovascular conditions such as atherosclerosis. Consequently, 
regulation of 7-oxysterol concentrations in the vascular wall may have a considerable 
influence on pathogenesis of these conditions.  




1.4. Novel Function For 11HSD1 In 7-Oxysterol 
Metabolism 
In addition to its metabolism of glucocorticoids, recent reports (using different 
animal models) have suggested a novel role for 11HSD1 in the inter-conversion of 
7-oxysterols (as mentioned in see sections 1.2.1 and 1.3.2). Several research groups 
have shown that 11HSD1 plays a role in formation of 7-KC from 7-
hydroxycholesterol (Hult et al., 2004) and that 11HSD1-mediated reduction of 7-
KC occurs in the (rat) liver (Schweizer et al., 2004). These studies on metabolism of 
7-oxysterols by 11HSD1 have been performed using enzyme from a variety of 
species (rat, rabbit, guinea pig, chicken, dog and human). In all species 11HSD1 
converted 7-KC to 7OHC but in some species 7- and/or 7OHC were also 
converted into 7-KC. The dehydrogenation of 7OHC was only specific to hepatic 
11HSD1 in the hamster (Arampatzis et al., 2005). Still, the preferential direction 
and the specificity of 11HSD1 for 7-oxysterols remain unclear and it has been 
proposed that the specificity of 11HSD1 for 7-oxysterols should be tested in an 
animal lacking the enzyme (Jessup and Brown, 2005). The contribution of 11HSD1 
to the formation of 7-oxysterols may also be considered a mechanism for removal of 
excess 7-KC. The contribution of 11HSD1 to regulation of 7-oxysterols in 
atherosclerotic plaque has not been addressed. 
1.4.1. Research That Identified A Novel Function For 11HSD1 
The existence of an additional unidentified pathway for metabolism of 7-KC in mice 
initially became evident from the work by Erikson et al., (1977). This identified 7-
hydroxycholesterol as a major metabolite upon hepatic perfusion with [3H]-7-KC in 
rats. More recently Lyons et al., (2002) proposed that metabolism of 7-KC in the 
liver would solely be catalysed by 27-hydroxylase. However, by performing work in 
mice carrying a homozygous null mutation in CYP27 (Cyp27-/-) the same group 
detected an increased rate of metabolism of 7-KC (compared with wild type 
controls) to an unknown product, as opposed to the reduced rate that they 
anticipated. This was evidence that mice do not have an absolute requirement for  




27-hydroxylase in order to metabolise 7-KC, but that an alternative route exists. 
Earlier work by Song et al., (1998) is consistent with this view, with the 
demonstration that NADP+-dependent metabolism of 7OHC in hamster microsomes 
generated 7-KC. They also showed that the enzyme involved was a type of HSD 
(“7HSD”) and reported its ability to metabolise oxysterols and glucocorticoids (e.g. 
hamster, Km for corticosterone, 1.2 µM and for 7OHC, 1.9 µM, with identical 
Vmax, ~170 nmol/min/mg protein). Further cloning and expression in a cell system 
identified this enzyme as 11HSD1; probably representing the major hepatic route of 
7-KC metabolism in the body (Hult et al., 2004). Subsequent work (Schweizer et al., 
2004) confirmed that inhibition of 11HSD1 by carbenoxolone abolished the 
formation of this 7-oxysterol metabolite by rat hepatic microsomes. This was the first 
report of the metabolic specificity of 11HSD1 for the 7-oxysterol pathway but the 
preferred substrate and the reaction equilibrium for this pathway were not 
determined. Further work has demonstrated clear inter-species differences in 
11HSD1-mediated metabolism of 7-KC. The hamster enzyme differs fundamentally 
from 11HSD1 in rat, human or guinea pig in that it accepts both 7-epimers (7OHC 
and 7OHC) as substrates for the dehydrogenase reaction. Equally, reduction of 7-
KC produces 7OHC and/or 7OHC in the hamster. In rat and guinea pig, however, 
only 7OHC is accepted as a substrate or formed following reduction of 7-KC (Hult 
et al., 2004). Inter-conversion of 7OHC and 7-KC has also been demonstrated 
recently in humans in vivo. Administration of deuterium-labelled isomers of 7OHC 
and 7-KC (d7–7OHC, d7-7-KC) to healthy volunteers, resulted in their direct inter-
conversion (Larsson et al., 2007), which the authors ascribed to the action of 
11HSD1. Although not tested directly, this is the first report on the role of human 
11HSD1 in determining circulating levels of 7-oxysterols.  
1.4.2. Different Substrates Exist For 11HSD Type1 
The main function attributed to 11HSD1 in vivo is to activate inert 11-keto 
glucocorticosteroids (e.g. cortisone, corticosterone) and form active hormones (e.g. 
cortisol, 11-dehydrocorticosterone). However, from the evidence published by 2005, 
it became clear that 11HSD1 might be involved both in oxysterol and in 
glucocorticoid metabolism, concomitantly. This dual metabolism of 11HSD1 




suggests that there are factors common to both classes of substrates which regulate 
these two pathways in the body. Indeed, conditions of glucocorticoid excess are 
commonly associated with dyslipidaemia (Morton et al., 2001). However, the 
specificity of 11HSD1 for, and the physiological consequences of, the interaction 
between these two pathways has not been determined or compared in different 
species. Indeed, enzymatic formation of 7-oxysterols (7-KC and 7OHC) by 
11HSD1 only recently attracted more attention following the suggestion that 
11HSD1 inhibition had the potential to prevent atherosclerosis and hyperlipidaemia 
(Hermanowski-Vosatka et al., 2005). Whilst the role for 11HSD1 in metabolizing 
glucocorticoids is well established, the physiological significance of the novel 
pathway of 7-oxysterol metabolism is not yet clear, as the functions of the substrate 
and product of 11HSD1-mediated 7-oxysterol metabolism are less well delineated. 
Generation of glucocorticoids by 11HSD1 is a potential pharmacological target for 
several metabolic diseases. Whether the same, or additional, benefits can be obtained 
by inhibiting 11HSD1-mediated metabolism of 7-oxysterols is not yet known. 
 
It is clarification of the interaction between glucocorticoids, 7-oxysterols and 
11HSD1 that forms the basis of the work presented in this thesis. Confirmation of 
the physiological and pathophysiological roles of glucocorticoid metabolism by 
11HSD1 has been greatly aided by the generation (in Edinburgh; Kotelevstev et al., 
1997) of mice with selective transgenic deletion of this enzyme. Determining 
whether 7-oxysterols also act as substrates for murine 11HSD1, would make it 
possible to use these knockout mice to clarify the importance of 11HSD1-mediated 
inter-conversion of 7-oxysterols in health and disease. 




1.5. Hypothesis And Aims 
The experimental work performed and presented in this thesis was based on the 
finding that 7-oxysterols are metabolised by the enzyme 11HSD1 in rodents. 
However, there was little evidence to suggest this function was conserved in murine 
11HSD1: this was a significant omission because much mechanistic work has been 
performed in mice with transgenic deletion of this enzyme. In addition it was not 
clear whether oxysterols compete with glucocorticoids for the active site of 
11HSD1 (with consequent implications for metabolism of both classes of substrate. 
Consequently, the work described in this thesis addresses the hypothesis that murine 
11HSD1 enzyme metabolises 7-oxysterols; which may have direct physiological 
consequences but also may modulate the activity of glucocorticoids. 
 
In order to investigate this hypothesis the following aims were set: 
 
1.    To investigate the kinetics of 11HSD1-mediated metabolism of 7-oxysterols 
using mouse recombinant protein and mouse tissue homogenates. 
 
2.   To determine whether 7-oxysterols and glucocorticoids compete for metabolism 
by 11HSD1. 
 
3.   To determine whether cellular cholesterol levels in vitro influence 7-oxysterol 
levels and the kinetics of glucocorticoid metabolism by 11HSD1. 
 
4.   To assess the impact of genetic deletion (or inhibition) of 11HSD1 in mice,  
on the plasma levels of 7-oxysterols. 
 
5.  To determine whether exposure to 7-oxysterols alters the function of isolated 
mouse aorta. 














Chapter 2. Materials and Methods 





All solvents and water were glass-distilled HPLC grade purchased from Fisher 
(Loughborough, UK) or from Rathburn (Walkerburn, UK). All radioactively-labelled 
species were purchased from GE Healthcare (Bucks, UK) and scintillation fluid 
GoldFlow, was from Meridian (Surrey, UK). All chemicals were from Sigma-
Aldrich (Gillingham, UK) or Fluka (Buchs, Switzerland) unless otherwise stated. 
Tissue culture reagents were from Lonza (Vervier, Belgium) and plastics from 
Costar Ltd (Corning, Sigma) or from BD Falcon (BD Biosciences, Bedford, USA).  
2.1. Chemicals 
5-Cholesten-3-ol-7-one (7-Ketocholesterol), 5-cholesten-3,7-diol (7-
hydroxycholesterol), 5-cholesten-3,7α-diol (7α-hydroxycholesterol); 4-cholesten-
7α-ol-3-one (C4), 5-cholesten-3,19-diol (19-hydroxycholesterol), 11α-
hydrocortisone (epi-F), 11-dehydrocorticosterone (A) and corticosterone (B) were 
purchased from Steraloids (Newport, Rhode Island, USA). 5-Cholesten-3,27-diol 
(27-hydroxycholesterol) was purchased from Avantis Polar Lipids (Alabama, USA). 
Hepta-deuterated isotopomers, d7–7OHC (7-hydroxycholesterol – 25, 26, 26, 26, 
27, 27, 27-d7), d7–7-KC (7-Ketocholesterol – 25, 26, 26, 26, 27, 27, 27-d7) and d7–
cholesterol (cholesterol – 25, 26, 26, 26, 27, 27, 27-d7) used as internal standards, 
were purchased from CDN Isotopes (Quebec, Canada).  
2.2. Buffers 
All buffers were prepared to give final concentrations as stipulated in brackets and 
pH was adjusted as appropriate.  
‘C’ buffer for preparation of [
3
H]4–A: NaCl (150 mM), EDTA (1 mM), Tris (50 
mM) were dissolved in water and the pH adjusted to 7.7 with concentrated NaOH, 
before glycerol was added (8%, v/v).  




High Potassium-physiological saline solution (KPSS): KCl (125 mM), MgSO4 
(1.17 mM), NaHCO3 (25 mM), KH2PO4 (1.18 mM), K2EDTA (0.03 mM), CaCl2  
(2.5 mM), D-glucose (5.5 mM) were dissolved in water and the pH adjusted to 7.4 
with concentrated NaOH. 
Homogenising buffer for placental tissue: ‘C’ buffer as above was used, to which 
dithiothreitol (DTT, 7.7 mg/50 ml) was added. 
Krebs–Ringer bicarbonate buffer (Krebs): NaCl (118 mM), KCl (3.8 mM), 
KH2PO4 (1.19 mM), CaCl2 (2.54 mM), MgSO4 (1.19 mM), NaHCO3 (25 mM) were 
dissolved in water and the pH was adjusted to 7.4 with concentrated NaOH. 
Potassium Phosphate Buffer (Phosphate Buffer): Final solution (0.1M, 1 L) was 
prepared from two stock solutions of KH2PO4 (1 M, 19.8 ml) and K2HPO4 (1 M, 
80.2 ml) in water, to which EDTA (0.1 M) was added and the pH adjusted to 7.5 
using KOH pellets. 
Phosphate Buffered Saline (PBS) was prepared using Potassium Phosphate Buffer 
as above, with NaCl (137 mM) and KCl (2.7 mM). The pH was adjusted to 7.4 with 
concentrated NaOH and the solution was sterilized in an autoclave before use. 
Physiological saline solution (PSS) was prepared using NaCl (119 mM), KCl (4.7 
mM), CaCl2 (2.5 mM), MgSO4 (1.17 mM), KH2PO4 (1.18 mM), K2EDTA (0.026 
mM) and D-glucose (5.5 mM). The pH was adjusted to 7.4 with concentrated NaOH. 
Recombinant protein (Tris) extraction buffer: NaCl (300 mM), Tris (50 mM), 
Triton-X100 (0.05%, v/v) were dissolved in water and the pH adjusted to 8.0 with 
concentrated NaOH. 
Sodium Phosphate Buffer: Final solution (40 mM, 1L) was prepared from two 
stock solutions of NaH2PO4 (0.2M, 46 ml) and Na2HPO4 (0.2 M, 154 ml) in water to 
which glycerol (8 %) was added and the pH adjusted to 7.4 using KOH pellets. 
Sucrose buffer for microsome preparation: sucrose (0.25M) was dissolved in 
water and the pH adjusted to 7.5 with concentrated NaOH. 
Tris NaCl assay buffer: Tris-HCl (50 mM) and NaCl (50 mM) were dissolved in 
water and the pH adjusted to 7.0 with concentrated NaOH. 
TG1 lysis buffer: NaCl (100 mM), EGTA (1 mM), EDTA (1 mM), MgCl2 (1 mM), 
glycerol (20%, v/v), Tris-HCl (20 mM) were dissolved in water and the pH was 
adjusted to 7.4 with concentrated NaOH. 





2.2.1. Drugs And Buffers Used In Myography Studies 
Acetylcholine (ACh, chloride salt): ACh (54.51 mg) was dissolved in water (30 ml, 
10-2 M) and stored in aliquots (500 µl). 
5-Hydroxytryptamine (5HT): 5HT (11.62 mg) was dissolved in water (30 ml, 10-2 
M) and stored in aliquots (1 ml). 
Noradrenaline (NA, bitartarate salt): NA (31.93 mg) was dissolved in water (10 
ml, 10-2 M) and stored in aliquots (500 µl). 
Potassium Chloride (KCl): KCl (14.91g) was dissolved in water (100 ml, 2M) and 
stored at 4°C. 
Sodium Nitroprusside (SNP): SNP (50 mg, pharmaceutical grade, David Bull 
Laboratories, Faulding, UK) was dissolved in water (500 ml), NaCl (0.9% v/v) was 
added and stock (10-2 M) stored in aliquots (500 µl). 
DMEM-L-Arginine: Medium, DMEM without L-arginine was custom made by 
Lonza (Vervier, Belgium). 
KPSS – DMEM-L-Arginine: KCl (123.7 mM) was freshly dissolved in the DMEM 
without phenol red or L-arginine, mixed and oxygenated (95% O2 and 5% CO2, 
37°C). 
2.2.2. Storage And Preparation Of Reagents And Buffers 
• All buffers were stored at 4°C. 
• All extraction solvents contained an antioxidant, butylated hydroxytoluene 
(BHT), at a final concentration of 50 µg/ml. The stock solution of BHT was 
prepared in ethanol (10 mg/ml). 
• HPLC grade solvents were all stored at room temperature and mixed in 
appropriate ratios or individually filtered (0.45µm HV membrane filters, Millipore 
Ltd, Watford, UK) before use in HPLC analysis.  
• Reacti vials were silanised in trichloromethylsilazine (TMCS) in toluene (5%) by 
sonication (10 min), then rinsed first with pure toluene followed by methanol, 
before they were air-dried (at RT). 




• Cofactors, chemical powders, stock solutions and dilutions of unlabelled and 
tritiated oxysterols and steroids were stored at -20°C, except for unlabelled ‘A’ 
which was kept away from light (wrapped in tin foil) and stored at –80°C. 
Subsequent dilutions of ‘A’ were prepared on the day. Cofactors were always 
dissolved in the relevant assay buffer for specific reactions. 
• Sterol, mixture of sterol and d7-sterol solutions (4 mg/ml, 10 mM) were prepared 
in ethanol containing BHT (50 µg/ml) as an antioxidant (Schroepfer, 2000). The 
vials were sealed under argon, sonicated (on ice, 10 min), then vortexed (400 rpm, 
RT, 10 min) until fully dissolved and stored in aliquots (500 µl) at -20°C. 
Dilutions were prepared in ethanol, under argon gas: vials were sealed and stock 
solutions stored at -20°C. If vials were opened more than three times, stocks were 
discarded. During the assay preparation all dilutions of sterols were kept on dry 
ice to minimize exposure to the air. 
• Reagents for GC/MS derivatisation were kept away from light and moisture, and 
stored in amber glass containers under argon and in a dessicator. 
• In all experiments room temperature (RT) was 18 – 22°C. 
2.3. General Lab Equipment 
• A Beckman Optima TLX Ultracentrifuge (GMI Inc, Ramsey, USA) was used for 
preparation of microsomes. 
• Separation of recombinant protein pellets was carried out in a Beckman J2-MC 
high-speed centrifuge (GMI Inc, Ramsey, USA). 
• Centrifugal steps requiring <3,000  g were carried out in a Heraeus labofuge-
400 (Thermo Fisher Scientific Inc, Waltham, USA).  
• Homogenization of tissues was carried out using a Pro200 homogenizer 
(ProScientific, Oxford, USA). 
• Samples for some of the GC/MS procedures were derivatized in a Memmert D88 
oven (Memmert, Nürnberg, Germany).  
• Aliquots of radiolabelled samples were analysed using Tri-carb Liquid 
Scintillantion Counter (Packard, Global Medical Instrumentation, Ramsey, USA). 




• Cell monitoring for tissue culture work was observed under light microscope 
(x40, Zeiss, Hertfordshire, UK). 
• Danish Myo-Technology 4-channel myographs (700MO) attached to Powerlab 
v4.0 data acquisition software were used for functional studies with mouse aortae. 
2.4. Animal Maintenance And Tissue Harvesting 
The following control and transgenic animals were used in the experiments described 
in this thesis. All transgenic animals were generated on, or back-crossed  (twelfth-
generation) onto, a C57Bl/6 background: 
 
• C57Black/6 mice (in-house stock, or from Harlan Ltd, Oxon, UK); 
• 11HSD1 deficient mice (11HSD1-/- (Kotelevtsev et al., 1997; Morton et al., 
2004) in-house colony); 
• 11HSD2 deficient mice (11HSD2-/- (Kotelevtsev et al., 1999) in-house colony); 
• ApoE knockout mice (ApoE-/- (Plump et al., 1992; Zhang et al., 1992) in-
houseolony); 
• 5 alpha reductase-1 (SRD5A1) heterozygous mice (5αSRD1+/-, Mahendroo et al., 
(1997) , Mahendroo et al., (2001), in-house colony); 
• Wistar rats (Harlan Ltd, Oxon, UK). 
 
All animals were bred at the Biomedical Research Facility (BRR, Little France, 
Edinburgh and at the BRR Western General Hospital, Edinburgh). All animals were 
maintained on standard chow diet and tap water ad libitum, under the 16/8 
(light/dark) cycle; room temperature was 19.5 - 23.5°C. 
All experimental procedures were performed under a UK Home Office Project 
Licence (Seckl, 60/3293) and personal licence (Miti, 60/10525). 
2.4.1. Tissue Collection  
All animals were sacrificed by decapitation or asphyxiation as required by 
experimental conditions. The standard procedure for tissue collection involved 
removing the liver, kidney and aorta. Liver and kidneys were dissected from the 




animals, wrapped in aluminium foil, placed on dry ice then stored at –80°C. Small 
amounts of liver (~0.1 g) were stored and kidney samples were cut in half. Aortic 
tissue was processed as described in section 2.4.5. 
2.4.2. Hepatic Subcellular Fractionation 
Livers were stored at –80°C until use when they were slowly defrosted on wet ice. 
Each sample was cut into small pieces (0.1 g) and disrupted repeatedly (15 sec) in 
glass tubes (10x1cm) containing sucrose buffer (1 ml). Tubes were stored on wet ice. 
Homogenates were transferred into further glass tubes (13x1cm) and sucrose buffer 
was added to 90% tube height. Samples were subjected to centrifugation (1000 g, 
4°C, 15 min) for separation of the nuclear fraction (pellet) and the supernatant was 
stored on wet ice and then transferred into Beckman ultracentrifuge tubes (5x1cm). 
A further centrifugal separation (13,000  g, 4°C, 30 min) was performed. The 
subsequent supernatant was collected in new Beckman tubes and another centrifugal 
separation was performed (23913  g, 4°C, 1h) to obtain light microsomes (pellet) 
and cytosolic fractions (supernatant). The supernatant was stored at –80°C. The 
remaining pellet of microsomes was re-constituted in sucrose buffer (500 µl), 
aliquots (40 µl) removed for immediate quantitation of protein (as in section 2.4.7) 
and remaining samples were stored at –80°C. 
2.4.3. Renal Homogenates 
Kidneys (~0.5 g) were kept on ice at all times and homogenized in Krebs or Sucrose 
buffer (1ml, on ice), then further diluted in Phosphate Buffer. Tubes containing 
homogenates were subject to centrifugation (500  g, 4°C, 2 min) and the 
supernatant harvested. Aliquots (10 µl) were removed immediately for determination 
of protein concentration (section 2.4.7) and the remaining samples frozen at –80°C, 
and only defrosted once. 





Placentae (a kind gift from Ms Lynne Ramage, Endocrinology, University of 
Edinburgh) were collected from female Wistar rats (Harlan Ltd, Oxon, UK) after 
cull, rinsed in PSS buffer, frozen immediately on dry-ice and stored at – 80°C. Two 
whole placentae were homogenized in the cold buffer (1 ml) and kept on wet ice at 
all times. Homogenates were stored in aliquots (500 µl) at –80°C and only defrosted 
once. 
2.4.5. Intact Aortic Preparations 
The thoraco-abdominal aorta was removed quickly post-mortem into cold (4°C) PSS, 
then transferred to cold (4°C) oxygenated (95% O2/5% CO2) PSS solution and 
dissected. Fresh aortae were gently handled using fine dissecting tools (FST, Inter 
focus Ltd, Cambridge, UK) under a dissection microscope (x20, Zeiss, Hertfordshire, 
UK). Periadventitial fibroadipose tissue and connective tissue were removed from 
the vessel and its aortic arch, whilst pinned out (Minutien Pins; FST, INterfocus Ltd, 
Cambridge, UK) in a silicone-coated dissecting dish (Sylgard, Dow-Corning, UK) 
containing PSS (at RT). Clean aortae were either tissue-tap dried and frozen (–80°C) 
or processed for functional analysis (sections 2.4.5.1 and 2.4.5.2). 
2.4.5.1. Frozen Aortae  
Whole, frozen aortae were pulverised in chilled tin foil under liquid nitrogen, using 
mortar and pestle, and then mechanically homogenised in ice-cold Krebs or 
Phosphate buffer (0.5 ml). Homogenates were kept on ice at all times, the remaining 
solid tissue was deposited by centrifugation (4000  g, 4°C, 2 min) and the 
supernatant was removed. An aliquot (40 µl) of supernatant was retained for 
immediate determination of protein concentration (section 2.4.7). Remaining 
samples were stored at –80°C until use. 





2.4.5.2. Fresh Aortae 
Freshly cleaned aorta (as described in section 2.4.5) was cut into 1.5 – 2 mm 
segments (4-5 rings from one animal) and immediately placed in either PSS buffer or 
DMEM medium without L-arginine, in a 24-well plate or mounted onto the 
myograph for incubation (section 2.10). 
 
2.4.6. Plasma Sampling 
Approximately 1ml of plasma was collected after pooling the blood from 2 – 3 mice. 
Blood was collected in EDTA-coated (1.6 mg/ml) vials (9 ml, Sarstedt, Monovette, 
Numbecht, Germany), gently inverted to mix pooled blood and plasma was separated 
by centrifugation (2000  g, 4°C, 15 min) and transferred to a fresh eppendorf. An 
aliquot of BHT antioxidant (50 µg/5µl, in ethanol) was added to each plasma sample 
(Sevanian et al., 1994; Siems et al., 2005; Tsai, 1984), argon was bubbled in and 
samples stored at –80°C. 
 
2.4.7. Quantitation Of Protein - Bradford Method 
The protein concentrations of tissue homogenates and subcellular fractions were 
determined colorimetrically using a Bio-Rad protein assay kit (Bio-Rad, Hemel 
Hempstead, UK) and the Bradford method of detection (Bradford, 1976). Protein 
assay dye reagent was diluted in HPLC water (1:5, freshly prepared) as well as a 
series of bovine serum albumin protein standards (concentration range 0.125 - 2 
mg/ml, stored at –20°C) prepared in water. Water was used as the Blank. The assay 
was performed in duplicate, by adding Bio-Rad diluted dye (200 µl) to the protein 
sample and protein standards (each, 10 µl). The dilutions of unknown proteins were 
prepared to yield concentrations, which corresponded to the range of the standard 
curve, based on the initial assessment of the colour change upon mixing the protein 
and the diluted dye. The plate was shaken to mix and allowed to stand (RT, 15 min – 




1h). UV absorbance was measured (λ595 nm) on a UV/visible spectrophotometer 
(Shimadzu, Milton Keynes, UK) and protein concentrations of undiluted samples 
were calculated (mg/ml) from the standard curve, allowing for the dilution factor. An 






        BSA (mg/ml) 
 
 
Figure 2.4-1 Protein assay standard curve generated for the calculation of 
protein concentration.  
Standard curves for Bio-Rad protein assay were generated from UV absorbance (λ595 nm) 
of known concentrations of bovine serum albumin (BSA, 0.125 – 2 mg/ml) and used to 
determine the unknown concentration of samples by interpolating their UV absorbance 
against the standard curve. 




2.5. Metabolism Of Steroids And Oxysterols By Murine 
Recombinant 11HSD1 (m11HSD1) 
2.5.1. Recombinant m11HSD1 Protein Purification 
A protein pellet (15 g) containing m11HSD1 was a gift from Dr Scott Webster 
(Endocrinology, University of Edinburgh). The cell pellet was re-suspended in 
“BugBuster” (Novagen, Merck Chemicals Ltd, Nottingham, UK) protein extraction 
reagent (5 ml/g of pellet), with lysonase (10 µl/g pellet, Novagen); i.e. endonuclease 
for degradation of all forms of DNA and RNA in order to increase protein yield. For 
complete inhibition of serine and cysteine proteases, one crushed protease inhibitor 
cocktail tablet (Complete Mini, EDTA-free, Roche, Indianopolis, USA) was added 
and the mixture incubated at RT with shaking (50 rpm, 30 min), then separated (6000 
 g, 4°C, 20 min) and the supernatant collected. 
 
Concomitantly, Talon Resin (Clontech, Saint-Germain-en-Laye, France) was 
prepared in five separate Falcon tubes (15 ml) by washing in ethanol (2x3ml), 
followed by centrifugation (6000  g, 4°C, 2 min), after which the ethanolic 
fractions were discarded. Talon resin was further washed with the extraction buffer 
(2x3ml, as listed in section 2.1.2.) and buffer was discarded leaving the activated 
resin. The supernatant was applied to the above resin, mixed and separated (6000 g, 
4°C, 2 min) and the supernatant removed (this represented Fraction 1, 15 ml). Tris 
extraction buffer (3 ml) was added to the resin and the supernatant collected after 
centrifugation (Fraction 2, 15 ml). This step was repeated generating Fraction 3 (15 
ml). Imidazole (3 ml, 10 mM) was then applied (3x) and all centrifugal supernatants 
saved (fractions 4, 5 and 6, 15 ml each). Imidazole solutions (3 ml of 100 mM and 
500 mM) were then added sequentially to the resin, generating Fractions 7 and 8 (15 
ml each), following centrifugation. 
 
Samples were prepared for electrophoresis from each of the above fractions 
containing: protein fraction (10 µl), NusPage sample buffer (4 µl) and protein 
reducing agent (1 µl), (Paisley, Invitrogen, UK). Samples were heated (100°C, 5 




min) and analysed by electrophoresis (200V, 400A, 30min), using Bis-Tris gel (12%, 
w/v, Invitrogen) with NusPage MES SDS (20x) running buffer along with protein 
standards (4 – 250 kDa, SeeBlue Plus-2 Pre-stained standard, Invitrogen). The gel 
was washed in water (3x) before Simply Blue Safe Stain (containing Coumassie G-
250, Invitrogen) was added (1 – 3h) to visualize the proteins on a gel. After staining, 
the gel was washed in water (2x) and a 32 kDa band, corresponding to m11HSD 
type 1 was observed with Fraction 7 and Fraction 8, as anticipated (Figure 2.5 – 1). 
These two fractions with m11HSD1 protein were further purified by dialysis using 
two separate dialysis tubes (0.05 µm, Milipore, Watford, UK) placed in extraction 
buffer (5L, 4°C, stirred, overnight).  
The two fractions containing m11HSD1 were combined (30 ml) and protein 
concentration was determined (section 2.4.7). Total protein (30 ml) was further 
concentrated (to 2 ml), using a Vivaspin20 10.000 kDa centrifugal concentrator 
(2x20 ml, VivaScienceAG, Hanover, Germany) by continuous spinning (3000  g, 
4°C, 30 – 90 min). The resultant purified m11HSD1 protein was present at a 
concentration of 1.4 mg/ml (2 ml) and was stored in aliquots (100 – 500 µl, 4% 
glycerol) at –20°C. 
2.5.2. Oxidation Of Corticosterone To 11-Dehydrocorticosterone 
Corticosterone (B, 10 mM, in ethanol) was stored at -20°C, following sonication, and 
further ethanolic dilutions of B were prepared as required. Recombinant m11HSD1 
protein (28 µg/ml) was incubated with unlabelled B (0.02 – 40 µM) and NADP (2 
mM) in Krebs Buffer (250 µl, final volume). Samples were incubated (0 – 120 min) 
and the reaction stopped by freezing (-20°C) or adding ethyl acetate (10x volume). 
The internal standard, epi-F (10 µg/ml, in ethanol) was added and steroids further 
extracted (3x) into ethyl acetate and the organic phase reduced to dryness under a 
stream of nitrogen (OFN, 60°C) and dried residues were stored at -20°C until 














Figure 2.5-1 Separation of m11HSD1-purification fractions. 
Coumassie blue-stained SDS polyacrilamide gel (12%, NusPage) with fractions 1 – 8 
collected upon purification of m11HSD1 protein. Fractions 7 and 8 (eluted with 100mM and 
500 mM Imidazole, respectively) contained 32 kDa m11HSD1 protein. All bands were 
compared with protein standards in lane 0 (SeeBlue Plus2, 4–250 kDa) as indicated. 




2.5.3. Oxidation Of 7-Hydroxycholesterol To 7-Ketocholesterol 
An ethanolic solution of 7OHC (10 mM, containing 50 µg/ml BHT) and subsequent 
ethanolic dilutions, were prepared as required and stored under argon at -20°C. The 
dehydrogenation of 7OHC (1 – 20 µM) was performed as described for steroids 
(section 2.5.2) with some modifications. The reaction was carried out using 
Phosphate Buffer (250 µl, final volume) containing cysteamine-HCl (20 mM) (Song, 
et al., 1998), as it was initially observed that the reaction occurred at a faster rate in 
this solution than in Krebs. Internal standards, C4 (5 µg/ml) and 19OHC (10 µg/ml), 
were added in place of epi-F, after the incubation. Oxysterol extraction from 
Phosphate Buffer was performed using petroleum ether (3x 6 ml). Organic extracts 
were reduced to dryness under argon (RT) and stored at -20°C until analysis by 
HPLC–UV (section 2.12.1.3). 
2.5.4. Reduction Of 11-Dehydrocorticosterone To Corticosterone 
2.5.4.1. Preparation Of Cofactor (NADPH) Regenerating System 
NADPH (20 mM) was prepared by co-incubating NADP+ (20 mM), glucose-6-
phosphate (40 mM) and glucose-6-phosphate dehydrogenase (0.1 unit/ml, from 
yeast, Roche, Mannhein, Germany). The enzyme was dissolved and stored in 
aliquots (0.1 unit/10 µl, sodium phosphate buffer containing 8% glycerol, as in 
section 2.2) at –20°C. NADPH generating mixture was mixed, covered in tin foil and 
stored on wet ice until use on the same day. Before use in the assay, the mixture was 
incubated (10 min, 37°C).  
2.5.4.2. Assay Conditions 
Ethanolic dilutions of unlabelled ‘A’ were prepared from concentrated stock (6 mM, 
in ethanol) on the day, to achieve the required concentration. The reaction mixture 
contained: NADPH generating system (2 mM, final volume, see section 2.5.4.1), 
m11HSD1 protein (28 µg/ml), unlabelled A (0.02 – 40 µM) in Krebs buffer  
(250 µl, final volume). Internal standard (epi-F, 10 µg/ml) was added following 




incubation (15 min – 3h), and steroids extracted exactly as described (section 2.5.2) 
until analysis by HPLC–UV (section 2.12.1.2). 
2.5.5. Reduction Of 7-Ketocholesterol To 7-Hydroxycholesterol 
An ethanolic solution of 7-KC (10 mM, containing 50 µg/ml BHT) and subsequent 
ethanolic dilutions were prepared and stored under argon at -20°C. The reductase 
assay was prepared as described (in section 2.5.3) for the dehydrogenase reaction, 
with minor amendments. m11HSD1 protein (28 µg/ml) was incubated with 7-KC 
(0.5 – 40 µM) and the NADPH generating system (2 mM, as in section 2.5.3.1) in 
phosphate buffer (250 µl, final volume). Samples were further incubated, oxysterols 
extracted and stored as described in section 2.5.3 until analysis by HPLC–UV 
(section 2.12.1.3). 
2.5.6. Controls And Quantitation 
In each of the above assays, control samples were included: “Blank” (with substrate, 
cofactor, but no protein), “No-cofactor” (with substrate and protein but no cofactor) 
and ‘Just protein’ (containing buffer and protein only). Tubes were maintained on 
wet ice, and substrate and cofactor were added last in quick succession. In all assays 
reactions were performed at least in duplicate and time of incubation was established 
for each reaction to allow product formation to conform to first order linear kinetics 
(approximately up to 30% conversion). 
With each assay, two duplicate standard curves were constructed using a series of 
dilutions representing known concentrations of A and B (0.02 – 40 µM) or 7-KC and 
7OHC (0.04 – 40 µM), as appropriate, and a fixed amount of relevant internal 
standard (as given above). The samples for standard curve preparation also contained 
cofactor (2 mM) and appropriate buffer (250 µl, final volume), but lacked protein, 
and were incubated simultaneously with the assay. Typically a minimum of eight 
points, in duplicate, were used on a standard curve.  




2.6. Metabolism Of Steroids And Oxysterols By m11HSD1 
Stably Transfected In CHO and HEK Cells 
2.6.1. Cell Culture 
All work was carried out in a tissue-culture hood and employed general sterile tissue-
culture laboratory techniques. Both HEK (Human embryonic kidney) and CHO 
(Chinese hamster ovary) cell types (from the European Collection of Cell Cultures 
EACC, Porton Down, UK 05030204 and 85050302 respectively), stably transfected 
with mouse or human 11HSD1 or 11HSD2, were a generous gifts from Dr Scott 
Webster and Mrs Margaret Binnie (Endocrinology, Edinburgh University). 
2.6.1.1. Charcoal-Stripped Serum  
Foetal calf serum (FCS, 0.5L) was defrosted at RT and dextran-coated charcoal (5 g) 
was added and stirred overnight (4°C). The mix was subjected to double filtration 
through sterile filter units (0.45 µm, then 0.22 µm, 500 ml volume), then heat-
inactivated (56°C, 30 min in water bath), cooled to RT, separated in aliquots (50 ml) 
and stored at –20°C. 
2.6.1.2. Thawing And Passaging Cells 
A cryovial of frozen cells, which had been stored in liquid nitrogen (-196°C), was 
placed on dry ice. Cells were thawed very quickly by agitating the vial by hand at 
37°C in a water bath, and then transferred to a T75 cm2 flask containing 10 ml pre-
warmed medium. 
Cells were maintained on a T75 cm2 dish in a humidified atmosphere (5% CO2, 95% 
air, 37 ºC) in an incubator for 48 h. HEK cells were maintained in Dulbecco's 
modified Eagle's medium (DMEM) and seeded on poly-D-lysine coated plates (50 
µg/ml, 5 min), whereas for CHO cells, Ham’s F12 essential medium (Ham’s F12) 
was used. Both media were supplemented with glutamine (2 mM), penicillin 
(100 units/ml), streptomycin (100 µg/ml), and heat-inactivated foetal calf serum 




(FCS, 10% v/v). For CHO cells transfected with mouse or human 11HSD1, Ham’s 
F12 medium was further supplemented with 100 µg/ml hygromycine. 
 
Prior to passaging, the cells were washed in PBS without calcium and magnesium (5 
– 10 mls, to remove divalent cations and serum). The cells were enzymatically 
displaced by adding 1x trypsin-EDTA (50 units/ml trypsin and 5 mM EDTA) 
solution (2 ml for T75 cm2 dish) and placed in an incubator (37°C, 2 – 5 min) until 
the cells had detached. Detachment of cells was carefully monitored under a light 
microscope. Often the flask was gently tapped in order to loosen all the cells. Cell 
number was counted using a haemocytometer. Trypsin was inactivated by adding 
fresh medium containing 10% FCS (15 ml in T75 cm2). The cell suspension was 
further split (1:5) between new T75 cm2 flasks, containing fresh pre-warmed 
medium. The flasks were returned to an incubator for cells to adhere until they were 
confluent (90%). Medium was changed every 2 – 3 days by aspirating and was 
discharged and replaced with a fresh pre-warmed medium. 
 
Prior to performing steroid or oxysterol assays, appropriate cells were seeded and 
treated with medium as above, containing dextran-coated charcoal stripped-FCS 
(10%, v/v) instead of FCS. When cells were confluent (90%), they were further 
seeded onto 6-well plates (PDL-coated, where appropriate) and maintained in 
medium with stripped serum to attach overnight. The same medium with stripped 
serum was used subsequently in all assays. 
 
Cell viability in tissue culture was measured by trypan blue exclusion staining. 
Counting was performed in triplicate and results averaged. 
2.6.1.3. Freezing And Storage Of Cells 
For long-term storage, 80 - 95% confluent cells were detached with trypsin/EDTA as 
described in section 2.6.1.2.  Cells were counted using a haemocytometer. The 
remainder of the cell suspension was subjected to centrifugation (210  g, RT, 5 
min) and the resultant pellet was re-suspended at 2x106 cells/ml in FCS containing 
dimethylsulphoxide (DMSO, 10% v/v). The cell content was transferred to a cryovial 




and placed inside a polystyrene rack, which was transferred onto dry ice for slow 
freezing, then placed at –80°C. After several days, the vials were transferred to liquid 
nitrogen for long-term storage. This freezing procedure ensures gradual freezing of 
the cells allowing better preservation, and improved success when reviving them 
from the low temperature. 
2.6.2. Oxidation Of Corticosterone To 11-Dehydrocorticosterone 
Aliquots of radio-labelled substrate ([3H]4–B) and unlabelled B were mixed and 
reduced to dryness (OFN, 60°C). The residue was dissolved in ethanol (0.01%, v/v) 
in DMEM to achieve concentrations of [3H]4–B (5 nM) and B (25 nM) and this 
medium was applied to the cells for 90 min. Steroids were then extracted from the 
medium as follows. 
2.6.2.1. Extraction Of Steroids From The Medium 
The method from Small et al., (2005) was adapted to give >90% extraction 
efficiency. The extraction was performed using Sep-pak C18 columns (360 mg, 55-
105 µm, Waters, Bedford, UK), attached to an empty syringe (2 ml) and a vacuum 
chamber, and further prepared for extraction by washing with methanol (2 ml), then 
water (5 ml), under a mild vacuum. Medium was passed through the column and the 
steroids retained. The columns were washed with water (5 ml) and steroids were 
eluted with methanol (2 mls). The eluate volume was reduced to a half, under OFN 
(60°C) and steroids were further extracted into ethyl acetate (2x3 ml, 400 rpm, RT). 
The organic phase was reduced to dryness (OFN, 60°C) and residues stored at –20°C 
until analysis by HPLC with radiodetection (see section 2.12.2.1). 
2.6.3. Oxidation Of 7-Hydroxycholesterol To 7-Ketocholesterol 
Freshly made DMEM containing stripped-FCS (10%, v/v) was used to prepare test 
solutions of unlabelled 7OHC (1 µM, 0.01% v/v ethanol). Cells were incubated (6 – 
24 h, 37°C) and oxysterols were extracted from the medium and cells as follows: 




2.6.3.1. Extraction Of Oxysterols From The Medium 
Medium was removed from cells into a glass vial (20x1.5 cm) and a mixture of 
deuterium-labelled internal standards, d7-7-KC (2 µg/50 µl) and d7-7OHC (0.5 
µg/50 µl) was added in a single aliquot (50 µl). Argon gas was flushed through all 
samples, and oxysterols were extracted (3x3 ml, 400 rpm, RT, 15 min) from DMEM 
media with a mixture of hexane:2-propanol (60:40), and from Ham’s F12 medium 
with chloroform:methanol (2:1). The organic phases were combined, evaporated 
under the stream of argon (RT) and residues dissolved in chloroform:methanol (2:1, 
350 µl), then stored at -20°C until analysis by GC/MS (see section 2.13). 
2.6.3.2. Extraction Of Oxysterols From The Cells 
After removing the medium, cells were washed in ice-cold PBS (twice, 2 ml/well) 
and lysed (200 µM, NaOH, 0.6 ml/well) by rocking the plate (60 rpm, 4°C, 20 min). 
The contents of each well were forced through a pipette tip repeatedly, for dispersal. 
An aliquot (100 µl) was removed for determination of protein concentration, and ice-
cold PBS with EDTA (200 µM, 0.5 ml) was added. This step was proven necessary 
by Brown et al., (2000b) as it increases extraction efficiency of 7-KC from cells by 
30%. Internal standards were added as described for media (section 2.6.3.1) and 
oxysterols immediately extracted (400 rpm, RT, 2 min) from lysed cells into 
methanol (2.5 ml) and hexane (10 mls). Phase separation was achieved (1000  g, 
4°C, 10 min) and the organic (upper) phase was removed and evaporated under 
argon (RT). The dried residues were dissolved in chloroform:methanol (2:1, 100 µl) 
and stored at –20°C until analysis by GC/MS (see section 2.13). 
2.6.4. Reduction Of 11-Dehydrocorticosterone To Corticosterone 
2.6.4.1. Preparation Of [3H]4 - 11-Dehydrocorticosterone 
[3H]4–11-dehydrocorticosterone (A) was always prepared from a freshly opened 
stock of [3H]4–corticosterone (B) in the following reaction mixture: 




[3H]4–B (50 µl, 4 µM), NAD
+ (200 µl, 25 mM) and placental homogenate (300 µl, 
section 2.4.4) were mixed in ‘C’ buffer (5 ml, final volume). The reaction was 
prepared in glass tubes, split between 3 tubes (~1.7 ml each) and incubated in a water 
bath with gentle rocking (60 rpm, 37°C, 4 h). Steroids were extracted into ethyl 
acetate (3x5 ml), by vortexing (400 rpm, RT, 2 min), and upper phases were 
combined and reduced to dryness (OFN, 60°C). The dry residue was dissolved in 
toluene (300 µl). To assess whether the conversion of [3H]4–B → [
3H]4–A was 
complete, an aliquot of product was analysed by HPLC (as in section 2.12). The 
concentration of [3H]4–A was calculated by measuring cpm/µl of radioactive 
emissions and comparing with that of initial [3H]4–B of known concentration. 
Cpm/µl were assessed by scintillation counting in the presence of scintillation fluid 
(3 ml, Meridian, Surrey, UK). 
2.6.4.2. Incubation With [3H]4 - 11-Dehydrocorticosterone 
Radio-labelled substrate ([3H]4–A, 5 nM, prepared as in section 2.6.4.1) together 
with unlabelled A (25 nM) was added to cells in medium exactly as described for the 
dehydrogenase reaction (2.6.4), with the exception of shorter incubation time (60 
min). 
2.6.5. Reduction Of 7-Ketocholesterol To 7-Hydroxycholesterol 
Cells were treated with 7-KC (1 µM, 0.01% v/v, ethanol) instead of [3H]4–A and A 
exactly as given in section 2.6.4. 
2.6.6. Controls And Quantitation 
Individual experiments were performed using cells from four separate passages. As a 
control, CHO and HEK cells not transfected with m11HSD1 were also used in 
order to account for residual levels of steroids or oxysterols in these cells. Cells 
transfected with m11HSD1 protein were also treated with medium containing 
ethanol (0.01%) as a vehicle, in place of [3H]4–steroid or 7-oxysterol, and a control 
with medium alone without cells was also included. One 6-well plate typically 
contained 7-KC, 7OHC and ethanol treatment (2 ml/well) or [3H]4–A, [
3H]4–B and 




ethanol treatment (2 ml/well). Treatments were performed in duplicate. For 
quantitation of oxysterols, standard curve samples were incubated on a 24-well plate, 
in duplicate. Medium (1 ml) with known concentrations of both 7OHC and 7-KC 
(5, 25, 50, 125, 250, 500 and 1000 nM each) were incubated together and separately 
(1000 nM, 7-KC or 7OHC only) for the duration of treatment. A new standard 
curve was generated during each assay to control for subtle differences in incubation 
and extraction of oxysterols from the medium. 
2.6.7. Metabolism Of Oxysterols By 11HSD1 In Cell Lysates 
HEK cells and CHO cells both stably transfected with m11HSD1 were used to 
prepare cell lysates. 
 
Cells were washed in ice-cold PBS, scraped off T75 cm2 flask with a plastic scraper 
and ‘TG1’ lysis buffer (2 ml) was added. Cells were lysed by rocking the plate (60 
rpm, 4°C, 20 min). Supernatant from the lysed cells was collected after 
centrifugation (4, 000  g, 4°C, 10 min) and stored in aliquots (500 µl) at –80°C. A 
further aliquot (50 µl) was removed for determination of protein concentration 
(Section 2.4.7).  
2.6.7.1. Reduction Of 7-Ketocholesterol To 7-Hydroxycholesterol 
The assay of 7-KC conversion to 7OHC was performed as described (section 2.5.5) 
for recombinant protein, with minor modifications. Cell lysates (50-100 µg/ml) were 
utilised with unlabelled 7-KC (500 nM - 5 µM) and radio-labelled substrate [3H]3–7-
KC (5 nM) and the reaction was incubated for 30 min. 
2.6.7.2. Controls And Quantitation For Cell Lysates 
The ‘Blank’, ‘No-cofactor’, ‘Just protein’ and un-labelled substrate controls were 
included per assay as described for murine recombinant protein (section 2.5.6). In 
addition, radiolabelled substrate, [3H]4–A, was used at a single concentration (5 nM) 
as a control for chemical degradation in the assay. 




2.7. Metabolism Of Steroids And Oxysterols By Microsomal 
11HSD1 Protein 
Hepatic microsomes were prepared as described in section 2.4.2. 
2.7.1. Oxidation Of Corticosterone To 11-Dehydrocorticosterone 
The 11HSD1 dehydrogenase reaction (B→A) mixture included: [3H]4–B (5 nM), 
unlabelled B (20 - 1000 nM), mouse hepatic microsomes (200 – 400 µg/ml) and 
NADP+ (2 mM), incubated in Krebs buffer (250 µl, final volume, 37°C, 30 min). The 
reaction was stopped by freezing (-20°C) or adding ethyl acetate (10x volume) into 
which steroids were extracted and the organic phase reduced to dryness (OFN, 
60°C). Dried residues were stored at -20°C until analysis by HPLC –radiodetection 
as described (section 2.12.2.1). 
2.7.2. Oxidation Of 7-Hydroxycholesterol To 7-Ketocholesterol 
The dehydrogenation of 7OHC to 7-KC was performed in phosphate buffer rather 
than Krebs. The reaction mixture contained: 7OHC (0.02 - 20 µM), mouse hepatic 
microsomes (200 - 400 µg/ml) and NADP+ (2 mM), incubated in phosphate buffer 
(250 µl, final volume, 37°C, 30 min-1h). The reaction was stopped by freezing  
(-20°C) or adding petroleum ether (10x v/v) then internal standards C4 (5 µg/ml) and 
19OHC (10 µg/ml) were added and oxysterols extracted (3x, 400 rpm, RT, 2min). 
Collated extracts were evaporated under argon and residues were stored at –20°C 
until analysis by HPLC – UV (section 2.12.1.2). 
2.7.3. Reduction Of 11-Dehydrocorticosterone To Corticosterone 
The reductase assays with mouse hepatic microsomes were set up as described for 
dehydrogenase (section 2.7.1) using [3H]4–A substrate (5 nM) and unlabelled A (20 – 
1000 nM), in place of [3H]4–B, and B; and the NADPH cofactor generating system 
(2 mM, section 2.5.4.1) instead of NADP+. Samples were processed as described in 




section 2.7.1 and stored at -20°C until analysis by HPLC – radiodetection (section 
2.12.2.1). 
2.7.4. Reduction Of 7-Ketocholesterol To 7-Hydroxycholesterol 
The reductase assay with mouse hepatic microsomes was set up as in section 2.7.2, 
but using 7-KC rather than 7OHC as the substrate and the NADPH cofactor 
generating system (2 mM, section 2.5.4.1) instead of NADP+. 
2.7.5. Controls And Quantitation 
In all microsomal dehydrogenase assays control samples of ‘Blank’, ‘No-cofactor’ 
and ‘Just protein’ were included and standard curve prepared as described for mouse 
recombinant protein in section 2.5.6.  
2.8. Metabolism Of Steroid And Oxysterols By 11HSD1 In 
Aortae 
For measurement of 11HSD1 activity in the vessel wall, aortic rings were prepared 
as described (section 2.4.5.2). All assays were performed on a 24-well plate by 
incubating the aortic rings (one/well, 37°C, 95% CO2, 5% O2) in DMEM (containing 
supplements as described in section 2.6.2) with [3H]4–steroids or oxysterols, 
typically for 16 - 24 hours. The order in which the rings were utilised was 
standardized and segments were dissected from the aortic arch then immersed in 
DMEM containing EtOH (vehicle), 7-KC, 7OHC, [3H]4–A and [
3H]4–B. 
2.8.1. Oxidation Of Corticosterone To 11-Dehydrocorticosterone 
DMEM containing [3H]4–B (10 nM) was prepared as in section 2.6.3, and was used 
to measure dehydrogenation by aortic rings, as reported previously, Small et al.,  
(2005). The extraction and detection of steroids was performed as described for 
cultured cells (section 2.6.3.1). Dried residues were stored at –20°C until analysis by 
HPLC – radiodetection (section 2.12.2.1).  




2.8.2. Oxidation Of 7-Hydroxycholesterol To 7-Ketocholesterol 
Aortic rings were incubated in DMEM containing 7OHC (1 µM) exactly as 
described for cells (section 2.6.3). 
2.8.3. Reduction Of 11-Dehydrocorticosterone To Corticosterone 
DMEM containing [3H]4–A (10 nM) in place of [
3H]4–B was added to aortic rings as 
in section 2.8.1. 
2.8.4. Reduction Of 7-Ketocholesterol To 7-Hydroxycholesterol 
Aortic rings were incubated in DMEM containing 7-KC (1 µM) as described for 
cultured cells (section 2.6.5). 
2.8.5. Controls And Quantitation 
All assays included vehicle controls (medium containing ethanol (0.01%, v/v) in 
place of [3H]4–steroids or 7-oxysterol), negative controls for tissues (medium and 
steroid or oxysterol without aortic rings) and blank samples (medium alone). For 
quantitation of oxysterols, standard curves were prepared as described in section 
2.6.7. After incubation, aortic rings were removed from each well, blotted on tissue 
paper and weight was recorded for subsequent velocity calculations (pmol/mg/day). 




2.9. Metabolism Of Steroids And Oxysterols By 11HSD2 
2.9.1. h11HSD2 Stably Transfected In CHO Cells 
CHO cells stably transfected with human 11HSD2 (h11HSD2) protein were 
maintained as in section 2.6.1 and used in subsequent steroid and oxysterol reaction 
assays. 
2.9.1.1. Oxidation Of 7-/7α-Hydroxycholesterol To 7-Keto-
cholesterol 
Assessment of dehydrogenation of 7- or 7α- hydroxycholesterols (1 µM) by 
11HSD2 in CHO cells was performed as described for m11HSD1 in HEK cells 
(section 2.6.3). The deuterium-labelled internal standards (d7–7-KC, 2 µg/50 µl and 
d7–7OHC, 0.5 µg/50 µl) were added and samples of cells and medium were 
processed as in sections 2.6.3.1 and 2.6.3.2. Dried organic extracts of oxysterols 
were stored at –20°C for subsequent analysis by GC/MS (section 2.13). 
2.9.1.2. Reduction Of 7-Ketocholesterol To 7-Hydroxy-
cholesterol 
The reduction of 7-KC (1 µM) by h11HSD2 in intact CHO cells was performed as 
described for m11HSD1 in HEK cells (section 2.6.5). Dried organic extracts of 
oxysterols were stored at -20°C for subsequent analysis by GC/MS (section 2.13). 
2.9.1.3. Controls And Quantitation 
In all assays controls were included and samples processed to generate a standard 
curve, as in section 2.6.6. 
2.9.2. Renal Homogenates  
Homogenates of mouse kidneys were prepared as described (section 2.4.3). 




2.9.2.1. Oxidation Of Dexamethasone To 11-Dehydro- 
dexamethasone 
Dexamethasone (DEX, 1 mM, in ethanol) was stored at -20°C, following sonication, 
and ethanolic dilutions were prepared as required. Renal homogenates as a source of 
m11HSD2 protein (200 – 400 µg/ml) were incubated with DEX (40 µM) and 
NAD+ (2 mM) in Krebs Buffer (250 µl, final volume). The internal standard (epi-F, 
10 µg/ml) was added after stopping the reaction. Samples were further extracted 
(section 2.5.2) into ethyl acetate (10x volume) and dried residues processed for 
analysis by HPLC – UV (section 2.12.1.1).  
2.9.2.2. Oxidation Of 7-Hydroxycholesterol To 7-Keto-cholesterol 
The ability of renal m11HSD2 to utilize 7OHC (1 – 20 µM) as a substrate was 
tested as described for DEX in section 2.9.2.1 but the reactions were performed in 
Phosphate Buffer. Internal standards d7-7-KC (2 µg/50 µl) and d7-7OHC (0.5 
µg/50 µl) were added after stopping the reaction. Samples were extracted as 
described for oxysterols with m11HSD1 (section 2.5.3), and evaporated residues 
stored at –20°C until subsequent analysis by GC/MS (section 2.13). 
2.9.2.3. Reduction Of 11-Dehydrodexamethasone To 
Dexamethasone 
Dilutions of 11-dehydrodexamethasone (11-DHDEX) were prepared from stock (1 
mM, in ethanol) as required. The reductase assay mixture was as described (section 
2.9.2.1) except for 11-DHDEX (40 µM) and NADH (2 mM) cofactor used in place 
of DEX and NAD+. Samples were further extracted as described in section 2.9.2.1 
and processed for analysis by HPLC – UV (section 2.12.1.1).  




2.9.2.4. Reduction Of 7-Ketocholesterol To 7-Hydroxy-
cholesterol 
Reduction of 7-KC (1 µM – 20 µM) by m11HSD2 substrate was assessed in 
phosphate buffer instead of Krebs, as described (section 2.9.2.3). Internal standards 
d7-7-KC (2 µg/50 µl) and d7-7OHC (0.5 µg/50 µl) were added after stopping the 
reaction. Samples were processed for extraction as described (section 2.5.5) and 
evaporated residues stored at –20°C for analysis by GC/MS (section 2.13). 
2.9.2.5. Controls And Quantitation 
Control samples were included and standard curves prepared for subsequent 
quantitation of steroids and oxysterols exactly as described (sections 2.5.6 and 2.6.6). 
2.10. Functional Studies In Isolated Mouse Aortae 
Small vessel wire myography (JP Trading, Denmark) was used to study isolated 
aortic ring preparations in order to measure responses to pharmacological agents. 
The response, as isometric force (mN), was measured in a Multi-Tissue wire 
myograph system 700MO (Danish Myo Technology, Copenhagen, Denmark) with 
four parallel chambers (6 ml) and data captured using MabLab/4e analogue-digital 
converter and displayed through ChartTM v3.6/s software (AD Instruments, Sussex, 
UK). 
2.10.1. Suspending Vessels In The Myograph 
Intact aortae were prepared for myography as described (section 2.4.5). Arterial rings 
(1.5 – 2 mm) were suspended between two parallel, intra-luminal wires, which were 
tightly secured onto a myograph (Mulvany and Halpern, 1976). Care was taken to 
prevent damaging the endothelium when inserting the wires (for de-
endothelialisation see section 2.10.2). Rings were suspended in four parallel 
chambers (6 ml, one ring per chamber) containing oxygenated (95% O2, 5% CO2) 
PSS (37°C) at all times. 





The most common method for removing the endothelium from small arteries is by 
mechanical disruption, usually by rubbing the luminal surface with a wire. Once the 
aortic rings were suspended in the myograph chamber, vessels were slightly 
stretched and a stainless steel Minutien pin (external diameter 150 µm; FST, 
Interfocus) was advanced into the lumen and used to gently rub the endothelial 
surface, taking care to minimize damage to the adjacent smooth muscle cells. 
2.10.3. General Experimental Protocol 
After mounting, the aortic rings were equilibrated in oxygenated buffer (95% O2 and 
5% CO2, 37°C), stretched to their optimum resting force (7.36 mN) (Bagnall et al., 
2006) and allowed to equilibrate (37°C, 20 – 30 minutes). As a standard initial 
procedure, maximum receptor-independent constriction in response to potassium 
(K+) was obtained by contracting the vessels three times with high potassium (125 
mM) buffer (KPSS). Subsequently, cumulative concentration-response curves were 
obtained in each vessel for 5HT (10-9 – 10-4 M) and a suitable concentration selected 
to produce 80% of the maximum response (EC80; 5HT, 3x10
-7 M, Figure 2.10–1). 
Subsequently, concentration-response curves were generated for acetylcholine (ACh, 
10-9 – 10-4 M), sodium nitroprusside (SNP, 10-10 – 10-3 M), noradrenaline (NA, 10-9 – 
10-4 M) and KPSS. Responses to vasodilators were obtained following sub-maximal 
contraction (EC80) with 5HT (Figure 2.10-1). 
 
In all experiments four aortic rings were used from each mouse; two with the 
endothelium undisturbed and a two from which the endothelium had been removed. 
Denudation was confirmed by the lack of relaxation to ACh following contraction 
with 5HT. The effect of 7-oxysterols on arterial function was further assessed by 
incubating the aortic rings with 7-KC or 7OHC in tissue culture medium. All 
contractions were expressed as force (mN) and as a percentage of the maximum 
contraction in response to KPSS; relaxations were expressed as a percentage of the 
contraction in response to EC80 5HT. Data were expressed as the average of two 
aortic rings for each animal. 










Figure 2.10-1 Determining the EC80 for 5HT in endothelium intact and denuded 
aortae. 
Cumulative concentration response curves to 5-hydroxytryptamine (5HT). Isometric force in 
response to 5HT (10-9 – 10-4 M) was measured in isolated mouse aortic rings with denuded 
(E-) or intact (E+) endothelium (E). All contractions were expressed as a percentage of the 
maximum response to KPSS. The concentration of 5HT giving 80% of the maximum 
contraction was selected (EC805HT, 3x10
-7 M). All data are mean ± SEM, n=8, in duplicate. 




2.11. Extraction Of Oxysterols From Biological Fluids And 
Tissue 
The detailed description of method development for processing of plasma and 
biological fluids is given in section 6.5.1. Internal standards were added to all 
samples prior to extraction (section 2.11.1). After each step of extraction, the dried 
residue was stored under argon at –80°C until further processing for GC/MS.  
2.11.1. Extraction From Mouse Plasma 
a) Solvent extraction 
All solvent mixtures (section 2.2.2) and mouse plasma samples (300 – 500 µl; 
section 2.4.6) were prepared as described. Argon was flushed through all samples 
and internal d7 standards were added (40 ng d7-7-KC, 10 ng d7-7OHC and 1 µg 
d7-cholesterol; total volume 50 µl). Oxidized cholesterols were extracted (twice) into 
diethyl ether in hexane (3 ml, 2:3). Samples were placed under argon, sealed and 
mixed vigorously (400 rpm, 4°C, 10 min). This step was repeated with each 
extraction. Organic phases were separated (1000  g, 4°C, 10 min), collated and 
evaporated under argon (RT). Once dissolved in toluene:ethyl acetate (1 ml, 1:1 
mix), samples were processed through a solid phase extraction (SPE). 
b) Solid-phase extraction (SPE) 
Samples were prepared for gas-chromatography using solid phase extraction 
(Simpson et al., (1992), Tippens et al., (1988)). Samples (1ml) were applied to 
“Diol” columns (2OH, Bond Elute, Varian, 100mg, 1ml), which were pre-
conditioned with toluene:ethyl acetate (2 ml, 1:1 mix). Oxidized cholesterols were 
eluted from the column with the same mix (2 ml) followed by chloroform (1ml). 
Total eluate (4 ml) containing cholesterol and cholesterol oxides was collected under 
mild vacuum. The samples were dried (argon, RT), dissolved in diethyl ether (2 ml) 
and subjected to hydrolysis. 




c) Hydrolysis (Saponification) 
In order to avoid decomposition of cholesterols and cholesterol oxides a modification 
of the methods of Brown et al., (1997) and Hodis et al., (1991) were applied 
involving mild ice-cold saponification, by incubating samples (60 rpm, 4°C, 2 h) in 
the dark (Tsai, 1984). In brief, samples were dissolved in diethyl ether (2 ml), and 
methanolic KOH (0.5 ml, 20% w/v) was added. Samples were sealed under argon, 
then covered in tin foil and mixed (60 rpm, 4°C, 2h). 
d) 2nd Solvent extraction 
Upon hydrolysis, the mixture was neutralized (pH 7.4) with acetic acid (300 µl, 20% 
v/v). Water (0.5 ml) and NaCl (0.15 M, 0.5 ml) were added to each sample to allow 
phase separation. Oxidized lipids were obtained following double extraction into the 
upper diethyl ether layer (400 rpm, RT, 2 min). Upon centrifugation (1000 , 4 °C,  
5 min) upper phases were collated and dried (argon, RT), then stored at  -20°C until 
further analysis by GC/MS (Section 2.13.2). 
  
It has been suggested by Csallany et al., (1989) and shown by Brown et al., (1997), 
that the analytical stages described should be performed rapidly, at low temperature, 
and in the absence of light (hydrolysis) and oxygen (by using argon gas), since the 
mere act of analysis may contribute to artefact formation during sample processing. 
2.11.2. Extraction From Tissues 
Aortic tissue (section 2.4.5.1) was homogenized under a stream of argon in 
chloroform:methanol (2:1 v/v) (Brown et al., (1997)). Internal standards (d7, section 
2.11.1) were added and oxysterols extracted (400 rpm, 2 min, RT) into the solvent 
mixture (2x). After the phase separation (1000  g, 4°C, 10 min), total lipids were 
collected in the solvent, evaporated under argon, re-dissolved in toluene:ethyl acetate 
and processed further as described for plasma samples (section 2.11.1). 




2.11.3. Extraction From Subcellular Fractions 
Extraction of oxysterols from cytosols or microsomal preparations (200 µg/ml), was 
achieved as described for plasma (section 2.11.1) with the single exception that 
200µl of the sub-cellular fraction was used as the starting material. 
2.11.4. Quantitation 
To determine concentrations of oxysterols in a mix, a standard curve was produced 
using a range of stock solutions of 7-oxysterols (0.005 – 200 µM) and cholesterol 
(0.05 – 2 mM), by adding each stock (10 µl) into H2O (500 µl) instead of sample. 
The internal standards (hepta-deuterated isomers, d7) were added as described 
(section 2.11.1) and processed identically. The values obtained were adjusted for the 
initial volume used in order to calculate the measurements in ng/ml plasma or ng/mg 
protein, as appropriate. 
2.12. Liquid Chromatographic Analyses Of Steroid And 
Oxysterols 
Radiolabelled substrates and products were detected by HPLC with online 
scintillation counting (HPLC – radiodetection). Unlabelled steroids and oxysterols 
were detected by HPLC with UV detection (HPLV – UV) or by GC/MS. When dried 
residues (from the assays described in sections 2.5 – 2.8) were analysed by HPLC–
UV, the identity of the peaks was also confirmed by GC/MS. Because components of 
DMEM caused interference with the HPLC–UV trace of 7OHC, samples from cell-
culture experiments were analysed by GC/MS only. The analytical conditions of 
chromatographic analyses were established and subsequent detection was performed 
as described (sections 2.12.1 – 2.13). 




2.12.1. HPLC With UV-Detection 
Unlabelled steroids and oxysterols were analysed using an HPLC-UV (Dionex, UK) 
system equipped with the photodiode array detector (PDA-100) with a UV/visible 
detection range (λ192 - 600 nm). The system comprised an autosampler (ASI-100) 
and a mobile phase pump (P680), linked to a C18 SunFire column (column length 15 
cm, internal diameter 4.6 mm, pore size 5 µm, Waters, Edinburgh, UK) and column 
heater (Igloo-Cil). Spectra for all compounds were recorded in 3D–scan mode 
(retention time vs. absorbance value vs. wavelength) and their absorption maxima 
and elution times determined for subsequent analysis. The system was controlled by 
the Chromeleon computer programme (ν6.7, Dionex, UK). 
2.12.1.1. Elution Of Steroids 
Steroidal extracts containing A and B were dissolved in mobile phase (0.45 ml, 60% 
water : 15% acetonitrile : 25% methanol) and an aliquot (120 – 200 µl) of each was 
injected into the Dionex HPLC UV-system. The total run time for steroid separation 
was 35 min at 35°C and 1.0 ml/min flow rate. Elution times of epi-F, A and B were 
typically 11.9, 19.4 and 29.5 min respectively. Elution times of epi-F, 11-DHDEX 
and DEX were typically 10.4, 16 and 19.8 min, respectively using 55% water : 20% 
acetonitrile : 25% methanol, mobile phase at 40°C and with 1.5 ml/min flow as 
shown in Figures 2.12 – 1 and 2.12 – 2. 









Figure 2.12-1 HPLC chromatogram of unlabelled steroid standards.  
11α-hydrocortisone (epi-F), 11-Dehydrocorticosterone (A) and corticosterone (B) were 
detected at 244 nm and separated at 35°C using water 60% : acetonitrile 15% : methanol 
25% mobile phase, at a flow rate of 1 ml/min. mAU, Mili ampere  
units mV; HPLC, High performance liquid chromatography. 








Figure 2.12-2 HPLC chromatogram of unlabelled steroid standards. 
Dexamethasone (DEX), 11-dehydrodexamethasone (11-DHDEX) and 11-hydrocortisone 
(epi-F) were detected at 244 nm and separated using water 55% : acetonitrile 20% : 
methanol 25% mobile phase (40°C, flow rate of 1.5 ml/min). mAU, Milli ampere units, mV; 
HPLC, High performance liquid chromatography. 
 
 
2.12.1.2. Elution Of Oxysterols 
Evaporated residues of oxysterol extracts were dissolved in mobile phase (0.45 ml, 
5% water : 95% acetonitrile) and an aliquot (150 – 200 µl)  was injected onto the 
Dionex HPLC UV-system. Oxysterols were eluted under isocratic conditions at a 
flow rate of 1.0 ml/min at 24°C. The total run time separation of oxysterols was 20 
min. Typical individual elution times were: Rt 14.5 min (7αOHC), Rt 14.9 min 
(7OHC) and Rt16.4 min (7-KC), and for their internal standards Rt 12 min (C4), and 
19 min, (19-OHC) as seen in Figure 2.12 – 3. Where necessary for the separation of 
7αOHC and 7OHC in the same assay, the peaks were also resolved using GC/MS 
(section 2.13) and absolute peak identity confirmed as shown (section 2.13). 







Figure 2.12-3 HPLC chromatogram of unlabelled oxysterol standards.  
All oxysterols were detected between 200-240 nm. 7-Ketocholesterol (7-KC) and 4-
cholestenone (C4) exhibited absorption maxima at 237 nm (black line) and 7-
hydroxycholesterol (7OHC) and 19-hydroxycholesterol (19-OHC) at 200 nm (blue line). All 
oxysterols were separated at 24°C using water 5% : acetonitrile 95% mobile phase at a flow 





2.12.1.3. Detection Of Steroids And Oxysterols 
Peaks were less than 1.5 min wide and peak height was 50x background. All steroids 
(epi-F, A, B, DEX and 11-DEX) were detected at 244 nm. Oxysterols were detected 
at 237 nm (7-KC and C4) and 200 nm (hydroxy-cholesterols) 





A standard curve was produced with each experiment to determine concentrations of 
oxysterols. Standard curves were prepared using a range of stock solutions (0.2 – 200 
µM) by adding a stock (10 µl) to H2O (500 µl) to obtain minimum of eight points. 
The quantities of oxysterols obtained were adjusted for the initial volume used in 
order to calculate the measurements in nmol/ml assay. Standard curve samples 
containing known concentrations of analyte were exposed to the same procedures as 
the samples under investigation. The dried residues were dissolved in the relevant 
mobile phase (60% water : 15% acetonitrile : 25% methanol for steroids; and 95% 
acetonitrile : 5% water for oxysterols). An internal standard, which absorbed at the 
same absorbance maximum as other steroids (244 nm), was used (e.g. epi-F to 
quantify A and B). If analytes within same assay absorbed light at two different 
wavelengths, then two internal standards were used (e.g. C4 at 237 nm with 7-KC 
and 19OHC at 200 nm with 7αOHC and 7OHC). After confirming the identity of 
peaks of interest and related internal standards, areas under the peaks were 
integrated. For each amount on the standard curve, the mean of duplicates was 
calculated for the ratios of peak areas over that of the related internal standard and 
plotted against the known amount. Regression lines were fitted and deemed 
acceptable if R  0.99. Steroid or sterol peaks of unknowns were integrated in the 
same way and ratios of area under the peak to internal standard were interpolated 
onto the standard curve to obtain the amount of analyte present. In the case of 
enzyme kinetics, the amount of product (pmol) was divided by time of incubation 
(min) and specific protein concentration (mg) used in the assay. This value was used 
as a measure of the reaction velocity (pmol/mg/min). Exemplar standard curves for 
quantitation of steroid and oxysterols are shown (Figures 2.12 – 4 and – 5). 









Figure 2.12-4 Standard curve for quantitation of steroids detected by HPLC–
UV.  
The standard curves representing the ratio of area of peaks 11-dehydrocorticosterone/epi-F 
(dashed line) and corticosterone/epiF (full line) plotted against known amounts of 11-
dehydrocorticosterone and corticosterone standards (nmol) at 244nm. The calibration lines 
were generated by linear regression. epiF, 11-hydrocortisone.  









Figure 2.12-5 Standard curve for quantitation of 7-oxysterols detected by 
HPLC–UV.  
The Standard curves representing the area of peak ratios 7-ketocholesterol/C4 (full line, 237 
nm) or 7-hydroxycholesterol/19OHC (dashed line, 200 nm) plotted against known amounts 
of 7-ketocholesterol or 7-hydroxycholesterol (ng) standards. The calibration lines were 
generated by linear regression. C4, 4-cholesten-7-ol-3-one; 19-OHC, 19-hydroxy-
cholesterol. 




2.12.2. HPLC With Radio-Labelled Detection 
Radio-labelled steroids and sterols were separated using reverse phase HPLC 
(Waters, UK). The system comprised an autosampler (717 plus) and a mobile phase 
pump (pump600, Berthold, UK), equipped with C18 Sunfire Symmetry column 
(column length 15 cm, internal diameter 4.6 mm, pore size 5 µm, Waters, Edinburgh, 
UK), column heater, and radioflow detector (LB509, Berthold) linked to a 
scintillation fluid pump. The system was controlled by the Chromeleon computer 
software (ν6.7, Dionex, UK). 
2.12.2.1. Elution Of Steroids 
Dried residues of steroidal extracts were dissolved in 0.8 ml mobile phase (60% 
water : 15% acetonitrile : 25% methanol) and an aliquot (60 - 100 µl) of each was 
injected into the HPLC system. The total run time for steroid separation was 35 min 
at 35°C and 1.0 ml/min flow rate. Elution times of [3H]4–A and [
3H]4–B were 
typically 12.4 and 17.5 min respectively (Figure 2.12 – 6). An additional peak at 13 
min (always less than 6% radioactivity) was present in some assays, when [3H]4–A 
was incubated with microsomal protein, but not in the ‘Blank’ control samples 
(lacking protein). This peak was believed to be a metabolite of [3H]4–A (e.g. 20-
dehydro-11-dehydrocorticosterone), but a standard was not available for 
confirmation. 









Figure 2.12-6 HPLC radio-chromatogram of [3H]4–steroid detection.  
Steroids ([3H]4–11-dehydrocostrticosterone, A and [
3H]4–costrticosterone, B) were extracted 
and dissolved in mobile phase (0.8 ml) of 60% water : 15% acetonitrile : 25% methanol 
(v/v/v). Sample was then injected into an HPLC system and steroids eluted using the same 
mobile phase at 1.0 ml/min flow rate, at 35°C. Separation of [3H]4–A and [
3H]4–B was 
achieved (bottom) with the approximate retention times (Rt 12.4 min and 17.5 min 
respectively). Control sample (‘Blank’) had no protein and, as expected, only substrate [3H]4-
B was detected (top). HPLC, High performance liquid chromatography. 




2.12.2.2. Elution Of Oxysterol 
Evaporated residues of radio-labelled oxysterol extracts were dissolved in mobile 
phase (0.8 ml, 15% water : 85% acetonitrile) and an aliquot (200 µl) of each was 
injected onto the HPLC. Oxysterols were eluted under isocratic conditions at a flow 
rate of 1.5 ml/min at 28°C. The total run time for oxysterol separation was 25 min 
with individual elution times of [3H]3–7-KC and [
3H]3–7OHC typically at 16 and 19 
min, respectively (Figure 2.12– 7). 
 
2.12.2.3. Detection Of Steroids And Oxysterols 
Detected peaks were less than 2 min wide and considered detectable if peak height 
was 5x background.  
2.12.2.4. Quantitation 
Steroids and sterols were quantified by on-line liquid scintillation counting (2 ml/min 
scintillation fluid). Detected peaks were integrated and relative peak area (%) 
recorded for the substrate and product. The amount of product formed (pmol) from a 
known amount of substrate (pmol) was then calculated and the values expressed per 
time of incubation (min) and specific protein concentration (mg) used in the assay. 
This value was then used as a measure of reaction velocity (pmol/mg/min). 
 









Figure 2.12-7 HPLC radio chromatogram of [3H]3–oxysterol detection.  
Oxysterols ([3H]3–7-Ketocholesterol, 7-KC and [
3H]3–7-hydroxycholesterol, 7OHC) were 
extracted and dissolved in 0.8 ml mobile phase of 15% water : 85% acetonitrile (v/v). An 
aliquot (200 µl) was then injected into an HPLC system and oxysterols eluted using the 
same mobile phase at 1.5 ml/min flow rate, at 28°C. [3H]3–7OHC and [
3H]3–7-KC were 
eluted at 16.9 and 19.5 min, respectively (bottom). The control sample (‘Blank’) had no 
protein and, as expected, only substrate [3H]3-7-KC was detected (top). HPLC, High 
performance liquid chromatography. 




2.13. Gas Chromatography-Mass Spectrometry (GC/MS) 
Gas chromatography-mass spectrometry (GC/MS) has been (Dzeletovic et al., 
(1995b), Dzeletovic et al., (1995a)) and is (Endo et al., (2008); Larsson et al.,  
(2007)) used extensively for plasma and tissue oxysterol analysis. The advantage of 
this technique is an exquisite power of separation. In addition the electron impact 
(EI) spectra provide further information regarding identity of analytes. The ultimate 
sensitivity in detection of 7-oxysterols is achieved when analysis is performed with 
the MS instrument operating in selective ion monitoring mode (SIM) combined with 
the capillary GC column for separation. However, pre-treatment (derivatisation) of 
the samples is necessary to render the oxysterols volatile. 
2.13.1. Gas Chromatography Conditions 
A capillary gas chromatograph (Trace GC, Thermo) coupled to an ion-trap, Polaris Q 
(Thermo, Hemel Hempstead, UK) mass spectrometer (MS) and equipped with a 
BPX5 capillary column (25 m, 0.32 mm internal diameter and 0.25 µm film 
thickness, from SGE, Alva, UK) was used for analysis. Helium was used as the 
carrier gas at a flow rate of 1 ml/min. The Polaris Q MS was operated using Xcalibur 
(ν10.0) software.  
 
The GC conditions were optimized as follows. The initial temperature was optimized 
at 180°C, near the boiling point of decane (174°C) in which samples were finally 
dissolved. The injector temperature was optimized at 270°C. Mass spectra were 
recorded at an electron ionisation energy of 70eV with an ion source temperature of 
200°C and an interface temperature of 250°C. All samples were prepared for 
injection in decane containing 2% BSTFA (80 µl) to ensure stability of derivatized 
sterols. 




2.13.2. Optimized Method 
The following final two methods were used in this thesis for analysis and oxysterol 
detection in the samples from tissue culture experiments (Method 1) and in 
biological fluids and tissues (Method 2). 
Method 1 – Analysis of cell culture samples. 
BSTFA and 1 % pyridine, 100 µl (Endo et al., (2008)) were added to the dried 
residue (60°C, 30 min) under argon in silanized reacti vials (as in section 2.2.2). 
Following derivatisation, samples were dissolved in decane (2% BSTFA) and 
transferred to GC/MS amber vials with inserts. The derivitised oxysterols were 
eluted using the following oven programme: initial temperature 180°C (1min), 
increased by 20°C/min until 300°C (1min) and then by 5°C/min until 330°C (8 min). 
The oven was then cooled by -10°C/min to 250°C (1 min). 
Method 2 – Analysis of biological fluids and tissues 
The dried residue (60°C) was incubated (30 min) with 350 µl pyridine : HMDS : 
TMCS (3:2:1, v/v/v;  Dzeletovic et al., (1995b), Larsson et al., (2007)) under argon 
and derivatized samples dissolved in 2% BSTFA in decane before being transferred 
into GC/MS amber vials with inserts. The derivitised oxysterols were eluted using a 
method modified from Larsson et al., 2007, oven programme – initial temp: 180°C 
(1min), increased by 35°C/min until 270°C (1min), then by 4°C/min until 300°C and 
temperature maintained for 12 min. 
2.13.3. Detection Of Oxysterols And Cholesterols 
Both GC chromatograms and mass spectral fragmentation patterns of trimethylsilyl-
ether derivatives of analytes were obtained using authentic standards. The mixture of 
d7 standards (1ml) was prepared from d7-7OHC (200 ng/µl, 50 µl) and d7-7-KC 
(200 ng/µl, 200 µl) in ethanol containing 50 µg/ml BHT. Of this solution, an aliquot 
(50 µl) was used for quantifying oxysterols (as in section 2.13.4). 





Full and SIM scans of ions were generated for all derivatized compounds: examples 
of spectra and SIM mass chromatograms of the derivatized-7oxysterols and 
cholesterol are shown in Figures 2.13 – 1 and –2. Derivatized 7αOHC and 7OHC 
had base peaks of m/z 456. Derivatized-7-KC had a base peak at m/z 472, while 
cholesterol yielded m/z 368. All of the compounds had characteristic retention times 
(Table 2 - 1). 
2.13.4. Quantitation 
Limits of detection were assigned as 3:1 signal to noise ratio. The area of the peak of 
the analyte was integrated and divided by that of the internal standard and compared 
to ratios generated from the standard curve. Lines of best fit were drawn to generate 
a standard curve of peak area ratio versus known amount (acceptable if R  0.99) and 
quantities of the unknown interpolated from the line. This value was used as a 
measure of the reaction velocity (pmol/mg/min) and levels (ng/ml fluid or ng/mg 
tissue). The amount of product detected in samples (pmol) was expressed over the 
time of incubation (min) and specific protein concentration (mg) in the assay or 
related to the volume of fluid/tissue analysed.  
2.14. Statistical Analysis 
All data in this thesis are presented as mean ± standard error of the mean (SEM) with 
statistical analysis stated in individual chapters. Student’s t-test, one-way or two-way 
ANOVA with Dunnett’s or Tukey’s post hoc test were performed, as appropriate, 
and data were analyzed using GraphPad Prism software v5.0 (GraphPad Software 
Inc. San Diego, USA, www.graphpad.com). Statistical significance was assumed 
when p < 0.05. 




            
 
Figure 2.13-1 GC/MS spectra of derivatized 7-oxysterols and cholesterol. 
Following analysis by gas chromatography mass spectrometry (GC/MS), the mass to charge 
(m/z) ratios of ions generated by the individual compounds were plotted against their relative 
abundance (%). Analysis was operated in full scan mode to determine the base peaks for 
TMS-7-oxysterols: a) 7OHC, m/z 456; b) 7OHC, m/z 456; c) d7-7OHC, m/z 463; d) 7-
KC, m/z 472; e) d7-7-KC, m/z 479), and TMS-cholesterols: f) Cholesterol, m/z 368; g) d7-
cholesterol, m/z, 375. 









Figure 2.13-2 GC/MS chromatograms of derivitised 7-oxysterols and 
cholesterol.  
The gas chromatography (GC) mass spectrometer was programmed in selective ion 
monitoring (SIM) mode to detect the following ions of TMS-7-oxysterols: 7-
hydroxycholesterol, 7OHC (m/z 456, 12.39 min); 7-hydroxycholesterol, 7OHC (m/z 456, 
14.09 min); deuterium-labeled 7OHC, d7–7OHC (m/z 463, 13.98 min); 7-ketocholesterol, 
7-KC (m/z 472, 17.83 min); deuterium-labeled 7-KC, d7–7-KC (m/z 479, 17.69 min); 
Cholesterol (m/z 368, 12.99 min) and deuterium-labeled cholesterol, d7–cholesterol (m/z 
375, 12.88 min). The relative abundance of each derivatised-compound was determined at 
an elution time (min) as given. m/z, mass to charge ratio. 









The most abundant ions of trimethylsilyl derivatives of cholesterol and oxysterols (m/z) were 
detected in the selective ion monitoring mode (SIM) mode by gas chromatography mass 







19OHC 353 2.0 11.9 
7OHC 456 4.0 12.83 
d7 – Cholesterol 375 6.0 12.88 
Cholesterol 368 6.0 12.99 
d7 – 7OHC 463 4.0 13.98 
7OHC 456 4.0 14.09 
d7 – 7-KC 479 6.0 17.69 
7-KC 472 6.0 17.83 
C4 472 6.0 20.1 














Chapter 3. Kinetics Of 7-Oxysterol Metabolism By 
11HSD1 





A novel role for 11HSD1 in metabolising 7-oxysterols, was first demonstrated in 
2004 (Hult et al., 2004; Schweizer et al., 2004). Prior to this, Song et al., (1998) 
showed that an NADP+ dependent 7α-hydroxycholesterol dehydrogenase (7αHCD) 
existed in hamster liver microsomes, which generated 7-ketocholesterol (7-KC) from 
either 7α-hydroxycholesterol (7αOHC) or 7-hydroxycholesterol (7OHC). 
Sequence analysis of 7αHCD at this time indicated the protein under investigation 
exhibited a high degree of homology to human 11HSD1 (Song et al., 1998). 
Subsequent work by Hult et al. and Schweizer et al., in 2004 demonstrated direct in 
vitro and in vivo evidence that human and rat 11HSD1 catalyse the inter-conversion 
of 7-KC and 7OHC. Cross-species comparison of reactions catalysed by 11HSD1, 
showed that 7-KC was reduced to 7OHC only, except in hamster in which 7αOHC 
was also formed (Arampatzis et al., 2005). At the onset of the work described in this 
thesis, emerging literature suggested a metabolism of 7-oxysterols by murine 
11HSD1 (Hult et al., 2004) but confirmation that 11HSD1 was the only enzyme 
catalysing this reaction in vivo had yet not been obtained. 
 
In vivo, the predominant direction of 7-oxysterol metabolism by 11HSD1 was 
anticipated to be reduction, as with glucocorticoids, converting 7-KC to 7OHC. 
Indeed, reduction of 7-KC was assigned to the action of rat hepatic 11HSD1 
(Schweizer et al., 2004). However Maeda et al., (2006) reported that microsomal 
11HSD1 utilises 7OHC to form 7-KC in all of the vertebrates tested, but the 
opposite reaction occurs only in rats; again the set-point for the equilibrium had not 
been assessed in mouse. The conversion of glucocorticoids by 11HSD1 in vivo is 
dependent on availability of endogenous cofactor, NADPH, generated by hexose-6-
phosphate dehydrogenase (H6PDH). Both enzymes are localized to the lumen of the 
ER and their direct physical interaction is required for 11HSD1 to act as a reductase 
(Atanasov et al., 2008; Atanasov et al., 2004). Importantly, in mice lacking H6PDH, 
glucocorticoid regeneration by 11HSD1 was abolished (Lavery et al., 2006) but a 
similar effect on metabolism of 7-oxysterols has not been investigated.  




Indeed there are not currently any reports considering the role of H6PDH in cofactor 
supply for metabolism of 7-oxysterols by 11HSD1. Studies with the mutant 
11HSD1 protein have only demonstrated in vitro a crucial role of the N-terminal 
region of the enzyme in determining its luminal orientation in ER. Such orientation 
of 11HSD1 within the ER is essential for efficient oxidation of cortisol as well as 
reduction of 7-KC (Frick et al., 2004). 
 
In addition to proving the metabolic benefit of 11HSD1 inhibition, transgenic mice 
lacking 11HSD1 (11HSD1-/-) have provided a valuable resource to determine the 
precise role of murine 11HSD1 in the metabolism of glucocorticoids (Kotelevtsev 
et al., 1997). Now, the same transgenic model provides a unique source for 
examining the role of murine 11HSD1 in the metabolism of atherogenic  
7-oxysterols. 
3.2. Research Hypothesis And Aims 
Key questions for the work in this chapter were: (1) can murine 11HSD1 catalyse 
the inter-conversion of 7-oxysterols and if so, (2) what is the predominant direction 
of the reaction. Complementary in vitro assays were used to clarify kinetics of this 
inter-conversion. Specific aims were: 
 
• To model, in silico, the potential interactions of 7-oxysterols with murine and 
human 11HSD1 proteins; 
• To determine whether murine 11HSD1 (m11HSD1) has the ability to catalyse 
the inter-conversion of 7-oxysterols, and determine the nature of the preferred 
substrate; 
• To compare the kinetic parameters of metabolism of 7-oxysterols by m11HSD1 
with those of glucocorticoids. 





3.3.1. 3-D Modelling Of 7-Oxysterols Bound To 11HSD1 
The following structures were used as templates to investigate the interactions of 7-
KC, 7αOHC and 7OHC with 11HSD1. All protein structures used were freely 
available from PubMed (www.pubmed.org, NCBI) and the protein database 
(PDB, http://www.rcsb.org/pdb/Welcome.do, NCBI). Sequence alignment was 
performed using ClustalW2 program (Larkin et al., 2007) available from 
www.ebi.ac.uk/tools/clustalw2/index.htm (accessed March, 2010). Accession 
numbers of the 11βHSD1 sequences are as follows: human NM_005525, mouse 
NM_008288, hamster, AY519498. 
 
The 3-D structures of crystalised murine 11HSD1 (m11HSD1, PDB ID: 1Y5M), 
or m11HSD1 in complex with corticosterone (PDB ID: 1Y5R, (Zhang et al., 
2005)), as well as human 11HSD1 (h11HSD1, PDB ID: 2BEL) in complex with 
NADP and carbenoxolone (Wu et al., 2006), were used for in silico modelling. 
Comparisons were made between the orientations of human and murine structures. 
The structure of m11HSD1 (1Y5R) contains both corticosterone and NADP+ 
(Zhang et al., 2005), and was used further to superimpose C7-oxysterol analogues. 
 
In addition, the 1FMC structure of 7α-hydroxysteroid dehydrogenase (EC 1.1.1.159, 
7αHSD) in complex with 7-oxo glycochenodeoxycholic acid was used (Tanaka et 
al., 1996), as it offered an excellent template for modelling the 7α-hydroxyl group, 
thus allowing alignment and positioning of 7α- and 7-hydroxyls and 7-keto groups. 
7αHCD was superimposed with 11HSD1 and the binding of 7-oxo-
glycochenodeoxycholic acid was merged into the structure of 11HSD1 as described 
later (section 3.4.2).  
 
The energy map of substrate binding into the active site of 11HSD1 protein were 
obtained using Autodock (freely available from http://autodock.scripps.edu, GNU 
General Public License). This program uses 3-D protein structure, as imported from 




PDB, to calculate energy maps for binding of a small molecule. Positioning the 
ligand into the site of interest is carried out by an algorithm, which aimed to find 
minimal energy conformations of the ligand in the pocket by rotating and translating 
the molecules. The results of this type of docking are then clustered into groups. The 
“middle" conformation for each cluster is then written out as a result for that cluster 
along with a predicted energy of interaction. Further LIDAEUS software (Taylor et 
al., 2008) kindly provided by Dr Steve Shave (University of Edinburgh, Laboratory 
of enzyme crystallography) was used to define the binding pocket . For visualising 
the structures of enzyme and compounds, the molecular graphics software, PyMOL 
(open source, DeLano Scientific LLC) was used, kindly provided by Dr Iain McNae 
(University of Edinburgh, Laboratory of enzyme crystallography). The distances 
between key functional moieties and catalytic residues in the active site were 
assessed using the same software.  
The 2-D representation of protein-ligand complexes from standard Protein Data 
Bank file input were performed using LigPlot (Wallace et al., 1995). To distinguish 
between the steric orientation of 7α- and 7β-hydroxycholesterols, the 2-D diagrams 
for each molecule were created with MarvinView by ChemAxon 
(http://www.chemaxon.com/products/marvin/marvinview/, accessed April, 2010) 
and used with LigPlot. Both, programs and resultant images were kindly provided by 
Dr Steve Shave (University of Edinburgh, Laboratory of enzyme crystallography). 
 
3.3.2. Oxidation Of 7-Hydroxycholesterol And 7-Hydroxy-   
Cholesterol To 7-Ketocholesterol By m11HSD1 
All oxysterols were prepared in ethanol containing butylated hydroxytoluene (50 
µg/ml), as described (section 2.2.2). The conversion of 7OHC and/or 7αOHC to 7-
KC was studied using the following assays and reaction velocities compared with 
those of conversion of corticosterone (B) to 11-dehydrocorticosterone (A): 
 
a) Recombinant m11HSD1 protein (28 µg/ml) was incubated with 7OHC or 
7αOHC (20 µM) or B (20 - 200 nM) and the cofactor NADP+ (2 mM) as described 
(sections 2.5.3 and 2.5.2, respectively). The kinetic parameters of metabolism of 




each substrate for m11HSD1 were also determined in the presence of NAD+ (2 
mM) instead of NADP+. 
 
b) HEK cells stably transfected to produce m11HSD1 protein were incubated with 
7OHC or 7αOHC (1 µM), as described (section 2.6.3), or with B (30 nM) as in 
section 2.6.2. 
 
c) Murine hepatic microsomes (WT) were used as a source of m11HSD1 as 
described (section 2.7.4). Microsomal protein (240 µg/ml) was incubated with 
7OHC or 7αOHC (20 µM) or with B (20 – 200 nM) and with 2mM cofactor (NAD+ 
or NADP+, as required). Similar experiments were performed using microsomes 
from 11HSD1-/- mice. 
 
d) Aortic rings (WT) express both 11HSD type 1 and type 2 isozymes (Hadoke et 
al., 2001). In this assay, aortic rings were used to investigate oxidation of 7OHC or 
7αOHC (1 µM) by 11HSD1, as well as oxidation of B (30 nM), as described 
(sections 2.8.2 and 2.8.1, respectively). In both assays, samples were incubated with 
the appropriate substrate and without exogenous cofactor, for 20 h. Similar 
experiments were repeated using aortic rings from 11HSD1-/- mice which only 
express 11HSD type 2 (Christy et al., 2003). 
3.3.3. Reduction Of 7-Ketocholesterol To 7-Hydroxycholesterol By 
m11HSD1 
The conversion of 7-KC to 7OHC and/or 7αOHC was studied using the following 
assays and reaction velocities compared with those of A → B: 
 
a) Recombinant m11HSD1 protein (28 µg/ml) was incubated with 7-KC (20 µM) 
or A (20 - 200 nM) and the NADPH (2 mM) generating system (sections 2.5.4.1 and 
2.5.5). To further explore the specificity of cofactor for this reaction, reduction was 
performed in the presence of NADH (2 mM) instead of the NADPH generating 
system. 
 




b) HEK cells stably transfected to produce m11HSD1 protein were incubated 
(37°C, 16h) with 7-KC (1 µM), or A (30 nM) as described (sections 2.6.5 and 2.6.4). 
 
c) m11HSD1 protein, obtained upon lysis of HEK293 cells as in section 2.6.7.1. 
This reaction was performed using protein from lysed cells (100 µg/ml) and radio-
labelled substrate ([3H]3-7-KC, 5 nM) together with unlabelled 7-KC (200 nM,  
1 µM, 20 µM). 
 
d) Murine hepatic microsomes (WT) were used as a source of m11HSD1 as 
described (section 2.7.4). Protein (260 µg/ml) was incubated with 7-KC (1 µM or 20 
µM) or A (20 - 200 nM), and one of the following cofactors, NADH (2 mM), 
NADPH (2 mM), or an NADPH-generating system (section 2.5.4.1). Similar 
experiments were performed using microsomes from 11HSD1-/- mice. Using the 
same assay conditions, the reaction was also performed with permeablized 
microsomes; prior addition of allameticine (500 µg/ml, 1-2h) was used to induce 
cationic permeability of the microsomes to allow substrate transport across the 
membrane (Pressman, 1976). 
 
e) Aortic rings (WT) were used to assess reduction of 7-KC (1 µM) by m11HSD1, 
as well as reduction of A (30 nM). The assay was performed as described (section 
2.8.4). Both assays were incubated for 20 h. Similar experiments were performed 
using aortic rings from 11HSD1-/- mice. 
3.3.4. Establishing Assay Conditions For 11HSD1 Bioassays With 
Steroids And 7-Oxysterols 
Initial experiments were performed with each source of enzyme in order to establish 
the conditions under which the reaction proceeded with first order kinetics (normally 
 30% conversion). Studies of the time-course of product formation were performed 
using m11HSD1 protein (28 µg/ml), microsomes (240 – 260 ug/ml) or cell lysates 
(100 µg/ml), and the velocity of product formation quantified after 0, 15, 30, 45, 60, 
90 and 180 minutes. From these, a single time-point and protein concentration were 




selected for subsequent experiments. For assays in which both dehydrogenation and 
reduction were evident (cells and aortic rings), a single time point (20 h) was chosen 
to achieve product formation for the reductase reaction (30% conversion) from both 
substrates; dehydrogenation proceeded on average ~2.5 times slower, reaching ~12% 
conversion. 
3.3.5. Michaelis-Menten Analysis Of 11HSD1 Enzyme Kinetics 
Purified recombinant enzyme (14 – 28 µg/ml) or preparations of WT hepatic 
microsomes (240 - 260 µg/ml) were incubated (see sections 2.5 and 2.7, with 
solutions of oxysterols (500 nM - 500 µM) or steroids (20 nM - 2 µM) representing a 
wide range of concentrations. Initial reaction velocities were measured, and 
conditions were chosen to achieve less than 30% of conversion of substrate to 
product; typically a reaction time of 50 min with recombinant protein (28 µg/ml) and 
30 min with hepatic microsomes (260 µg/ml). 
3.3.6. Metabolism of 7-Oxysterols By 11HSD2 
The oxidation of 7OHC or 7αOHC and reduction of 7-KC by 11HSD2 was 
investigated using the following models and the reaction velocities were compared 
with those of oxidation of dexamethasone (DEX) to 11-dehydrodexamethasone (11-
DHDEX), or reduction of 11-DHDEX to DEX: 
 
a) CHO cells stably transfected to generate h11HSD1 protein were incubated with 
7OHC, 7αOHC or 7-KC (1 µM), as described (section 2.9.1). 
 
b) Kidney homogenates from WT and 11HSD1
-/-
 mice were used as a source of 
11HSD2 as described (section 2.9.2). Samples containing protein (400 µg/ml) were 
incubated with 7OHC, 7αOHC or 7-KC (20 µM) and one of the following 
cofactors, NAD+, NADP+(both dehydrogenase), NADH or NADPH (both reductase) 
(2mM) to test for product formation with each appropriate substrate-cofactor 
combination.  
 




c) m11HSD2 activity in aortic ring preparations from 11HSD1
-/-
 mice was 
assessed in an assay of oxidation of 7OHC (1 µM) or reduction of 7-KC (1 µM). 
The reaction was performed as described (sections 2.8.2 and 2.8.4). A control assay 
using aortic rings from WT mice (which express both 11HSD1 and 11HSD2) 
(Christy, 2003; Christy et al., 2003) was performed in the same experiment. 
3.3.7. Detection Of Oxysterols 
Dried extracts from the bioassays described in this chapter were analysed by HPLC 
or GC/MS. 
3.3.7.1. HPLC Analysis Of Oxysterols 
All HPLC analyses of steroids and oxysterols were performed using UV- and on-line 
scintillation detection as described (sections 2.12.1 and 2.12.2). 
3.3.7.2. GC/MS Analysis Of Oxysterols 
The final method for detection of oxysterols using gas chromatography with mass 
spectrometry (GC/MS) is described in section 2.13.2. Selected ions were used to 
detect each of the specific derivatised compounds as described (section 2.13.3) and 
these are detailed in Table 2 - 1. 
The initial approach to detection of oxysterols involved determination of running 
conditions, retention time, peak abundance, peak characteristics and separation from 
other oxysterols. A full scan of ions generated by each compound was recorded 
initially in the mass range of m/z 200-700 amu. Ions were selected for use in selected 
ion monitoring (SIM) mode with an isolation width of 6.0 amu. During method 
development, two types of derivative were compared: methoxyamine-trimethyl silyl 
imidazoles (MO-TMSI) (Schweizer et al., 2004), prepared using methoxyamine HCl 
(2%) with TMSI; and trimethyl silyl (TMS) derivatives, prepared using either bis-
(trimethyl silyl)-tri fluoroacetamide (BSTFA) (Endo et al., 2008; Prunet et al., 2006), 
or trimethylchlorosilane (TMCS) (Dzeletovic et al., 1995b; Larsson et al., 2007). The 
latter two methods were found most robust in derivatisation of oxysterols in extracts 
generated by bioactivity assays. 




3.3.8. Data Analysis Of Kinetic Parameters 
All data obtained from HPLC-UV detection were quantified as described in section 
2.12.1.5, and quantitation of all GC/MS data was performed as in section 2.13.4. 
 
The velocity of product generation was calculated using the Michaelis-Menten 
equation (1) and a double reciprocal plot (2) of 1/V vs 1/[S]. Kinetic parameters of 
Vmax and Km were calculated using Graph Pad Prism v5.0. 
Equation (1):  V = Vmax[S] /(Km + [S]) 
For a single-substrate enzyme reaction that follows Michaelis-Menten kinetics, 
equation 1 describes enzyme velocity as a function of time. V – velocity (rate) of the 
reaction, [S] – concentration of substrate, Vmax – maximum velocity and Km – 
Michaelis-Menten constant for the reaction.  
Vmax is a measure of how fast the enzyme can go at full speed. Km is a measure of 
how much substrate is required for the enzyme to get to full speed. Km is the 
substrate concentration at half the limiting velocity (When [S] = Km, then V = ½ 
Vmax). The ratio of Vmax/Km measures the efficiency of the enzyme, which is 
ultimately limited by the rate of diffusion of the substrate to the enzyme. 
A Lineweaver-Burke double reciprocal plot (equation 2) of enzyme kinetics provides 
a linear representation of (1). 
Equation (2):  1/V = ((Km/Vmax)*1/[S]) + 1/Vmax 
3.3.9. Statistical Analysis 
All data are mean ± standard error of the mean (SEM). For m11HSD1 purified 
recombinant protein, the means obtained from three individual experiments were 
calculated. All experiments using animal tissues were carried out using tissues from 
6 (hepatic microsomes) to 14 (aortae) animals. Each assay was performed in 
duplicate or triplicate as indicated in Methods and final values of the mean per 
animal were taken for analysis. Statistical significance was determined using 
unpaired Student’s t-test (section 2.14). 





3.4.1. Method Development  
Prior to commencing analysis of oxysterols, several aspects of methodology were 
optimized, as follows. 
3.4.1.1. Handling Of Oxysterol Solutions 
All oxysterol solutions were handled and stored under argon and prepared using 
BHT (50 µg/ml in ethanol) as this prevented oxidation of solutions and further 
peroxide formation. The stability of each solution was initially monitored weekly by 
HPLC-UV photodiode-array analysis (section 2.12) and examples of such scans of 
solutions of 7OHC, with and without formation of peroxides, are given in  
Figure 3.4 – 1. By monitoring stability it was established that argon should be 
flushed into the vial of solution every time it was opened, and solutions should be 
discarded if opened more than 3 times. During assay preparation, to avoid thermal 
degradation and oxidation, oxysterol solutions were kept on dry ice, in a polystyrene 
box. 








Figure 3.4-1 HPLC-UV 3-D scan of 7OHC plotted in a 2D orientation.  
Photodiode-array scans of oxysterol solutions were performed using HPLC-UV analysis. The 
spectrum of 7OHC is plotted in 2-D orientation as elution time from the HPLC column (x-
axis) vs. wavelength (y-axis). A) A single peak was detected in a freshly prepared solution of 
7OHC (195 nm, Rt19min), whereas B) the effect of storage on the stability of 7OHC was 
demonstrated by the formation of oxidation products, indicated by a non-identified peak (N.I. 
195 nm, Rt14.8min) and peroxides (220 nm, Rt8.5min) (Caboni et al., 1997), in addition to 
the original 7OHC peak (195 nm, Rt19 min). The peaks in Rt 0=6.0 minut represent the 
solvent front. Rt, Retention time; nm, nanometers; min, minutes. 




3.4.1.2. Recovery Of Steroids And Oxysterols From Buffers 
The efficiency of steroid extraction from Krebs buffer was tested prior to starting the 
experiments and is reported in Table 3 - 1, showing maximal extraction efficiency 
with ethyl acetate. 
 
 














Glucocorticoids were extracted from Krebs buffer using the solvents listed. Extracted 
samples (n=3) were dried, dissolved in mobile phase and analysed by HPLC. The 
percentage recovery was calculated by expressing the peak area of the extracted sample 
over the peak area of the un-extracted sample. The most efficient recovery for 
glucocorticoids was achieved with ethyl acetate. DCM, dichloromethane. 
 
 
All reactions for oxysterol assays were performed in phosphate buffer (see section 
3.3.2) since the reaction occurred at a faster rate compared with that in Krebs buffer 
of the same pH (possibly due to the absence of salts in the phosphate buffer (Song et 
al., 1998)). The efficiency of oxysterol extraction into solvents from phosphate 
buffer was tested as reported (Table 3 - 2). Maximal extraction efficiency (> 90%) 
was obtained with petroleum ether. However, following incubation (37 °C, air) the 
recovery reduced (60-80%), probably due to instability of oxysterols. To avoid 
thermal degradation during sample processing, solvent was always evaporated under 
argon and at RT rather than at 60 °C. 
Solvent 
Percentage Recovery  

























Oxysterols were extracted from phosphate buffer using the solvents listed. Extracted 
samples (n=3) were evaporated under argon, dissolved in mobile phase and analysed by 
HPLC. The percentage recovery was calculated by expressing the peak area of extracted 
sample over the peak area of the un-extracted sample. The most efficient recovery for 
oxysterols was achieved with petroleum ether. The range of solvents was selected based on 




3.4.1.3. Recovery Of Oxysterols From DMEM And Cells 
Three separate solvent mixtures were compared to permit extraction of oxysterols 
from DMEM or Ham’s F12, based on published references: 
 
•  (1) Hexane : 2-propanol (60 : 40) (Freeman, 2005)  
•  (2) Chloroform : methanol (2 : 1) (Siems et al., 2005)  and  
•  (3) Diethylether : hexane (3 : 2) (Endo et al., 2008) 
 
 Extraction of oxysterols from DMEM could be performed using either mixture  
No (1) or No (2), but using mix No (3), the phase separation did not occur. With 
mixture No (1) phase separation was achieved faster (1000  g, 4°C, 5 min) whereas 
longer centrifugal step was required using mix No (2) (1000  g, 4°C, 20 min).  
To shorten the time of extraction and reduce sample exposure to the air, oxysterols 


















Extraction of oxysterols from Ham’s F12 medium could only be performed using 
Mix No (2), as phase partition was not achieved with any other solvent mixture.  
 
For the extraction of oxysterols from lysed cells, phase separation was only achieved 
using methanol : hexane (1:4) yielding ~95% recovery when PBS with EDTA was 
added (section 2.6.3.2) as previously described (Brown et al., 1997).  
 
Subsequent analysis of extracts by GC/MS (section 2.13) suggested that all of the 
above selected solvent mixtures permitted detection of 7-oxysterols (sensitivity  
5 pmol/µl on column). 
3.4.1.4. Derivatisation Of Oxysterols For Detection By GC/MS 
The most widely-used reaction for derivatisation of oxysterols prior to GC/MS 
analysis is silylation. In this reaction a hydrogen atom is replaced by an alkylsilyl 
group (most often trimethylsilyl, TMS), which further prevents interaction with the 
stationary phase of the gas chromatographic column. TMS derivatives of oxysterols 
were more volatile, less polar and more thermally-stable than their parent 
compounds. Thus they yielded a lower limit of detection, due to improved peak 
intensity and symmetry (Blau and Halket, 1993; Knapp, 1979). Various conditions 
were tested for the silylation reactions using reagents already described (section 
3.3.7.2):  
1) Incubation time 
During pilot work, it was noticed that a prolonged, overnight derivatisation resulted 
in ~ 60% loss in abundance of derivatised 7-oxysterols, whereas greater abundance 
(> 75%) of 7-oxysterols was obtained using derivatisation times between  
30 min - 3h. 




2) Temperatures (RT – 100°C) 
Heating was required to facilitate the reaction (45 – 60°C). Peak height and shape 
upon analysis were maintained when samples were incubated at these temperatures 
for up to three hours. A shorter incubation time (30 min) and higher temperature 
(60°C) were chosen for analysis. 
3) Sample purification  
The use of a size exclusion column of Lipidex-5000 (Packard, Pangbourne, UK) to 
purify the samples by removing excess derivatisation reagents resulted in 
irreproducible peak heights. Consequently, this step was omitted from further 
analyses. 
4) The use of silanised Reacti vials 
This step to deactivate the surface of the glass reaction vials contributed further to 
improved abundance and stability of derivatised compounds and, therefore, silanised 
vials were always used for sample processing.  
5) The use of catalyst (pyridine). 
Pyridine (1 %) was added for catalysis and gave improved peak symmetry when 
combined with either of the TMS derivatives. 
6) Silylation 
Care was taken to minimize exposure of derivitising reagents to air and moisture. 
Samples being processed were kept under argon at all times, while stored or dried in 
the hot block. Repeated use of TMSI demonstrated that the product formed yielded 
poor peak symmetry and reproducibility, but this method was used initially for 
confirmation of HPLC assays until further development could be performed using 
alternative silylation reagents. A mixture of Bis(trimethyl)silytrifluoroacetamide 
(BSTFA) and Trichloromethylsilazine (TMCS) (4:1) resulted in products yielding 
the same peak shape and abundance as BSTFA alone, however, this method was 
more costly. 




The yields of derivative formed using BSTFA with pyridine (1%) versus pyridine: 
Hexamethyldisilazine (HMDS) : Trichloromethylsilazine (TMCS) (3:2:1, v/v/v) were 
compared (section 2.13.2) in combination with the following oven programs 
1) Modified method from the literature: initial temp: 180°C (1min), Ramp 1: 
35°C/min until 270°C (1min), Ramp 2: 4°C/min until 300°C and maintained for 12 
min (Dzeletovic et al., 1995b; Larsson et al., 2007). 
2) In-house method: initial temp: 165°C (1min), Ramp 1: 20°C/min until 300°C 
(1min), Ramp 2: 5°C/min until 330°C (8 min), Ramp 3: 10°C/min until 250°C (1 
min). 
The initial temperature was maintained around 174°C as this is the boiling 
temperature of decane, in which the derivatised samples were finally dissolved.  
 
Overall peak symmetry was improved utilising BSTFA/pyridine in particular in 
combination with Method (2). However the use of Method (1) resulted in a 40% 
better abundance of derivatised oxysterols prepared by the pyridine : HMDS : TMCS 
mixture. The latter derivatisation method was ultimately proven to be more sensitive 
for detection of trace amounts of oxysterols in the plasma and other biological tissues 
compared with BSTFA/pyridine. However, the BSTFA/pyridine derivatisation 
method was used successfully at early stages for analysis of dried residues from 
tissue culture experiments or samples generated for confirmation of the HPLC 
results. 
3.4.2. Substrate Modelling 
3-D modelling of 7-oxysterols and docking of these structures into the enzyme active 
site of 11HSD1 was performed as described in sections 3.4.2.2 and 3.4.2.3, prior to 
in vitro assessment of the substrate preference of 11HSD1. 
3.4.2.1. DNA sequence alignment of 11βHSD1 Enzymes 
Prior to substrate modelling alignment of the known amino-acid sequences of 
11βHSD1 was performed to highlight the differences between the active sites of 
11βHSD1 from three different species, human, murine and hamster. The comparison 




of DNA sequences revealed good similarity of the enzyme structures ~78% (Figure 
3.4. – 2) as shown before (Arampatzis et al., 2005; Hult et al., 2004). 
3.4.2.2. Overlay of Enzyme Structure  
The C-terminal part of 11HSD1 contains active site motif with the catalytically 
important sequence which is crucial for catalysis and proton transfer between 
substrate and cofactor: Asn143 – Ser170 – Tyr183 – Lys187 (N-S-Y-K), also referred to as 
catalytic tetrad (Filling et al., 2002), as described in section 1.2.1.1. The presence of 
NADP+ within the crystal structure, in particular, allows in silico modelling of 
physiological binding by superimposing the structures of human (2BEL) and murine 
(1Y5R) structures of 11HSD1 (Figure 3.4 – 3A). The actives sites showed close 
similarity in orientation of the murine and human active sites as demonstrated in 
Figure 3.4 – 3A. The 3-D structures were subsequently used to simulate binding by 
7αOHC, 7OHC or 7-KC. 
3.4.2.3. Substrate Binding To Active Site 
In order to establish orientation of the oxygenated residues at the C7 position, the 
structure of 7αHSD in complex with 7-oxoglycochenodeoxycholic acid (1FMC) was 
used. When the active sites of 7αHCD (1FMC) and m11HSD1 (1Y5R) were 
overlaid, the tyrosine residue of 1FMC and the 7α-hydroxyl group of the ligand 
superimposed with the tyrosine of IY5R and the 11-hydroxyl group of 
corticosterone. Therefore, the 3-D structure of the 7αOHC was drawn using 
computer software, to resemble the 3-D orientation of 7-oxoglycochenodeoxycholic 
acid (Figure 3.4 – 3B). Subsequently, the steric positions of the 7-hydroxyl and  
7-keto groups of 7OHC and 7KC, respectively were orientated in relation to 
7αHCD. All three structures of 7-oxysterols were fitted in the active site based on 
the energy maps created as described in the methods. This resulted in 10 clusters 
formation for each small molecule binding to the active site. The “middle" 
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A closer view of the orientation of the functional group at the C7 position of the 
three 7-oxysterols is shown Figure 3.4 – 3C-D. 
 
Modelling of either 7-KC or 7OHC with h11HSD1 showed that Ser170 and Tyr183 
were 2.95 Å from either the C7-ketone or C7-hydroxyl residue and the C4 of the 
nicotinamide ring was 2.40 Å and 2.95 Å away from Tyr183, respectively, compatible 
with favourable bond lengths for reactions to occur.  
A)           B) 
      
C)            D) 
        
Figure 3.4-3 In silico modeling of 7-oxysterols and their binding to murine and 
human 11HSD1 structures 
A) In silico models of murine (m11HSD1, purple) and human (h11HSD1, teal) enzyme 
structures overlaid; The active site residues in the murine and human enzyme may be 
superimposed very closely.  B) 3-D structures of 7OHC (pink) and 7-KC (blue) were 
compared with that of 7-oxoglycochenodeoxycholic acid (green) by overlaying the molecules 
to establish special orientation. C) Structure of murine 11HSD1 with surface of the protein 
and overlaid 7-oxysterol substrates, 7-KC (yellow), 7OHC (pink) and 7OHC (turquoise). D) 




The overlaid 3-D structures of 7-oxysterols - 7-KC (yellow), 7OHC (pink) and 7OHC 
(turquoise) which are substrates for 11HSD1, showing the different stereochemistry at the 




To further confirm that the structures of 7-oxysterols have the orientation of a 
substrate, rather than of an inhibitor, the 7-oxysterol models were also compared 
with the 3-D orientation of glucocorticoids and carbenoxolone (inhibitor) in 2BEL 
structure. Binding of an inhibitor (carbenoxolone) was such that it positions itself 
within the rings of corticosterone, to prevent its further binding to the active site. The 
orientation of 7-oxysterols within the active site, however, resembles that of the 
substrate and favours catalysis. The 3-D analysis with m11HSD1 indicated that, 
during catalysis, the A ring of 7-oxysterols is orientated towards the interior of the 
enzyme, as seen in Figure 3.4 – 4A-B, whereas with corticosterone 11HSD1 
interacts with the D ring. As such the orientation of the C7 group in 7-KC assumes 
the same position as that of the C11 group in corticosterone rotated by 180°. 
Therefore these two groups possibly locate within a similar binding site, 
corresponding to the murine or human 11HSD1 active site (Wu et al., 2006). The 
differences in the ring orientation of these two classes of substrates might possibly 
influence the kinetic of 11HSD1.  
 
Figure 3.4 – 4C-E shows the interaction of Ser170 and Tyr183 with the 7-oxysterol 
substrates and Tyr183 with the NADPH. These are the highly conserved interaction in 
SDR proteins (Jornvall et al., 1995).  
 
 





   A)          B) 
  
 C)      D)          E) 
 
 
Figure 3.4-4 In silico models of glucocorticoids and oxysterols binding as 
substrates to m11HSD1 
A) 11-Dehydrocorticosterone (green) and 7-ketocholesterol (7-KC, yellow) were 
superimposed within the active site of m11HSD1. Superimposed substrates are orientated 
with the 7-keto group of 7-KC facing the active site. The catalytic tetrad of the m11HSD1 
(1Y5R) is comprising Asn, Ser, Tyr and Lys residues. B) In contrast, rotational symmetry of 
A) by 180°C results in the 11-keto group of 11-dehdyrocorticosterone facing the active site. 
C) Interaction of the active site residues with the superimposed structures of 7OHC 
(turquoise) and 7OHC (Pink). D) Interaction of m11HSD1 with overlaid 7-oxysterol 
molecules (7OHC, 7OHC and 7-KC). E) A closer view of the interactions between 7OHC 
(pink) and 7-KC (yellow) with the key residues of the active site and NADP+.  




Critical distance of hydrogen bonding between 7-oxysterols and murine 11HSD1 
molecule are shown in Table 3 – 3.  
 
Upon modelling of 7-KC with m11HSD1 (Fig 3.4 – 4D-E), Ser170 and Tyr183 were 
3.2Å and 3.3Å respectively from the C7 ketone of 7-KC. Carbon atom on C7 ketone 
was 3.0Å from the nicotinamide C4. The planar structure of 7-KC suggested 
favourable catalysis with all three hydrogens on Tyr183, Ser170 or NADP+  (see Table 
3 – 3).  
 
Upon modelling of 7OHC into the active site of m11HSD1 (Fig 3.4 – 4A-C) Ser170 
and Tyr183 were 2.8 Å and 2.7 Å respectively from the C7 hydroxyl of 7OHC. 
In the same model, carbon atom on C7 hydroxyl was 3.0 Å from the nicotinamide C4 
(Table 3 – 3). The chair orientation assumed by 7OHC provided a favourable 
orientation for catalysis within the m11HSD1. 
 
Upon modelling of 7αOHC into the active site of m11HSD1 (Fig 3.4 – 4C-D), 
Ser170 and Tyr183 were 4.5Å and 4.8Å respectively from the C7 hydroxyl of 7αOHC. 
Carbon atom on C7 hydroxyl was 3.0 Å from the nicotinamide C4. In contrast to 
7OHC, the 90°C “tilt” in orientation of the C7-hydroxyl group in 7αOHC, showed 
that 7αOHC was less tightly bound within the active site (Figure 3.4 – 4C-D), as it 
was positioned too far away for efficient interaction (Table 3 – 3).  
 
Overall the results of in silico docking of substrates into the active site of 
m11HSD1 suggested that 7OHC and 7-KC, but not 7αOHC are putative substrates 
for this enzyme. Further distances obtained in this experiment are tabulated below. 
Further 2-D LigPlot representation of substrate-protein interaction is detailed as 
shown in Figure 3.4 – 5. 
 





Table 3-3 Critical distances of hydrogen bonding between substrates for 
11HSD1 and enzyme active site residues. 
 
 
The numbers represent the distances (in angstroms, Å) of functional groups on carbon C7 of 
7-oxysterols to a key residue (serine, Ser170; tyrosine, Tyr183 and lysine, Lys187) in the active 
site of murine 11HSD1 enzyme (PDB structure: 1Y5R) as obtained using Pymol software. 












Figure 3.4-5 Interaction of 7-oxysterols with murine 11HSD1 protein.  
A) 2-D LigPlot representation of murine 11HSD1 (m11HSD1, PDB structure 1Y5R) 
enzyme catalytic residues interacting with 7-hydroxycholesterol. 2-D LigPlot representation 
of active site catalytic tetrad interacting with B) 7-ketocholesterol, C) 7-hydroxycholesterol 
and D) 7-hydroxycholesterol orientation of which (B-D) is represented using MarvinView 
software (ChemAxon). Overall the results of in silico docking of substrates into the 
m11HSD1 active site suggested that 7OHC and 7-KC, but not 7αOHC, are putative 
substrates for this enzyme. Key distances, from the active C7 oxygen on 7-oxysterols to 
serine (Ser170) and tyrosine (Tyr183) residue and to cofactor (NADP or NADPH) is given in 
angstroms (Å) as obtained using Pymol software. Lys187 (lysine), Asn143 (asparagine). 




3.4.3. In Vitro Assessment Of 11HSD Activity  
Purified recombinant m11HSD1, or protein present in HEK293 cells were used to 
characterise the reduction and dehydrogenation of 7-oxysterols. Further sources of 
m11HSD1, (lysed cells, hepatic microsomes and aortic rings) were also used. In all 
models, the reaction direction was co-factor-dependent and this was controlled, 
where possible, by modifying assay conditions. In intact cells, the reaction was 
driven by the endogenous cofactor.  
3.4.3.1. Purified Recombinant Protein 
Both 7-KC and 7OHC were metabolised by m11HSD1 to give the resultant 
products, 7OHC and 7-KC, respectively (Figure 3.4 – 5), and reduction proceeded 
more rapidly than dehydrogenation. Metabolism of glucocorticoids, however, 
proceeded at a much faster rate and again showed the expected pattern of 
predominant reduction and slower dehydrogenation. Conversion to 7-KC was not 
observed when 7αOHC was used as a substrate, nor was 7αOHC generated as a 
product upon reduction of 7-KC by 11HSD1. The identities of products were 
confirmed by two different chromatographic methods (HPLC-UV and GC/MS). 










Figure 3.4-6 Metabolism of steroids and oxysterols by m11HSD1 
(recombinant protein).  
A) Metabolism of steroids by m11HSD1. Velocities of reduction (RED) of 11-
dehydrocorticosterone (A) to corticosterone (B), (blue) and dehydrogenation (DEH) of B → A 
(green) were measured. Reduction by m11HSD1 was predominant over dehydrogenation. 
B) Metabolism of 7-oxysterols by m11HSD1. Velocities of reduction (RED) of 7-
ketocholesterol (7-KC) to 7-hydroxycholesterol (7OHC) (red) and dehydrogenation (DEH) 
of 7OHC → 7-KC (purple) were measured. Reduction of 7-KC by m11HSD1 was 
predominant over dehydrogenation of 7OHC. All data are mean ± SEM, compared using 
Student’s t-test, n=6, *p<0.05, **p<0.01. 




The presence of cofactor was necessary for these reactions to proceed. Metabolism 
of 7OHC was observed in the presence of either NAD+ or NADP+ (velocity  
0.022 ± 0.010 vs. 0.035 ± 0.020 pmol/µg/min respectively, n=3), while reduction 
utilized NADPH cofactor only.  
 
In addition to assessing the ability to convert specific substrates, reaction kinetics 
were determined (Vmax and Km) by generating a Michaelis-Menten plot and a 
Lineweaver-Burk transformation of it (exemplar Figure 3.4 – 7 and –8). Kinetic 
constants were compared between all substrates (7-KC, 7OHC, A and B) as given 
in Table 3-4. 7OHC binds better to 11HSD1 compared with 7-KC as indicated by 
a lower Km value. On the other hand, the enzyme preference for glucocorticoids over 
7-oxysterols is demonstrated by the lower Km values for the former, suggesting 
tighter binding of conventional substrates. Maximal velocity (Vmax) of conversion of 
glucocorticoids by 11HSD1 showed that these reactions are approximately 40 times 
faster than that of 7-oxysterols (Figure 3.4 – 7A & – 8A). Efficiency of 11HSD1 
conversion of substrates was calculated by obtaining the ratio of Vmax/Km and these 
measurements also suggest that murine recombinant 11HSD1 is converting 11-
dehydrocorticosterone more efficiently than oxysterols. Furthermore, recombinant 
11HSD1 converts 11-dehydrocorticosterone over 30-times more efficiently than 
corticosterone; and 7-ketocholesterol almost 3-times more efficiently than 7-
hydroxycholesterol. 
 





      A)               B) 
 
 
          [B, nM]            [1/B, nM-1] 
 
 
Figure 3.4-7 Enzyme kinetics – Metabolism of glucocorticoids by m11HSD1 
A) Michaelis-Menten Plot of velocities of conversion of corticosterone to 11-
dehydrocorticosterone (dehydrogenation) by recombinant m11HSD1; Vmax (pmol/µg/min) 
and Km (nM) were calculated. B) Lineweaver-Burk Plot, representing the linearised plot of 
(A). All data are mean ± SEM, n=3, in duplicate. 




     
  A)              B) 
 
 
  [7-KC, µM]    1/[7-KC], µM-1 
 
 
Figure 3.4-8 Enzyme kinetics – metabolism of 7-oxysterols by 11HSD1  
A) Michaelis-Menten Plot of the velocities of conversion of 7-KC to 7OHC (reduction) by 
recombinant m11HSD1 protein. Km (µM) and Vmax (pmol/µg/min) were calculated B) 
Lineweaver-Burk linear plot of (A). All data are mean ± SEM, n=3, in duplicate. 





Table 3-4 Summary of kinetic constants for reactions catalysed by 
recombinant m11HSD1.  
 
 
Michaelis constants (Km, µM) and the maximal velocities (Vmax, pmol/µg/min) were 
calculated for each direction of metabolism of glucocorticoids (GC) and oxysterols by murine 
recombinant 11HSD1 (m11HSD1). Lower Km values indicate that GCs are better 
substrates for 11HSD1 than 7-oxysterols and that 7OHC binds more tightly to the enzyme 
than 7-KC. Efficiency of 11HSD1 conversion of substrates was calculated by obtaining the 
ratio of Vmax/Km, µl.min/µg for glucocorticoids and Vmax/Km µl.min/ng for 7-oxysterols. 
These measurements suggest that 11HSD1 is converting 11-dehydrocorticosterone almost 
15-times more efficiently than corticosterone; and likewise metabolizes 7-ketocholesterol 3-
times more efficiently than 7-hydroxycholesterol. Vmax of conversion of glucocorticoids by 
11HSD1 was approximately 40 times higher than that recorded for 7-oxysterol. All data are 
mean ± SEM, compared using an unpaired Students t-test, *p<0.05 compared with 




3.4.3.2. m11HSD1 In Intact And Lysed Cells 
In order to simulate the intracellular environment, the velocity and favoured direction 
of metabolism by m11HSD1 expressed, following stable transfection, in CHO or 
HEK293 cells was assessed. Data relating to directionality from CHO cells proved to 
be variable but HEK293 cells, stably transfected with mouse HSD11B1, proved more 
robust. Therefore, these transformed HEK293 cells were also used for assessment of 
the metabolism of oxysterol by 11HSD1. Negative controls were the non-
transfected cells, in which conversion of steroids or oxysterols was not detected. The 




11-Dehydrocorticosterone 0.2 ± 0.25 8.56 ± 4.06   87.18 ± 13.78 *
Corticosterone 1.78 ± 0.56  4.82 ± 0.65 2.69 ± 0.57 
7-Ketocholesterol 1269 ± 282 * 0.116 ± 0.03   0.07 ± 0.006 * 
7-Hydroxycholesterol 327.6 ± 98.5 * 0.010 ± 0.001 0.03 ± 0.003 




identities of assay products were confirmed by both HPLC with radio detection and 
GC/MS (sections 2.12.1.5 and 2.13.4).  
 
Reduction of glucocorticoids (keto steroids) by m11HSD1 proceeded more rapidly 
than dehydrogenation of hydroxy steroids (Figure 3.4 – 8A) and this was consistent 
with results obtained using recombinant enzyme (section 3.4.3.1). Measurements of 
inter-conversion of 7-oxysterols by m11HSD1 in HEK293 cells showed that 
dehydrogenation and reduction proceeded at similar rates (Figure 3.4 – 8B) but these 
rates were slower than those measured using glucocorticoids as substrates. 7αOHC 
was not a substrate for these reactions, as product (7-KC) was not detected upon 
analysis. Likewise 7αOHC was not generated from 7-KC.  
 
HEK293 cells demonstrated the ability to sequester added oxysterols and so the 
distribution of the added substrates following incubation was assessed and amounts 
of products formed were quantified in the cells and the medium. The data are 
expressed as a percentage of total oxysterol recovered and are presented in  
Figure 3.4 – 9. A large percentage of the 7-KC (~ 70%) provided for reduction was 
retained in the media, while only ~ 20% entered the cells. 7OHC is more readily 
transported across the cell membrane into the cell (with only ~ 30% of the amount 
provided remaining in the media). The products of dehydrogenation (i.e. 7-KC) were 
detected in the media, whereas the product of reduction (i.e. 7OHC) was mainly 
retained in cells.  
 
To bypass any problems with entry of 7-KC into cells, reduction of this oxysterol 
was also performed using m11HSD1 harvested from lysed HEK293 cells. In this 
case the velocity of production of 7OHC obtained (1.62 ± 0.51 pmol/mg/h) was 
slower compared with that observed in intact cells (see 3.4.3.2) but, nevertheless, 
faster than that observed using the recombinant protein alone (see section 3.4.3.1). 
Likewise, the Km associated with the reaction was lower (77.7 ± 45.1 µM) compared 
with that ascribed to recombinant m11HSD1 (see Table 3 - 4) indicating tighter 
binding of this substrate to 11HSD1 in the simulated intracellular environment.  




   





Figure 3.4-9 Metabolism of steroids and oxysterols by m11HSD1 generated 
in HEK293 cells. 
A) Velocities of reduction (RED) of 11-dehydrocorticosterone (A) to corticosterone (B), (blue) 
and dehydrogenation (DEH) of B → A (green) were measured in intact HEK293 cells. 
Reduction was predominant over dehydrogenation B) Velocities of reduction (RED) of 7-
ketocholesterol (7-KC) to 7-hydroxycholesterol (7OHC) (red) and dehydrogenation (DEH) 
of 7OHC → 7-KC (purple) by m11HSD1 proceeded at a similar rate. All data are mean ± 
SEM, compared using unpaired Student’s t-test, n=6, in duplicate, ** p<0.01, n.s., not 
significant.










Figure 3.4-10 Distribution of 7-Oxysterols between HEK293 cells and the 
medium following incubation. 
HEK293 cells stably transfected to produce m11HSD1 were used to assess reduction 
(RED) of 7-ketocholesterol (7-KC) and dehydrogenation (DEH) of  
7-hydroxycholesterol (7OHC). With each substrate added to cells for the incubation, the 
amounts of remaining and newly-formed oxysterol were quantified in the medium and in the 
cells. When 7OHC was added as a substrate, 20±7% of the total amount recovered 
accumulated in the cells, and 37±6% remained in the medium. Newly formed 7-KC was 
detected in cells (14±3% of the amount of recovered substrate) and in the medium (12±4%). 
When 7-KC was added as a substrate, 80±1% of the amount recovered was detected in the 
medium, and only 14±4% had entered the cells. 7OHC that is formed from 7-KC was 
detected in both media (2±2% of the amount of recovered substrate) and cells (3±1%). All 
data are mean ± SEM, n=6, in duplicate. 




3.4.4. Ex Vivo Assessment Of 11HSD1 Activity  
Hepatic microsomes and aortic rings were used as a source of membrane bound 
11HSD1 to establish the preferred direction for metabolism of 7-oxysterols ex vivo. 
3.4.4.1. 11HSD1 Metabolism In Murine Hepatic Microsomes  
Reduction of 11-dehydrocorticosterone to corticosterone was predominant and, 
although dehydrogenation of corticosterone was also observed, it proceeded at a 
slower rate than reduction (Figure 3.4 – 11A). Therefore the kinetics of steroid 
metabolism in microsomal protein from WT murine livers was consistent with those 
described for recombinant protein and the intact cells (see sections 3.4.2.1 and 
3.4.3.1). Reactions only proceeded in the presence of cofactor and the identities of 
products were confirmed by HPLC-UV detection and GC/MS. 
 
The NADP+-dependent dehydrogenation of 7OHC proceeded in microsomes, as 
with stably transfected HEK293 cells, in the presence of cofactor but reduction of  
7-KC was not observed under any conditions tested. The preference for cofactor was 
assessed and it was established that formation of 7-KC from 7OHC could utilise 
either NAD+ or NADP+ (Maser and Netter, 1989) with similar preference (velocity 
1.25 ± 0.20 vs. 1.35 ± 0.40 pmol/µg/min respectively, n=3).  
 
Numerous manipulations were attempted to encourage the reduction of 7-KC. To 
address concerns over access of 7-KC to the luminal surface of microsomes, 
reduction of 7-KC was also assessed with the addition of the permeabilisation agent 
allametecine. In a separate assay, reduction of 7-KC was assessed using the NADPH 
generating system. Despite the addition of allametecine, or use of the NADPH 
generating system, the reduced product, 7OHC, was not generated (Figure 3.4 – 
11B). Reduction of 7-KC also did not proceed in the presence of the cofactor NADH. 
Following incubation, the percentage of 7-KC remaining in the incubate was close to 
100% of that added (Table 3 - 5), indicating the substrate was stable and the 
 
 










Figure 3.4-11 Metabolism of steroids and oxysterols by 11HSD1 in murine 
hepatic microsomes. 
A) Metabolism of steroids by 11HSD1 in murine hepatic microsomes showing predominant 
reduction of 11-dehydrocorticosterone (blue), and slower dehydrogenation of corticosterone 
(green). B) The metabolism of 7-oxysterols in murine hepatic microsomes proceeds only by 
dehydrogenation (7-hydroxycholesterol (7OHC) → 7-ketocholesterol (7-KC), purple) and 
the product of reduction (7-KC → 7OHC) was not detected. All data are mean ± SEM, n=6, 
in duplicate, **p<0.01. N.D., not detected. 




explanation for lack of measurable activity was not due to degradation or alternative 
routes of metabolism of the substrate. Some product formation (2.3 ± 0.6 %) was 
detected in the reduction assay upon GC/MS analysis. This was above the limit of 
detection (L.O.D.) and only within two fold of blank, therefore it is still within the 
error of the assay quantitation. In the same assay majority of the substrate was 
successfully recovered (89.6 ± 2.2%, Table 3 – 5). 
 
As with other models tested, 7αOHC was not a substrate for microsomal 
m11HSD1, nor was 7αOHC generated as a product of reduction of 7-KC. Again, as 
shown in Table 3 - 5, 7αOHC was stable under these conditions. 
 
 












This table summarises the percentage of substrate remaining and product formed during 
incubation of 7-oxysterols with hepatic microsomes from wild type mice.  
7-Oxysterols were quantified by GC/MS.  All data are mean ± SEM, n=6 in duplicate. 
7OHC, 7-hydroxycholesterol; 7OHC, 7-hydroxycholesterol; 7-KC, 7-ketocholesterol. 
 
 
Assay (n=6) % Product 
% Remaining 
substrate 
7αOHC → 7-KC 0 98.0 ± 1.8 
7OHC → 7-KC 26.5 ± 2.4 66.2 ± 0.9 
7-KC → 7OHC 2.3 ± 0.6 89.6 ± 2.2 




In addition to assessing the ability of murine microsomal 11HSD1 to convert 
specific substrates, reaction kinetics were determined (Vmax and Km) and constants 
obtained summarised (Table 3 - 6). Km values for glucocorticoids acting as 
substrates were three orders of magnitude lower than those of 7-oxysterols, 
signifying their ability to bind more tightly to m11HSD1. Vmax (Table 3 - 6) for 
oxidation of 7OHC was three orders of magnitude lower than that for 
glucocorticoids (pmol/mg/min vs. pmol/µg/min), showing faster metabolism of 
glucocorticoids in comparison with 7-oxysterols. Efficiency of 11HSD1 conversion 
of substrates was calculated by obtaining the ratio of Vmax/Km (µl.min/ng), and 
these measurements suggest that hepatic 11HSD1 in microsomal preparation is 
converting 11-dehydrocorticosterone eight time more efficiently than corticosterone. 
Further, both of these substrates were also metabolised more efficiently by 
microsomal 11HSD1 compared with 7-hydroxycholesterol. 
3.4.4.2. 11HSD1 Reaction Specificity For 7-Oxysterols 
The specificity of 11HSD1 to convert 7-oxysterols (7OHC, 7αOHC or 7-KC) was 
assessed using hepatic microsomes from 11HSD1-/- mice. When 7OHC was used 
as a substrate, conversion to 7-KC was not detected (whether either NAD+ or NADP+ 
were used as cofactors). Furthermore the majority of 7-KC added was successfully 
recovered (86.1 ± 4.2 %) from an assay utilising microsomes from 11HSD1-/- mice, 
and was similar to that of recovery obtained using microsomes from C57Bl/6 mice. 
This finding implies lack of any other routes of metabolism of 7-KC under the 
conditions tested, supporting the hypothesis that only 11HSD1 is responsible for 
mediating the conversion of 7OHC to 7-KC in these preparations. Products were 
also not formed when 7αOHC was added as substrate. 





Table 3-6 Summary of kinetic constants for murine microsomal 11HSD1. 
 
The binding constants (Km) and the maximal velocities (Vmax) were calculated for each 
direction of metabolism of steroids and oxysterols by 11HSD1 in murine hepatic 
microsomes. The preference of m11HSD1 to accept glucocorticoids as substrates over 7-
oxysterols was demonstrated by a Km value, which was three orders of magnitude lower. 
The velocities (Vmax) of 11HSD1 oxidising 7-hydroxycholesterol were three orders of 
magnitude lower than that of oxidation of corticosterone (pmol/mg/min vs. pmol/µg/min). 7-
Ketocholesterol was not reduced by m11HSD1. (n/d, not detected). Efficiency of 11HSD1 
conversion of substrates was calculated by obtaining the ratio of Vmax/Km, µl.min/µg for 
glucocorticoids and Vmax/Km µl.min/ng for 7-oxysterols These measurements suggest that 
11HSD1 is converting 11-dehydrocorticosterone more efficiently than corticosterone or 7-




Murine Hepatic Microsomes 







1268 ± 539 1.19 ± 0.18 83.21 ± 12.39 
Corticosterone 4199 ± 2095 0.04 ± 0.01 10.87 ± 2.74 





7-Ketocholesterol n/d n/d n/d 
7-Hydroxy-
cholesterol 
3500 ± 326 32.6 ± 9.9 0.009 ± 0.01 




3.4.4.3. Conversion Of Steroids And 7-Oxysterols By 11HSD1 In 
Murine Aortic Rings 
The pattern of metabolism of steroids by 11HSD1 in murine aortic rings in 
culturewas consistent with the nature of the reactions described for hepatic 
microsomes (see section 3.4.4.1). Reduction of 11-dehydrocorticosterone proceeded 
(on average 2.5x) faster than the dehydrogenation of corticosterone. Approximately 
10 - 20% conversion was observed in the dehydrogenation direction after 24 h  
(Figure 3.4 – 12).  
As expected, genetic disruption of 11HSD1 resulted in a significantly lower rate of 
reduction of 11-dehydrocorticosterone but not complete ablation (see footnote *) 
Detection of product generated by dehydrogenation was expected due to the presence 
of 11HSD2 in the vascular wall (Christy et al., 2003) and unexpectedly, the velocity 
of 11HSD2 reaction increased following the genetic disruption of 11HSD1 as in 
Figure 3.4 – 12.  
  
Formation of products of both reduction of 7-KC and dehydrogenation of 7OHC 
was detected as shown in Figure 3.4 – 13. Interestingly, genetic disruption of 
11HSD1 resulted in a substantially significant reduction in the rate of metabolism 
of 7-oxysterols in both directions. Oxysterols were not metabolised by 11HSD2 in 
the aortae. Lastly, 7-KC was not formed by aortic rings from either WT or KO mice 
incubated with medium containing 7OHC. Nor was 7OHC formed upon 




NOTE: * Originally created 11HSD1-/- mice (Kotelevtsev et al., 1997) had targeted deletion 
of this gene (HSD11b1) for exons 3 and 4 (and thus expression) from P1 and P2 promoters. 
These promoters are widely expressed in most tissues of MF1 background mice. Once mice 
were backcrossed onto C57Bl/6 background of mice it appeared that some of the residual 
expression of 11HSD1 protein is still observed, coming from a P1-promoter in tissues like 
lungs (~10-30%). Residual activity (~10%) of 11HSD1 has later on also been observed in 
the vascular tissues from 11HSD1-/- mice (Dover et al., 2006)), where some of the 
11HSD1 protein made from this promoter may still be present. It is thus assumed that the 
residual activity comes from the P1 and P2 promoters if these promoters are used in 
vasculature, but these findings are currently under investigation in the laboratory. 
 











Figure 3.4-12 Metabolism of steroids by aortic rings from C57Bl/6 and 
11HSD1-/- mice. 
Metabolism of steroids by reduction (blue, 11-dehydrocorticosteron (A)  corticosterone (B)) 
and dehydrogenation (green, BA) of substrates by 11HSD isozymes by aortic rings from 
C57Bl/6 and 11HSD1-/- mice was assessed following an overnight incubation (24h). 
Reduction of A was dominant in the C57Bl/6 mice and was significantly reduced in the 
11HSD1-/- mice. The dehydrogenation occurred at a faster rate in the 11HSD1-/- mice 
compared to C57Bl/6. All data are mean ± SEM, compared using unpaired Student’s t-test, 
n=10, **p<0.01 vs. velocity of same reaction in tissue from C57Bl/6 mice. 











Figure 3.4-13 Conversion of 7-oxysterols by aortae from C57Bl/6 and 
11HSD1-/- mice. 
Metabolism of 7-oxysterols by reduction of 7-ketocholesterol (7-KC, purple) and 
dehydrogenation of 7-hydroxycholesterol (7OHC, red) by 11HSD1 by aortic rings from 
C57Bl/6 and 11HSD1-/- mice was assessed following an overnight incubation (24 h). 
Reduction and dehydrogenation occurred at a similar rate in aortic rings from C57Bl/6 mice 
but these velocities were both significantly reduced in the aortic rings from 11HSD1-/- mice. 
However, residual activity was still detected in the 11HSD1-/- vessels (values significantly 
different from zero). All data are mean ± SEM, compared using unpaired Student’s t-test, 
n=6, **p<0.01 vs. velocity of the same reaction in tissues from C57Bl/6 mice. 




3.4.5. Does 11HSD2 Inter-Convert 7-Oxysterols In Stably Transfected 
Cells? 
This question was addressed first in utilising CHO cells stably transfected with 
human HSD11B2 to generate h11HSD2 recombinant protein. Dehydrogenation and 
reduction of steroids were tested using dexamethasone (DEX) and 11-
dehydrodexamethasone (11-DHDEX) as substrates. These synthetic steroids were 
chosen since 11-DHDEX is a substrate for reduction by 11HSD2, whereas 11-
dehydrocorticosterone is not (Best et al., 1997). The h11HSD2 transfected in cells 
preferentially metabolised DEX to 11- DHDEX, while the reverse reaction catalysed 
by the same enzyme was recorded at very low rate, 40% vs.  ~10 % conversion. 
 
In the assay of 7-oxysterol conversion by recombinant h11HSD2, a product was not 
generated from 7-KC (reduction), 7αOHC or 7OHC (both dehydrogenation), as 
seen in Table 3 - 7. Negative controls (non-transfected cells) were also included, in 
which conversion of neither steroids nor oxysterols could be detected.  
 
To ensure the oxysterols were able to penetrate the CHO cells, both media and cells 
were analysed to ascertain the distribution of oxysterols post-incubation. The data 
were expressed as percentage product formed and percentage substrate remaining 
(Table 3 - 7). Overall around 80% of 7-oxysterols was recovered from the assay and 
distribution per cell or medium is expressed as a percentage of the total 7-oxysterols 
recovered. Most of 7-KC was recovered from media (97.1 ± 0.03 %) and very little 
penetrated the cells (< 2%). Of the total 7OHC or 7αOHC recovered, on average 
>60% was present in the cells and ~30% in the medium. Therefore, lipophilic 
oxysterols 7αOHC and 7OHC (not 7-KC) readily traversed the membrane of CHO 
cells, but did not bind to the 11HSD2 enzyme, as seen by the lack of relevant 
product in the assay. 













This table demonstrates the lack of product formed by h11HSD2 expressed in stably 
transfected CHO cells. Cells were treated with 7-oxysterols (1µM, 16 h) and the amount of 
product formed both in the cells and in the medium were measured and detected by GC/MS. 
The vast majority of each substrate was recovered and had not been converted to the 
anticipated product. All data are mean ± SEM, n=4, in duplicate. 7OHC,  
7-hydroxycholesterol; 7OHC,7-hydroxycholesterol; 7-KC, 7-ketocholesterol. 
 
 
3.4.6. Does Renal 11HSD2 Have A Role In Oxysterol Metabolism? 
A second model was tested to assess whether oxysterols were substrates for murine 
11HSD2; the use of tissue homogenates avoided difficulties in access invoked by 
intact outer cell membranes. Murine kidneys contain both isozymes of 11HSD and, 
therefore, reactions were performed using renal homogenates from 11HSD1-/- mice.  
 
Metabolism of steroids could be detected, confirming the integrity of the enzymatic 
preparation. Renal 11HSD2 preferentially metabolised dexamethasone to 11-
dehydrodexamethasone. The assay conditions of dehydrogenation and reduction of 
reactions (DEX → 11-DHDEX and 11-DHDEX → DEX, respectively) were such to 
achieve 20-30% product formation (reaction velocities were not calculated). 
 
In the assay of dehydrogenation of 7OHC or 7αOHC, a product was not formed 
(Table 3 - 8). Likewise, in the assay to test reduction of 7-KC, a product was not 
detected using HPLC although a very small percentage of 7OHC was quantified 
(1.8 ± 0.6%) using GC/MS, a technique with superior sensitivity. These data showed 
that 11HSD2 does not play a role in the metabolism of 7-oxysterols to any 
Reaction % Product % Remaining substrate 
7OHC → 7-KC 0 98.0 ± 0.7 
7OHC → 7-KC 0 96.4 ± 0.3 
7-KC → 7OHC 0 97.1 ± 0.1 




significant degree. Some depletion of 7αOHC and 7OHC was noticed, suggesting 
formation of an alternative product (although the presence of this product was not 
detected under the chromatographic conditions used), whereas substrates were fully 
recovered from blank samples containing buffer alone confirming chemical stability 













This table demonstrates the lack of proposed product formed by m11HSD2 in renal 
homogenates from 11HSD1-/- mice. Very small amounts of proposed products were formed 
during incubation with 7-hydroxycholesterol (7OHC) and 7-ketocholesterol (7-KC). An 
unknown product was also formed in each assay, accounting for loss of substrate. All data 
are mean ± SEM, n=4, in duplicate. 7OHC, 7-hydroxycholesterol. 
Reaction % Product % Remaining substrate 
7OHC → 7-KC 0 68.0 ± 2.8 
7OHC → 7-KC 2.6 ± 2.4 56.2 ± 1.7 
7-KC → 7OHC 1.8 ± 0.6 84.3 ± 3.2 





The work presented in this chapter tested the hypothesis that m11HSD1 will accept 
7-oxysterols as substrates. The initial aim of this work was to investigate the ability 
of 7-oxysterols to bind to and interact with the active site of m11HSD1. In silico 
modelling suggested that the relevant functional groups assumed positions within the 
enzymatic active site to permit catalysis. Secondly, this work investigated the 
directionality of the 11HSD1 enzyme utilizing 7-oxysterol as substrates in three 
different systems: recombinant protein, membrane associated enzyme from hepatic 
microsomes and an ex vivo preparation of murine aortae. Data obtained using all 
three systems demonstrate that murine 11HSD1 can catalyze dehydrogenation of 
7OHC and 7-KC, whereas not all models allowed reduction to proceed.  
The directionality of individual reactions could also be influenced by cofactor 
supply. The direct comparison of this metabolism using tissues from C57Bl/6 and 
11HSD1-/- mice, demonstrated specificity of m11HSD1 as being the only enzyme 
in the liver capable of executing these reactions with 7-oxysterols, as this reaction 
was abolished upon deletion of 11HSD1. Lastly the kinetic data also highlight the 
differences between the characteristics of metabolism of 7-oxysterols and 
glucocorticoids by 11HSD1: these interactions are further explored in Chapter 4. 
  
The kinetics of metabolism of 7-oxysterols by m11HSD1 had not been studied at 
the outset of the work leading to this thesis. Furthermore the kinetics of oxidation 
and reduction of 7-oxysterols had not been compared with those of glucocorticoids. 
In fact, it is only recently that the crystalised murine protein has become available 
(Zhang et al., 2005) for in silico modelling of interactions of substrates and inhibitors 
with the active site. This advance has been driven through increased interest in 
11HSD1 as a therapeutic target for obesity and cardiovascular diseases, and various 
models of crystalized 11HSD1 have now been generated for modelling purposes 
(Hosfield et al., 2005). 




3.5.1. In Silico Modeling Of 7-Oxysterol Binding To Murine And 
Human 11HSD1 
Comparison of murine and human enzymatic structures showed that a considerable 
similarity existed in the orientation of key active site residues (the catalytic tetrad). 
Indeed the catalytic sites of human, rat and murine 11HSD1 share 79% homology 
with respect to amino acids and previously the least variation in the architecture of 
the active site (of those species tested) has been shown between human and murine 
11HSD1 (Hult, 2004). The cofactor binding sites are also virtually identical 
between the proteins from these species (Hult et al., 2006). For these reasons, the 
murine enzyme is considered a good model for comparison of enzyme structure and 
substrate interaction in silico, closely mimicking the human enzyme and facilitating 
translational research. Furthermore the availability of transgenic murine models 
lacking 11HSD1 merits further investigations of novel metabolism of this enzyme 
for potential therapy.  
 
The catalytic tetrad of murine and human enzymes comprise Asn, Tyr183, Ser170 and 
Lys residues and they require a cofactor (NADP+/NADPH) for catalysis. These 
highly conserved residues are orientated within the lipophilic substrate-binding 
pocket of the protein (Jörnvall et al., 1995). This pocket is formed by the substrate-
binding loop, which resembles a tunnel through which substrates gain access to the 
active site. It was previously hypothesized that this enzyme’s location within 
microsomal membranes favours binding of lipophilic substrates (such as 7OHC and 
cortisol) through the substrate-binding pocket (Ogg et al., 2005). 
 
A close model to m11HSD1 (m7αHSD bound to a 7-oxysterol-like molecule, PDB 
ID: 1FMC) represented a great resource with which to simulate potential steric 
positioning of the oxygenated groups of 7-oxysterols and their orientation in the 
binding tunnel of 11HSD1. This was simply an approach to approximate the 
putative binding of 7-oxysterols to the active site of 11HSD1, since the crystal 
structure of m11HSD1 combined with the 7-oxysterols was not available at the time 
(and remains unavailable). More refined positioning of the substrates into the active 




site of PDB model of m11HSD1 was performed by generating the energy maps for 
ligand-protein interaction. These have allowed exact positioning of substrate within 
suggested site points in the binding pocket of a protein. By further performing 3-D 
docking of substrates into the active site of m11HSD1 (as described in section 
3.4.1) the distances between key active residues and side chains were obtained.  
It became apparent that 7OHC and 7-KC, but not 7αOHC, may bind to m11HSD1 
with sufficient proximity to permit catalysis, as the interacting residues were within 
acceptable hydrogen bond distance. The differences between molecular structures of 
7OHC and 7-KC were examined using 3-D reconstructions. The orientation of both 
7-KC and 7OHC suggested favourable binding to the active site of 11HSD1, 
although chair orientation of 7OHC resulted in its 7-hydroxy group being located 
slightly further from Tyr183 residue in the active site in the mouse than the 7-ketone 
of 7-KC. 
 To further explore the in silico predictions of the suitability of these 7-oxysterols 
as substrates for 11HSD1, kinetics were investigated using a series of 
complementary in vitro and ex vivo model systems.  
3.5.2. In Vitro And Ex Vivo Assessment Of 11HSD1 Activity  
Having established that both 7OHC and 7-KC were likely ligands for m11HSD1, 
their rates of inter-conversion were tested in vitro and ex vivo. All models of 
m11HSD1 were able to accept 7OHC, but not 7αOHC, as a substrate, and convert 
it to 7-KC; thus confirming the prediction provided by the in silico analysis. At the 
outset it was not certain whether reduction of 7-KC by m11HSD1 would generate 
more than one product (7αOHC and/or 7OHC). In this work stereo-specificity for 
the formation of the 7-isomer over 7αOHC was established. The data presented 
show that most (but not all) models used were able to reduce 7-KC to 7OHC to 
some degree but 7αOHC was not formed under any circumstances tested. Thus, the 
substrate specificity observed here indicates that m11HSD1 is similar to the human 
and rat enzyme in substrate preference, as described in the literature (Hult, 2004). 
Only 11HSD1 in hepatic microsomes from the hamster does not exert this stereo-
specificity and forms both 7OHC and 7OHC upon reduction of 7-KC (Maeda et 
al., 2006). Sequence alignment, as performed and presented in Figure 3.4 – 2 




highlights some of the differences between enzyme from three different species, but 
the catalytic parts of the sequences share very high homology. Further insight to this 
difference might be obtained by comparison of tertiary structure of the hamster 
protein with those of human and mouse structures.  
 
The rates of metabolism of 7-oxysterols by m11HSD1 were compared with those of 
glucocorticoids. As expected and by design, m11HSD1 metabolised glucocorticoids 
in all ex vivo and in vitro model systems used and reduction predominated, consistent 
with the literature (Kotelevtsev et al., 1997; Lavery et al., 2006). Interestingly, 
reduction of 7-KC by m11HSD1 was detected in some test systems but not others, 
whereas dehydrogenation of 7OHC could be measured consistently.  
 
Mirroring the pattern for glucocorticoids, murine recombinant 11HSD1 inter-
converted 7-oxysterol as substrates in both directions but with a preference for 
reduction of 7-KC. However, while this approach proved very useful for direct 
comparison of the ability of 11HSD1 to use oxysterols and steroids as substrates, it 
reflected a scenario distinct from the natural physiological environment where 
11HSD1 is membrane bound. To address this issue, further reactions were carried 
out using HEK293 cells stably transfected to generate m11HSD1 and primary 
tissues ex vivo naturally expressing 11HSD1; thus moving the focus from the 
purified protein to the enzyme specifically associated with membranes. 
 
In these further model systems, 7-oxysterols were still metabolised less efficiently by 
11HSD1 compared with glucocorticoids, characterised by slower rates of reaction 
and much higher binding constants (Km in high µM vs. low µM, respectively). These 
findings, however, do not necessarily mean that 11HSD1 will have a lesser role to 
play in oxysterol over glucocorticoid metabolism, as the velocities of enzymatic 
reactions are determined in part by substrate concentrations. In atherosclerosis the 
levels of oxysterols exceed those of glucocorticoids by three orders of magnitude 
(from low nM (GC) to low µM (oxysterols)) (Brown and Jessup, 2009) and thus 
there may be significant turnover of 7-oxysterols.  
 




In systems utilising membrane bound 11HSD1, differences between metabolism of 
the two types of substrate were revealed with respect to the equilibrium set-point 
between reduction and dehydrogenation. It is well established that, within a suitable 
cellular environment, reduction is the preferred direction of 11HSD1 for 
metabolism of glucocorticoids (Atanasov et al., 2004; Bujalska et al., 2005; Lavery 
et al., 2006). 
 
However, the data presented here show that lower Km values were consistently 
obtained for dehydrogenation of 7OHC compared with those for reduction of 7-KC, 
implying the enzyme’s preference to act as a dehydrogenase with this class of 
substrates. This phenomenon was even more pronounced in hepatic microsomes in 
which reduction of 7-KC by 11HSD1 could not be invoked. This is surprising given 
that in this model 11HSD1 is orientated within the microsomal lumen in close 
proximity to H6PDH (Balázs et al., 2009; Bujalska et al., 2005), which is normally 
sufficient to provide excess NADPH co-factor to drive reduction, when supplied with 
G6P and NADP+. Certainly, in vitro studies by Frick et al., (2004) using wild-type 
recombinant 11HSD1 in intact cells, engineered to face into the lumen of ER, and a 
mutant K5S/K6S 11HSD1 engineered to face the cytoplasm, demonstrated that the 
11HSD1-luminal orientation was essential for efficient reduction of 7-KC.  
 
A number of approaches were taken to ensure the integrity of the microsomal 
preparations in order to establish the right conditions for 7-KC reduction to occur. In 
each assay, conditions were used (e.g. high concentration of NADPH, use of 
alamethecine) which allowed reduction of glucocorticoids to proceed efficiently and 
predominate over dehydrogenation, indicating appropriate handling of the tissue. In 
the face of compelling evidence, still only a very small percentage of 7-KC was 
reduced (as detected using GC/MS, seen in Table 3 – 5) by 11HSD1 in hepatic 
microsomes. For this purpose, a cofactor generating system was added and 
alternative co-factors (NADH in place of NADPH) were explored. These 
manipulations did not succeed in promoting reduction of 7-KC. It was possible that 
higher concentrations of NADPH were required for reduction of 7-KC in comparison 
to those used in experiments involving reduction of glucocorticoids. On the other 




hand both NADP+ and NAD+ cofactors were also accepted by m11HSD1 in the 
formation of 7-KC from 7OHC, as is the case for conversion of glucocorticoids 
(Christy, 2003). Indeed, in many species NADP+/NADPH as opposed to 
NAD/NADH is the preferred set of cofactors for 11HSD1, but in the mouse there is 
less clear distinction between these two cofactors for the glucocorticoid metabolism 
(Arnold et al., 2003).  
 
To further address the concern over lack of reducing cofactor in vitro, HEK293 cells 
were co-transfected with human 11HSD1 and H6PDH enzymes (collaboration with 
(Dakin, 2008)). Although in control cells the proportions of reduction and 
dehydrogenation reactions were relatively closely matched (60 : 40% respectively), 
upon co-expression (Figure 3.5 – 1), glucocorticoid metabolism proceeded mainly as 
a reductase and dehydrogenation was significantly reduced (80 : 20 % respectively)  
A significant increase in 7-KC reduction was also observed under the same co-
expression conditions and dehydrogenation of 7OHC was suppressed, but it 
nevertheless remained the dominant reaction over reduction of 7-KC (Dakin, 2008). 
Overall these findings suggest that metabolism of 7-oxysterols by 11HSD1 is less 
dependent on H6PDH in determining its kinetics as compared to glucocorticoids, and 
other factors must be at play to allow dehydrogenase activity of 7OHC to 7-KC to 
persist (Maeda et al., 2006). It might be informative to repeat some of these 
experiments in primary hepatocytes, which have high expression of H6PDH. One of 
the concerns with these cells as a model, however, is the existence of highly active 
competing pathways: various aldo- and keto- reductases and CypP450s in 
hepatocytes which may also contribute to metabolism of oxysterols (Jin and 
Pennings, 2007).  
 
A further factor that could have impaired reduction is a barrier to access of 7-KC into 
the cell and microsomal lumen. During the inter-conversion assay using HEK293 
cells, it became apparent that oxysterols were sequestered in the cells. They could be 
extracted from both media and the cells, whereas most steroids (> 95 %) were 
recovered from the medium only. However 7OHC was rapidly sequestered whereas 
7-KC was mainly found in the medium. Thus the substrate for reduction may have 




been prevented from entering the cell in substantial quantities. Indeed  
 
7-KC generated by dehydrogenation of 7OHC appeared also to be rapidly exported 
back into the medium. Little is known about transport of 7-oxysterols across outer 
cell membranes (Olkkonen et al., 2006) or into the microsomal compartment, 
although active transporters exist in the liver, which facilitate the movement of other 
oxysterols and cholesterol (Baldan et al., 2009; Gelissen et al., 2006) in a highly 
regulated manner. 
 
HEK293 cells, which are derived from kidney (Graham et al., 1977) may not express 
the correct transporters to allow efficient entry of 7-KC and perhaps the experiments 
may be repeated in a hepatic cell line. One would, however, predict that their 
lipophilic nature would allow them to passively penetrate the cell membrane. 
  
To explore penetration of the microsomal membrane further, a membrane 
permeabilising agent (allameticine) (Banhegyi et al., 2004) was included in the 
assays to facilitate 7-KC transport across the ER membrane. Furthermore, it was 
postulated that a longer incubation was required to allow the potentially slower 
(compared with glucocorticoids) diffusion of oxysterols through the microsomal 
membrane. However, even when this was attempted, reduction was still not 
observed. Concerns were raised regarding heat-induced degradation of sterols during 
permeabilisation of microsomes for periods longer than 2h (reviewed by Schroepfer, 
(2000)) and thus longer incubations were avoided. 
 
The transport of 7-KC across the microsomal membrane may be dependent on 
various associated proteins (such as Sterol Regulatory Element Binding Proteins 
(SREBPs), to which 7-KC can bind in vivo (Brown et al., 2002). These may not have 
been present or active in the microsomal preparations, although in cells SREBP 
transcription factors are usually associated with the lumen of endoplasmic reticulum 
or Golgi apparatus in their unstimulated state (Espenshade et al., 1999).  
 
 











Figure 3.5-1 Metabolism of steroids and oxysterols by 11HSD1 in stably 
transfected HEK293 cells. 
HEK293 cells stably expressing the gene for h11HSD1 were transiently transfected with 
human hexose 6-phosphate dehydrogenase (hH6PDH). Data are expressed as a % of 
conversion of substrate (200 nM steroid, 1 µM oxysterols).  
A) Velocities of reduction (RED) of 11-dehydrocorticosterone to corticosterone, (blue) and 
dehydrogenation (DEH) of corticosterone (green) were measured. In control cells the 
proportions of reduction and dehydrogenation reactions were similar (60 : 40%, respectively) 
but upon co-expression, glucocorticoid metabolism proceeded mainly as a reductase (80 : 
20%, respectively). B) Metabolism of 7-oxysterols by reduction (RED) of 7-ketocholesterol 
(red) and dehydrogenation (DEH) of 7-hydroxycholesterol (7OHC, purple) by h11HSD1 
proceeded in favor of dehydrogenation of 7OHC. Upon co-transfection with 11HSD1 and 
H6PDH a significant increase in reduction of 7-KC and decrease in dehydrogenation of 
7OHC were observed compared with control, however dehydrogenation of 7OHC was still 
the dominant reaction. All data are mean ± SEM, compared using unpaired Student’s t-test, 









Certainly the transcriptional regulation of these processes would not have been active 
in tissue homogenates. HEK293 cells express all three isoforms of SREBP: 
SREBP1a, SREBP1c and SREBP2 (Hannah et al., 2001), although they are subject 
to feedback regulation by cholesterol, which blocks the proteolytic release of SREBP 
molecules from the membrane. Sterols have their greatest inhibitory effects on 
SREBP-2. It would appear that HEK293 cells may be able to carry out the transport 
of 7-KC, yet there was still a lack of reduction of 7-KC by 11HSD1. 
 
There are reports showing that 7-KC interferes with the structured phospholipid 
bilayer of the cell membranes and perhaps of the ER membrane (Massey and 
Pownall, 2006), causing significant changes in the biophysical properties of the lipid 
bilayer, by locating close to the membrane interface. 7-KC may embed itself between 
the non-polar lipid tails in the ER membrane where it has a tendency to form crystals 
(Massey, 2006), and as a result, the transport of 7-KC may have been impaired 
across the membrane into the lumen of ER. Crystal formation may also have 
disrupted the association between 11HSD1 and H6PDH, preventing the coupling 
necessary to allow reduction to proceed. In Chapter 4 however, data will be 
presented showing that reduction of glucocorticoid can still take place efficiently in 
the presence of high concentrations of 7-KC so this is unlikely to be the explanation. 
It still remains unclear why only glucocorticoid metabolism has occurred under the 
same conditions. The balance to favour reduced and oxidized cofactor may simply be 
achieved better in vivo (Braakman et al., 1992), because of constant provision of 
cofactor by the regulatory enzymes sensing the redox state of the ER and responding 
to demand. 
 
One of the questions raised in this Chapter was whether 11HSD1 was the only 
enzyme capable of catalysing the inter-conversion of 7OHC and 7-KC. To address 
this, the use of 11HSD1-/- animals was vital. Since formation of reaction product 
was not detected in the microsomes from 11HSD1-/- mice, this suggests that 
11HSD1 is the only enzyme metabolizing 7-oxysterols in this compartment of 
hepatocytes. Further, there was not an obvious involvement of 11HSD2 in 
metabolizing 7-oxysterols since renal homogenates of 11HSD1-/- mice were unable 




to inter-convert 7-oxysterols. Previously, and also reported here, human HEK293 
cells transfected with 11HSD2 could not convert 7-KC (Schweizer et al., 2004).  
To an extent, these findings are in line with those of carbenoxolone inhibiting  
7-oxysterol metabolism, observed by Schweizer et al., (2004), although 
carbenoxolone is not a selective inhibitor as it inhibits both isozymes of 11HSD, 
and also affects prostaglandin synthesis (Walker and Andrew, 2006). The above data 
showing dual directionality of 11HSD1 suggest that the dehydrogenase activity of 
this enzyme may contribute to accumulation of 7-KC in for example macrophages 
and vascular cells. The in vitro findings should of course be carefully extrapolated 
onto an in vivo system, where many additional factors influence reaction direction, 
enzyme expression and enzyme structure. It has been speculated that inhibition of 
11HSD1 may reverse the lysosomal accumulation of 7-KC (Brown et al., 2000b; 
Jessup and Brown, 2005), supporting the data in this chapter that 11HSD1 
predominantly performs dehydrogenation of 7OHC to 7-KC. The dehydrogenation 
reaction of 11HSD1 may thus contribute to 7-KC accumulation, leading to its 
further deleterious effects on tissue.  
 
Findings from the work in this chapter support previous assertions in the literature 
that 11HSD1 is providing a major route of oxysterol metabolism  
in the liver (Jessup and Brown, 2005), and show that indeed this may be the case in 
other tissues too, including the vasculature. Previously investigations of 11HSD1 in 
aortic rings have only utilised glucocorticoids as substrates (Dover et al., 2006; 
Morris et al., 2003); thus aortic rings from 11HSD2-/- mice,  
as a source of 11HSD1, were used to determine their ability to metabolize  
either 7OHC or 7-KC. The virtual absence of product following incubation of 
oxysterols with vessels from 11HSD1-/- mice confirmed in vitro findings by others 
(Schweizer et al., 2004) that 11HSD2 does not metabolise 7-oxysterols. Hence 
within the vessel inter-conversion of oxysterols will be catalysed solely by 
11HSD1, which will dictate the balance of these species and potentially regulate 
and differentiate the biological functions or toxic actions they possess. 
 




There are several implications from the data presented in this chapter. Firstly, the 
dominance of reduction over dehydrogenation is less marked for 7-oxysterols than 
for glucocorticoids, and indeed, under some circumstances, dehydrogenation occurs 
exclusively. If 7-KC and 7OHC have differential physiological effects, then these 
observations are important to understand the role of 11HSD1 in determining the 
balance of their local levels and actions. It will be important to extrapolate these 
findings to an in vivo model. Since 11HSD1 may metabolize both glucocorticoid 
and 7-oxysterols, competition may occur between these pathways in vivo depending 
on the local concentrations of each substrate. This work is further explored in 
Chapter 4. Lastly, it is important to establish whether 7-oxysterols have distinctive 
biological effects, which may be regulated via inter-conversion by 11HSD1. 














Chapter 4. Interaction Between Metabolism Of  
7-Oxysterols And Glucocorticoids By 11HSD1 





The findings from the previous chapter established that 7-oxysterols are substrates 
for m11HSD1. However, whilst 11HSD1 inter-converts 7-oxysterols, the preferred 
reaction direction is different from that of glucocorticoids. Since  
7-oxysterols bind to 11HSD1, they may compete with glucocorticoids for 
metabolism by the this enzyme (Balázs et al., 2009; Robinzon et al., 2003). 
Consequently, through substrate competition for 11HSD1, 7-ketocholesterol (7-KC) 
or 7-hydroxycholesterol (7OHC) may modulate glucocorticoid production by 
11HSD1 and, thereby, its activity in target tissues. Since pre-receptor metabolism of 
glucocorticoids by 11HSD1 regulates access of glucocorticoids to the 
glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) (Tomlinson et al., 
2004a), the modulation of glucocorticoid metabolism by 7-oxysterols may also 
influence activation of these receptors. The directionality of 11HSD1 may also be 
regulated by these small lipids (in addition to the well-known regulation of 
directionality conferred by H6PDH (Atanasov et al., 2004)) through competition for 
cofactor. Such regulation maybe of particular importance in atherosclerosis, for 
example, which is associated with increased levels of oxysterols which are readily 
sequestered into macrophages and perivascular adipocytes (Kritharides, 1995) both 
of which express 11HSD1. 
 
The nature of the competition between these alternative and conventional substrates 
for 11HSD1 has not been studied to date. However there is limited evidence of 
these types of interactions from studies of other 7-oxygenated substrates; it has been 
shown that 7-neurosteroids can act as inhibitors of human 11HSD1 (Nashev et al., 
2007); although this report does not fully elucidate the nature or the magnitude of 
this interaction. Recent work with other 7-hydroxylated compounds related to 
steroids also report competition between different substrates for metabolism by 
11HSD1 (Robinzon et al., 2003). For example, bile acids such as chenodeoxycholic 
acid (CDCA) can inhibit 11HSD1 activity (Escher et al., 1998; McNeilly et al., 
2006). More recently, work performed during the execution of this thesis, showed 
that 7-KC was more potent than 7OHC at inhibiting the conversion of 




glucocorticoids by 11HSD1 in human adipocytes (Wamil et al., 2008). However, in 
the same study the effect of 7-oxysterols on dehydrogenation of glucocorticoids by 
11HSD1 was not tested. 
4.2. Research Hypothesis And Aims 
The work in this chapter addressed the hypothesis that 7-oxysterols inhibit 
metabolism of glucocorticoids by 11HSD1. Secondly, it tested the hypothesis that 
the preferred direction of glucocorticoid metabolism by 11HSD1 will be influenced 
in vitro by the cellular levels of cholesterol, the precursor of 7-oxysterols. 
  
The specific aims for the work described in this chapter were: 
 
• To determine whether 7-oxysterols inhibit glucocorticoid metabolism by 
11HSD1; 
• To establish the kinetic parameters to describe this competition; 
• To determine whether an increase in, or reduction of, cellular levels of cholesterol 
and 7-oxysterols alters the kinetics of 11HSD1-mediated glucocorticoid 
metabolism. 
4.3. Methods 
4.3.1. Inhibition Of 11HSD1-mediated Reactions  
The following model systems were used to investigate inhibitory kinetics: 
 
1)  Recombinant m11HSD1 protein, 
 
2)  Recombinant m11HSD1 protein generated in stably-transfected HEK293 cells, 
 
3)  Murine hepatic microsomes. 




4.3.1.1. Preparation Of Oxysterol Solutions 
All oxysterols were prepared in ethanol containing butylated hydroxytoluene (BHT; 
50 µg/ml), as described (section 2.2.2). The stock solution (30 mM, under argon) 
was further diluted in ethanol to achieve a 10 mM stock (Lizard et al., 1999). Serial 
dilutions were prepared in phosphate buffer or in culture medium (DMEM). 
 
For microsomal assays assessing the ability of 7-oxysterols to inhibit glucocorticoid 
conversion, solutions representing a range of concentrations of 7-oxysterols were 
prepared in ethanol, of which 5 µl was added to each assay, to obtain final 
concentrations of 10-10 - 10-4.5 M.  
 
For tissue culture experiments, stock solutions of individual oxysterols (section 
2.2.2) were prepared in DMEM. Of these stocks, an appropriate volume (2 ml/well) 
was added to the cells to obtain final concentrations of 10-10 - 10-4.5 M). A mixture of 
oxysterols containing 19-OHC, 22-OHC, 25-OHC, 27-OHC and 7-oxysterols was 
prepared as a stock solution, by combining aliquots of each (10 mM, 500 µl in 
ethanol) under argon, and vortexing (RT, 10 sec). The solvent was removed by 
evaporation (argon, RT) and dried residue was dissolved in ethanol (500 µl, 
containing 50 µg/ml BHT). The stock of mixture of oxysterols was sealed under 
argon, sonicated (on ice, 10 min) then vortexed (400 rpm, RT, 10 min) until fully 
dissolved. Further dilutions of oxysterols were made in DMEM or buffer, as 
appropriate.  
4.3.1.2. Inhibition of Dehydrogenation of Corticosterone By 7-
Oxysterols 
a) Characterisation of inhibitory kinetics by Dixon Plot: recombinant protein (20 
µg/ml) was incubated with cofactor (NADP+, 2 mM) as in section 2.5.2, and in the 
presence of four concentrations of substrate corticosterone (B; 5 µl; 20, 25, 100 and 
200 nM) plus each of four different concentrations of inhibitor (7OHC; 5 µl; 1, 2, 5 
and 10 µM). 




b) Assessment of IC50 in intact HEK293 cells stably-transfected to produce 
m11HSD1. Cells were exposed to medium containing radioactive substrate ([3H]4-
B, 30 nM) as in section 2.6.2. Assays were performed in 12-well plates (105 
cells/ml/well) and individual oxysterols (5 µl/per well, final concentration 10-10 – 10-
4.5 M, 0.01% ethanol control) were added to the medium together with the 
glucocorticoid (30 nM) and incubated; typically for 45 – 60 min. After incubation, 
cell morphology was checked by light microscopy, since supra-physiological 
concentrations of oxysterols had been used. 
 
c) Assessment of inhibition ex vivo: was performed using murine hepatic 
microsomes (260 µg/ml) as in section 2.7.1. The velocity of 11HSD1 oxidation of 
B  A, (B, 20 nM) was assessed in the presence of various concentrations of 7-
oxysterols (5 µl, 7-KC, or 7OHC, final concentration 10-10 – 10-4.5 M) as an 
inhibitor. Upon obtaining concentration of 7OHC that caused 50% inhibition (IC50) 
further kinetic parameters of metabolism of B (20 nM – 2 µM) in the presence of 
single concentration of 7OHC (IC50) or vehicle (0.01% ethanol control) and using 
protein concentration as above were also determined. Michaelis-Menten and 
Lineweaver-Burke Analysis were performed as described in section 4.3.1. 
4.3.1.3. Inhibition Of Reduction Of 11-Dehydrocorticosterone By 
7-Oxysterols 
a) Characterisation of inhibitory kinetics by Dixon Plot: recombinant m11HSD1 
(20 µg/ml) was incubated (30 min, RT) with cofactor (NADPH, 2 mM) as in section 
2.5.3 and in the presence of four concentrations of substrate, 11-
dehydrocorticosterone (A) (500 nM, 1, 5, 10 µM) with each of four concentrations of 
inhibitor (7-KC, 5 µl of 500 nM, 1, 2,10 and 20 µM). 
 
b) Assessment of IC50 in HEK293 cells stably-transfected to produce m11HSD1. 
Cells were exposed to medium containing radioactive substrate ([3H]4-A, 30 nM) as 
described in section 2.6.4. Assays were performed on 12-well plates (1 ml/well) and 
individual oxysterols (5 µl/per well, final concentration 10-9-10-4.5 M, 0.01% ethanol 




control) were added, together with unlabelled A (30 nM) and incubated; typically for 
45 – 60 min. 
 
c) Assessment of inhibition in vitro: was performed using murine hepatic 
microsomes (260 µg/ml) as in section 2.7.3. The velocity of the reduction of A  B 
(A, 20 nM) was measured in the presence of various concentrations (sections 4.3.1.2) 
of 7-oxysterols as inhibitors (5 µl, 10-10 – 10-4.5 M). 
4.3.2. Detection Of Oxysterols 
Detection of steroids and oxysterols was achieved using HPLC with UV- and on-line 
scintillation detection as described (sections 2.12.1 and 2.12.2, respectively). 
4.3.3. Controls And Quantitation 
All measurements of enzyme velocity in sections 4.3.1 and 4.3.2 were carried out 
within the linear range of substrate-to-product formation (<30% substrate 
conversion). Each experiment was carried out in duplicate and controls of vehicle 
(ethanol, 0.01%) alone were included.  
4.3.4. Cholesterol Manipulation In Vitro  
Cellular cholesterol levels were manipulated by utilizing the cholesterol-carrier, 
methyl--cyclodextrin (MCD). HEK293 cells, transfected with HSD11B1 to 
generate m11HSD1 recombinant protein (section 2.6.1), were plated on 6-well 
plates and incubated overnight in medium containing stripped serum (10%). The next 
day cells were maintained in serum-free media (DMEM, 1h), before being exposed 
to the following treatments: 
4.3.4.1. Cholesterol Depletion 
For cholesterol depletion, cells were treated with MCD (10 mM, in DMEM, 37°C, 
1h), as this was expected to reduce membrane cholesterol by ~89% (Francis and et 
al, 1999). According to previous work utilizing the same procedure (Danthi and 
Chow, 2004), cells maintained reduced cholesterol levels for at least 48 h following 




30 – 60 min treatment. Since cellular cholesterol levels were successfully reduced 
after 1h incubation, this time point was used in further experiments. Control cells 
treated with DMEM only were also included on the same plate.  
4.3.4.2. Cholesterol Loading 
To increase cholesterol levels in the cell membrane, MCD (5 mM, in DMEM, 
37°C, 1h) was prepared in a complex with cholesterol (200 µg/ml) to give 
Cholesterol:MCD at a molar ratio of 1:8, as described by Klein et al., (1995). 
Cholesterol (10 mg/ml) was dissolved in chloroform:methanol (2:1, v/v, 1 ml), then 
transferred to a Falcon tube containing MCD (5 mM, 66.9 mg) and chloroform (19 
ml), vortexed (RT, 1 min), sonicated (RT, 3 min) and solvent was evaporated under 
argon. The dried residue was re-solubilised in DMEM (20 ml) and incubated in a 
water bath (60 rpm, 37°C, 16 h) (Levitan et al., 2000), in order to form a cholesterol 
complex chelated with MCD (chol-MCD, 1:8, 5mM). After incubation, the 
mixture was subject to double filtration (as in section 2.6.1.1) and the filtrate used for 
subsequent cell treatment. However, using this initial method of complex formation, 
the levels of cholesterol remained the same between control and treated cells  
(67 ± 9 vs. 72 ± 12 µg/mg protein, control vs. loading) and thus an alternative 
approach was sought. 
 
A new method of augmentation of cellular cholesterol levels was applied by 
treatment with a commercially-available, cholesterol-loaded MCD (chol:MCD, 5 
mM), termed “water-soluble cholesterol”, at a molar ratio 1:6 chol:MCD). “Water-
soluble” cholesterol was dissolved in DMEM (0.01% ethanol) to obtain a 10 mM 
solution. Control cells were treated with serum-free DMEM. A further set of cells 
was subject to cholesterol loading followed by exposure to MCD (10 mM, 37 °C, 
30 min and 1h) to subsequently reduce cellular cholesterol levels. 
4.3.4.3. 11HSD1 Activity - Steroid Conversion 
Following either depletion of (section 4.3.3.1), or loading with (section 4.3.3.2) 
cholesterol, cells were washed in DMEM (37°C), then in PBS (4°C) and 
measurements of 11HSD1 activity were performed. Cells (5x106 cells/well) were 




incubated in serum-free DMEM containing [3H]4-B or [
3H]4-A (30 nM per well, 1 h) 
for subsequent measurement of dehydrogenation or reduction respectively by 
11HSD1, as described (sections 2.6.2 and 2.6.4, respectively). Steroids were 
extracted from the media (section 2.6.2.1) and analysed as in section 2.12.2.1. 
4.3.4.4.  Determination Of Cholesterol And 7-Oxysterol Levels 
Cells were washed in PBS (4°C) then lysed (NaOH (200 µM), 0.6 ml/well) by 
rocking the plate (60 rpm, 4°C, 20 min) (Brown et al., 1997), and an aliquot of 
cellular lysates (100 µl) was removed for determination of protein concentration 
(section 2.4.7). The remaining cellular lysate was used for extraction of cholesterol 
and 7-oxysterols (sections 4.3.3.2 and 2.6.3.2). The organic phases were evaporated 
(argon, RT) and samples stored at -20°C until analysis by GC/MS (section 2.13.2). 
4.3.4.5. Controls And Quantitation 
For quantitation of oxysterols and cholesterol in cells depleted of, or loaded with, 
cholesterol, deuterium-labelled internal standards (d7-7-KC, d7-7OHC, 50 µl) and 
d7-cholesterol (10 µg/10 µl) were added to cells and media (sections 2.6.3.1 and 
2.6.3.2). 
 
For quantitation of cholesterol, a standard curve representing a range of 
concentrations of cholesterol (0.5, 1, 2.5, 5, 10, 12.5, 20, 50 and 100 µM) was 
prepared. Medium (1 ml) containing cholesterol (10 µl) and oxysterols (10 µl) in the 
absence of cells was incubated for the duration of treatment (section 4.3.4.3), on a 
24-well plate, in duplicate and all other controls were included, as described (section 
2.6.6). A new standard curve was generated during each assay to control for 
differences in incubation and extraction. An exemplar standard curve of cholesterol 
is shown (Figure 4.3 – 1). 










Figure 4.3-1 Exemplar standard curve for quantitation of cholesterol 
The standard curve representing the ratio of peak areas (cholesterol/d7-cholesterol) vs. a 
known amount of cholesterol (µg). A linear regression equation was obtained for standard 
curve, and line (teal) was deemed acceptable if R2 > 0.98. All data are mean ± SEM, n=3, in 
duplicate. Chol, Cholesterol. 




4.3.5. Data Analysis Of Enzyme Kinetics 
The percentage inhibition of enzyme velocity by 7-oxysterols was calculated as a 
ratio of conversion rate in the presence of inhibitor to the conversion rate in the 
presence of vehicle (ethanol) and multiplied by 100. For calculation of velocity of 
product generation, non-linear regression analysis of data was performed and the 
Michaelis-Menten equation applied as described (section 3.3.8, equation 1). Kinetic 
parameters (Vmax and Km) were calculated using Graph Pad prism v5.0.  
 
Ki values were obtained from the Lineweaver-Burke plot or by applying Global Fit 
Analysis (global nonlinear regression, Graph Pad, Prism v5.0) where an R2 value =1 
(representing the goodness of the fit of the regression lines) indicates competitive 
inhibition. A Dixon Plot was generated as the reciprocal of the rate of reaction 
velocity for each substrate concentration [S] against inhibitor concentration [I] as 
follows:  
 
Equation 1:  1/V = (Km [I]/ Vmax [S] Ki) + 1/Vmax (1 + Km/[S]); 
 
Intercept:  Ki = Km/(Vmax*[S]*slope); 
 
Slope = Km/VmaxKi [S]; 
 
The enzyme inhibition constant (Ki) was estimated from the graph (e.g.  
Figure 4.4 – 1) (1/V vs. [I]) using the value for the intercept of the extrapolated 
regression line on the x-axis (i.e. when y=0, [I] = –Ki) or calculated from the slope. 
Intercepting lines were produced by plotting the data for several substrate 
concentrations and the point of interception of these lines represents the value of Ki. 
The different types of inhibition may be distinguished as follows: 
 
A competitive inhibitor – acts only to increase the apparent Km for a substrate, the 
Vmax remains unchanged. An increase in [S] at constant [I] decreases the degree of 




inhibition. The lines of Dixon plot converge above the x-axis, and the value of [I] 
where the lines intersect is –1/Ki. The intercept on the y-axis is 1/Vmax. 
 
The only effect of a non-competitive inhibitor is to decrease Vmax. The values of 
apparent Km remain unchanged. The lines of the Dixon plot converge on the x-axis, 
and the value of [I] where the lines intersect is –Ki (at 1/Vmax = 0). The intercept on 
the y-axis is 1/Vmax (at [I] = 0).  
 
The un-competitive inhibitor decreases Vmax and Km to the same extent. The lines 
of Dixon plot are parallel. 
 
4.3.6. Statistical Analysis 
All data are mean ± standard error of the mean (SEM). For purified recombinant 
m11HSD1, the means were obtained from three individual experiments. All 
experiments using animal tissues were carried out using tissues from 6 animals. Each 
assay was performed in duplicate or triplicate. Statistical significance was 
determined using Student’s unpaired t-test. 





4.4.1. Kinetics Of Inhibition Of Dehydrogenation of Glucocorticoids 
by Oxysterols 
The actions of 7-oxysterols to inhibit 11HSD1-mediated glucocorticoid oxidation 
were explored using several models. Attempts were also made to investigate the 
reverse scenario, in which dehydrogenation of 7-oxysterols by 11HSD1 was 
assessed in the presence of glucocorticoids (100 nM). However, under these 
circumstances, the conversion of 7-oxysterols by m11HSD1 could not be measured 
in the presence of glucocorticoids, due to stronger binding and faster metabolism of 
glucocorticoids by 11HSD1 (as established in section 3.4.3). The presence of the 
vehicle (ethanol, used to dissolve the inhibitor) did not affect the reaction rate in the 
amounts used. The presence of 7OHC or 7-KC did not compromise viability of 
HEK293 cells, as assessed using trypan blue staining (section 2.6.1.2). 
4.4.1.1. Inhibition of Glucocorticoid Dehydrogenation Catalysed 
by Recombinant m11HSD1 
A Dixon Plot was used to identify of the mode of inhibition of glucocorticoid 
metabolism mediated by oxysterols and for estimation of the dissociation constant 
(Ki). In Figure 4.4 – 1 a plot of 1/V versus [7OHC], as the inhibitor, is shown in the 
presence of substrate (B), thus assessing the potency of 7OHC to inhibit the 
oxidation of B. This Dixon plot showed that 7OHC could competitively inhibit 
11HSD1-mediated inactivation of corticosterone, since the regression lines 
intercepted above the x-axis. At low physiological substrate concentrations (B, 25-50 
nM) the inhibitory effect of 7OHC was more noticeable than at higher 
concentrations of B (100 nM), whereas inhibition by 7OHC was not seen at 200 nM 
concentration of substrate. 










Figure 4.4-1 Dixon plot of 1/v vs. [7OHC] acting to inhibit metabolism of 
corticosterone to 11-dehydrocorticosterone by recombinant m11HSD1.  
Conversion of corticosterone (B) to 11-dehydrocorticosterone (A) was quantified in the 
presence of NADP (2 mM), and 7-hydroxycholesterol (7OHC; 1, 2, 4 and 10 µM). 
Reaction velocities (v, pmol/µg/min) were calculated for each concentration of B (25, 50, 100 
and 200 nM). A graph of 1/v versus inhibitor (7OHC) concentration (Dixon Plot) was 
constructed and resembles the pattern for competitive inhibition of corticosterone 
metabolism. The dissociation constant (Ki) for potency of 7OHC as an inhibitor was 
determined where the lines on the graph converged above the x-axis (range of B, 25 – 100 
nM) and was 908 ± 53 nM. Data are mean, SEM range was ± 3 – 15 pmo/µg/min (omitted 
for clarity of figure), n=3, in duplicate. 




The Ki of 7OHC was estimated as 908 ± 53nM. From the intercept on the y-axis, 
the 1/Vmax value is obtained, whereby Vmax was estimated as 0.192 ± 0.020 
pmol/µg/min and this was unchanged in the presence of inhibitor (Vmax 0.212 ± 
0.008 pmol/µg/min). The apparent Km values increased (54.5 ± 2.5 – 178.4 ± 21.0 
nM) in the presence of inhibitor (25 – 100 nM). Therefore, the Dixon plot resembled 
competitive inhibition. 
4.4.1.2. Inhibition Of Glucocorticoid Dehydrogenation Catalysed 
By m11HSD1 Expressed In HEK293 Cells. 
The inhibitory potency of 7OHC was explored in HEK293 cells transfected to 
generate m11HSD1. Inhibition of the dehydrogenation of glucocorticoids (B → A) 
was concentration-dependent and observed at concentrations of 7OHC as low as 
100 nM (Figure 4.4. – 2A). An IC50 of 0.5 µM was assigned (Table 4 - 1). These 
experiments were extended to include other endogenous oxysterols (Figure 4.4. – 
2B). Of those tested, 7OHC was the most potent. Other oxysterols (including 7-KC) 
did not significantly influence the activity of 11HSD1, even when tested at 
concentrations as high as 100 µM (Figure 4.4 – 2B). 




  A)              C) 
 
  B)              D) 
   
 
 
Figure 4.4-2 The relative abilities of different oxysterols to inhibit metabolism 
of glucocorticoids by 11HSD1. 
The abilities of selected oxysterols to inhibit (A,C) dehydrogenation of corticosterone to 11-
dehydrocorticosterone and (B,D) reduction of 11-dehydrocorticosterone to corticosterone 
were tested in vitro. Percentage inhibition relative to vehicle  
(% Control) was calculated after treating HEK293 cells expressing m11HSD1 with the 
relevant oxysterol diluted in DMEM (1 nM – 10 mM). Data are mean ± SEM from a minimum 
of n=3-6 experiments performed in duplicate for cholesterol and for each oxysterol (7-
hydroxycholesterol, 7OHC; 7-ketocholesterol, 7-KC; hydroxycholesterol, OHC).  




4.4.1.3. Inhibition of Dehydrogenation Catalysed By 11HSD1 in 
Murine Hepatic Microsomes 
Kinetic parameters describing inhibition of dehydrogenation of glucocorticoids by 
7OHC were further determined in murine hepatic microsomes using various 
substrate concentrations to determine inhibitory concentrations. The potency of 
7OHC to inhibit metabolism of corticosterone (IC50) of 2.2 µM was assigned and is 
summarised in Table 4 - 1 and a graphical example is shown in Figure 4.4 – 3A.  
 
The potency of 7OHC to inhibit dehydrogenation of corticosterone by microsomal 
11HSD1 was further analysed by constructing Michaelis-Menten and Lineweaver-
Burke Plots (Figure 4.4 – 4A & B), yielding a Ki = 1.70 ± 0.06 µM. The maximal 
velocities (Vmax) remained unchanged in the presence of inhibitor  
(26.01± 9.90 pmol/mg/min), compared with control (35.9 ± 15.8 pmol/mg/min). The 
apparent Km values increased in the presence of inhibitor (951.5 ± 250 vs. 
244 ± 18 nM in control) resembling competitive inhibition.  
 
 










Concentrations (IC50) of 7-hydroxycholesterol (7OHC) or 7-ketocholesterol (7-KC) 
resulting in 50% inhibition of metabolism of glucocorticoids by m11HSD1. The rates of 
dehydrogenation of corticosterone (B) or reduction of 11-dehydrocorticosterone (A) were 
measured in HEK293 cells and murine hepatic microsomes (MLM), in the presence of a 
fixed substrate concentration (20 nM) and a range of concentrations of inhibitor (10-10 - 10-4.5 
M). The IC50 values for 7OHC show that it was a better inhibitor of dehydrogenation of B 
than 7-KC was of reduction of A. Data are mean ± SEM, n=6. n/i., inhibition not observed. 
HEK293 MLM 
IC50 (µM) 
Dehydrogenation of Corticosterone 
7OHC 0.486 ± 0.090 2.2 ± 0.4 
7-KC n/i n/i 
 Reduction of 11-Dehydrocorticosterone 
7OHC n/i n/i 
7-KC 35.7 ± 2.8 19.4 ± 1.2 





   A)            B) 
 
   Log10[7OHC, M]           Log10[7-KC, M] 
 
 
Figure 4.4-3 Inhibition of glucocorticoid metabolism by 7-oxysterols. 
Concentration-dependent inhibition of A) dehydrogenation of corticosterone (20 nM) by 7-
hydroxycholesterol (7OHC; 10-10 – 10-4 M), and B) reduction of 11-dehydrocorticosterone 
(20 nM) by 7-ketocholesterol (7-KC; 10-10 – 10-4 M) in murine hepatic microsomes. All data 
are mean ± SEM, n=5, in duplicate. 











Figure 4.4-4 Michaelis-Menten Plot and Lineweaver-Burke transformation of 
velocities of dehydrogenation of corticosterone by 11HSD1 in the presence 
and absence of 7OHC 
A) The velocity of dehydrogenation of corticosterone was assessed in murine hepatic 
microsomes (n = 5 - 6), and presented as a Michaelis-Menten Plot. A range of 
concentrations of corticosterone was incubated in the presence of vehicle (ethanol; filled 
circles,) or in the presence of 7OHC at the previously established IC50 concentration (2.2 
µM; open circles). B) Lineweaver-Burke – double reciprocal plot. A plot of 1/v against 1/s of 
reaction velocity in the presence of a range of concentrations of corticosterone was 
compared in the presence of vehicle or 7OHC. Both Plots show an inhibition of the 
conversion of B to A by11HSD1 in the presence of 7OHC. All data are mean ± SEM, n=5, 
in duplicate. 




4.4.2. Kinetics Of Inhibition Of Reduction of Glucocorticoids by 
Oxysterols 
4.4.2.1. Inhibition Of Reduction of Glucocorticoids Catalysed By 
Recombinant m11HSD1 
The kinetics of glucocorticoid metabolism in the presence of 7-oxysterols were 
explored using Dixon plots. Figure 4.4 – 5 shows a plot of 1/V versus [7-KC], testing 
the ability of 7-KC to inhibit reduction of 11-dehydrocorticosterone by 11HSD1. In 
the presence of the lowest concentration of substrate used (500 nM), 7-KC showed a 
pronounced inhibition of reduction of A. Its inhibitory actions were diminished with 
increasing concentrations of A (1 µM – 10 µM). The lines of 1/V at each substrate 
concentration converged above the x-axis and the value for Ki was estimated as 7.33 
± 1.76 µM. The Vmax was 6.85 ± 1.58 pmol/µg/min in the presence of inhibitor and 
this was unchanged from control (7.2 ± 2.0 pmol/µg/min). The apparent Km values 
did not increase (0.386 ± 0.020 – 0.446 ± 0.080 µM) in the presence of inhibitor (500 
nM – 5 µM), resembling a very weak competitive inhibition. 
 
4.4.2.2. Inhibition of Glucocorticoid Reduction Catalysed by 
m11HSD1 expressed in HEK293 cells 
7-KC was a weak inhibitor of the reduction of 11-dehydrocorticosterone to 
corticosterone (Figure 4.4 – 2C), achieving only 40% inhibition even at the highest 
concentration used (100 µM). Thus an IC50 was not assigned. Therefore, again in this 
model, 7OHC was a better inhibitor of dehydrogenation (B→A) than 7-KC was of 
reduction (A→B). Again these experiments were extended to include other 
oxysterols (including 7OHC), none of which inhibited reduction of A to B, 
although cholesterol alone exhibited some inhibitory effects (Figure 4.4 – 2D). 










Figure 4.4-5 Dixon plot of 1/v vs. [7-KC] acting to inhibit reduction of  
11-dehydrocorticosterone to corticosterone by recombinant m11HSD1.  
The velocity of reduction of 11-dehydrocorticosterone (A) to corticosterone (B) was 
quantified in the presence of NADPH (2mM), and 7-ketocholesterol (7-KC) as an inhibitor 
(500 nM, 1, 2, 10 and 20 µM). Reaction velocities (v, pmol/µg/min) were calculated for each 
concentration of A (500 nM, 1, 5 and 10 µM). A graph of 1/v versus inhibitor (7-KC) 
concentration (Dixon Plot) was constructed and resembles the pattern for competitive 
inhibition of 11-dehydrocorticosterone metabolism. The dissociation constant (Ki) for 
potency of 7-KC as an inhibitor was determined where the lines on the graph converged 
above the x-axis (range of A, 0.5 - 1 µM) and was 7.3 ± 1.7 µM. 7-KC. Data are mean; SEM 
range was ± 0.02 – 0.3 pmo/µg/min (omitted for clarity of figure), n=3, in duplicate. 




4.4.2.3. Inhibition of Reduction Catalysed by 11HSD1 in Murine 
Hepatic Microsomes  
The ability of 7-KC to inhibit metabolism of 11-dehydrocorticosterone (IC50) is 
summarised in Table 4 -1 and a graphical example is shown in Figure 4.4 – 3B. 7-
KC was a weak inhibitor of the reduction of 11-dehydrocorticosterone, and further 
analysis (Michaelis-Menten and Lineweaver-Burke) of its potency to inhibit this 
reaction by microsomal 11HSD1 was not conducted. Thus in this model as well, 
7OHC was a better inhibitor of dehydrogenation (B→A) than 7-KC was of 
reduction (A→B). 
4.4.3. Cholesterol Depletion In Vitro  
Incubating HEK293 cells stably-transfected to produce m11HSD1, with culture 
medium containing MCD resulted in a reduction of cholesterol levels. Total levels 
of cholesterol were reduced by ~87% within 1h of treatment compared to controls 
(Figure 4.4 – 6). 
 
Cholesterol depletion reduced the levels of 7-oxysterol in HEK293 cells and in some 
cases these levels were undetectable (Limit of detection (LOD) 3.2 ± 0.2 pmol/mg). 
Basal levels of 7-oxysterols were always detected in control cells (DMEM only), in 
the following ranges, 7-KC: 19.40±1.08 pmol/mg and 7OHC: 4.37±1.90 pmol/mg. 
These levels were within the range reported for the intact cells treated with vehicle 
only (Chapter 3). 
 
The ability of 11HSD1 to convert steroids in the cells was monitored, in both the 
reductase and dehydrogenase directions upon cellular depletion of cholesterol with 
MCD. As anticipated, in controls the conversion of 11-dehydrocorticosterone to 
corticosterone by 11HSD1 predominated over the reverse reaction. Interestingly, 
the depletion of cellular cholesterol or 7-oxysterol levels in HEK293 did not 
influence 11HSD1 activity, in either the reductase or dehydrogenase directions 
(Figure 4.4 – 7). 










Figure 4.4-6 Cholesterol manipulation in vitro. 
HEK293 cells expressing m11HSD1 were depleted of cholesterol using methyl--
cyclodextrin carrier (MCD, 10 mM), while upload of cholesterol was achieved using a 
complex of cholesterol with the MCD carrier (Chol:MCD, 1:6, 5 mM). The levels of 
cholesterol in the cells were measured using gas chromatography/mass spectrometry 
(GC/MS). All data are mean ± SEM, n=4, in duplicate, expressed per milligram protein. 
Differences were assessed using 1-way ANOVA, **p<0.01. 











Figure 4.4-7 The influence of cellular cholesterol content on the velocity of 
glucocorticoid metabolism by m11HSD1. 
HEK293 cells stably-transfected to express m11HSD1 were treated with DMEM contianing 
methyl--cyclodextrin (MCD, 10 mM, 1h) or cholesterol in a complex with MCD 
(Chol:MCD, 1:6 ratio, 1h). Control cells were treated with culture medium only (DMEM). 
After manipulation of cholesterol, the reaction velocity was measured in the reductase (red, 
A → B) and dehydrogenase (blue, B → A) directions. The reaction velocities were expressed 
as pmol/mg protein/h. Incubation of cells with the cholesterol lowering complex, MCD, 
depleted cells of cholesterol (Figure 4.4 - 6) but did not affect directionality of 11HSD1. 
Incubation of HEK293 cells with cholesterol in complex with MCD (Chol: MCD), resulted in 
cholesterol loading. This treatment significantly lowered the rate of reduction of A → B and 
there was a trend for an increase in velocity of dehydrogenation of B → A (p=0.09). Thus 
cholesterol loading, but not depletion, alters the set-point of the equilibrium of 11HSD1. All 
data are mean ± SEM, n=4, in duplicate. Differences were assessed using unpaired 
Student’s t-test. DMEM, Dulbecco’s modified Eagle’s medium. 




4.4.4. Cholesterol Loading - Cholesterol:MCD Complex 
Incubation of HEK293 cells with cholesterol complexed with MCD resulted in a 
significant increase (p<0.01) in cholesterol levels compared with controls  
(Figure 4.4 – 6). To test that this treatment was reversible, cells loaded with 
cholesterol were then treated with MCD, and this successfully lowered the 
cholesterol levels (105.6 ± 9; **p<0.01 vs. loading) within 30 min or returned them 
to those of control levels (78.4 ± 12 µg/mg) within 1h of treatment. 
 
The levels of 7-oxysterols were more readily detected after cholesterol loading, and 
levels of 7-KC were significantly higher compared with control (7-KC: 39.48 ± 3.01 
vs. 19.40 ± 1.08 pmol/mg; p<0.05), while in the case of 7OHC there was a trend 
(p=0.08) towards increased concentrations (7OHC: 17.6 ± 2.4 pmol/mg vs. 
undetected, LOD 3.2 ± 0.2 pmol/mg) compared with control. 
 
Following cholesterol loading, the velocity of reduction of 11-dehydrocorticosterone 
to corticosterone was significantly reduced (Figure 4.4 – 7), compared with control 
and there was a trend for an increased rate of dehydrogenation of corticosterone. 





The work presented in this chapter tested the hypothesis that the presence of 7-
oxysterols influences the metabolism of glucocorticoids by 11HSD1. The initial 
aim of this work was to investigate the competition for 11HSD1 metabolism by the 
two classes of substrates, glucocorticoids and 7-oxysterols. Subsequently the 
influence of in vitro manipulation of cellular cholesterol levels on metabolism of 
glucocorticoids by 11HSD1 was investigated. 
4.5.1. 7-Oxysterols Compete With Glucocorticoids For Metabolism By 
m11HSD1 
Kinetic parameters determined in this chapter indicate that 7-oxysterols not only act 
as substrates for 11HSD1 but also compete with glucocorticoids (the conventional 
substrates) for metabolism by this enzyme. Three different approaches were taken to 
test the competition between 7-oxysterols and glucocorticoids for metabolism by 
m11HSD1, using: recombinant m11HSD1 protein, murine hepatic microsomes 
and intact (HEK293) cells stably expressing m11HSD1. Two different approaches 
were used to assess the Ki for binding of each 7-oxysterol; Lineweaver-Burk and 
Dixon plot (both linearised representations of the Michaelis-Menten equation). It has 
been shown before that Dixon plots do not provide a more robust estimate of Ki than 
Lineweaver-Burk plots (Kakkar et al., 1999) and the values obtained between the 
two approaches were certainly comparable. However, Dixon plots were used in order 
to establish the type of inhibition between the two classes of substrates. 
 
The estimates of Ki were important as they predict whether the inhibitory actions of 
7-oxysterols on glucocorticoids are likely to occur in vivo, taking into account 
physiological levels of these substrates. The range of inhibitory concentrations of  
7-oxysterols used in this work, encompassed the physiological range of  
7-oxysterols present in human plasma (low nM) and the pathophysiological levels 
(low µM) detected in atherosclerotic plaques (Brown et al., 1997; Dzeletovic et al., 
1995a; Dzeletovic et al., 1995b; Prunet et al., 2006). The inhibitory concentrations 




obtained using all three approaches described above have predicted that 
concentrations of 7-oxysterols in a range between 900 nM and 8 µM may have 
potent inhibitory actions on metabolism of glucocorticoids by 11HSD1 in the body.  
 
Interestingly, the work in this chapter also demonstrates that 7-oxysterols, but not 
other oxysterols, inhibit glucocorticoid metabolism, at least in HEK293 cells. 
Previous investigations (Biasi et al., 2004; Steffen et al., 2006) have mostly studied 
the effect of individual oxysterols on cell viability. However, oxysterols may have 
synergistic effects that exacerbate pro-apoptotic actions suggesting that combinations 
of different oxysterols should be applied to these models (Lizard, 2006). Such 
conditions were investigated in the work described here, but a mixture of oxysterols 
did not display the ability to inhibit the metabolism of glucocorticoids by 11HSD1. 
However, this situation in other cells, particularly during disease pathogenesis may 
be more complex: for example, during macrophage accumulation in atherosclerotic 
plaque development. It would be anticipated that macrophages might accumulate 
oxysterols, which could further promote apoptosis of these cells as well as inhibit the 
11HSD1-mediated conversion of glucocorticoids (Hadoke et al., 2009). 
 
Consistently in each approach, the inhibitory effects of 7-oxysterols on 
glucocorticoid metabolism were concentration-dependent and reached half maximal 
inhibitory concentrations (IC50) in concentrations ranging from 0.5 – 20 µM. 7-KC 
and 7OHC acted in opposite ways, with 7-KC slowing the rate of reduction but 
7OHC diminishing dehydrogenation catalysed by 11HSD1. The effects of 7OHC 
were more pronounced, particularly at lower concentrations of glucocorticoids. The 
kinetic measurements showed that 7OHC was a strong competitive inhibitor of 
dehydrogenation of corticosterone but it did not inhibit the reduction of 11-
dehydrocorticosterone. One interpretation of this finding is that inhibitory actions of 
7OHC may act to predominantly slow dehydrogenation of corticosterone, thereby 
sustaining the predominant generation of active glucocorticoid via reduction of 11-
dehydrocorticosteorne, in rodents. 
 




Based on the demonstration that both 7-KC and 11-dehydrocorticosterone can be 
metabolised by 11HSD1, it was expected that 7-KC would act as a potent 
competitive inhibitor of 11HSD1 reductase activity. However, although this effect 
could be seen in all model systems, 7-KC was consistently less effective as an 
inhibitor of reduction, compared with 7OHC acting to prevent dehydrogenation. 
During preparation of this thesis a paper by Balázs et al. (2009) reported that they 
could not detect any inhibition of human 11HSD1 reductase activity in lysates or 
HEK293 cells by 7-KC or 7OHC. Even in HEK293 cells stably expressing 
11HSD1 and H6PDH (Dakin, 2008), inhibition of reductase activity by 7-KC was 
not observed. However this is not the case in all cells tested. Balázs et al. have 
reported ony the inhibition of 11HSD1 reductase activity by 7-KC (IC50 8.1 ± 0.9 
µM) in differentiated THP-1 macrophages, and half as efficiently by 7OHC (of 
reductase), whereas Wamil et al., (2009) have shown inhibitory actions of 7-KC on 
reductive metabolism by 11HSD1 in 3T3-L1 human adipocytes. It is unclear why 
11HSD1 activity is differentially affected by 7-KC or 7OHC but perhaps this 
effect is cell type dependent. It is possible that cell-specific inhibition by 7-KC is due 
to differential post-transcriptional modification of 11HSD1 in vivo (such as 
phosphorylation, or glycosylation at asparagine207 (Asn207)) which are known to be 
essential for enzyme activity in either direction (Agarwal et al., 1995). Such post-
transcriptional modification may not affect the binding or catalysis of 
glucocorticoids, but may interfere with the binding of 7-oxysterols. Another 
indication that the ability of 7-oxysterols to inhibit 11HSD1-mediated GC 
metabolism is cell-specific is provided by the fact that some cells accumulate 7-
oxysterols more readiy than others (a characteristic example being adipocytes and 
macrophages (Brown and Jessup, 1999, 2009)). However, overall the findings 
presented in this Chapter are generally consistent with those in Ch3, in that 7-KC is 
less able to bind efficiently to the active site of 11HSD1. 
 
The converse argument may also be proposed, that glucocorticoids inhibit 
metabolism of 7-oxysterols by 11HSD1. Indeed, this possibility has been raised 
previously in relation to non-glucocorticoid substrates by Robinzon et al., (2003). 
This has been briefly explored in this thesis, but conversion of 7-oxysterols by 




11HSD1 could not be measured in the presence of 100 nM glucocorticoids. It 
appears that, due to lower rates of inter-conversion of 7-oxysterols, the presence of 
glucocorticoids can overcome the ability of 11HSD1 to metabolise 7-oxysterols (as 
established in section 3.4.3) and the same phenomenon is likely to happen in vivo. 
 
It is likely that, under conditions of low circulating glucocorticoids, 7-oxysterols will 
have greater potential to inhibit 11HSD1-mediated metabolism of glucocorticoids 
(as elucidated by the Dixon plot analysis). In contrast, the inhibitory potency of 7-
oxysterols is likely to be attenuated when glucocorticoid levels increase e.g. in the 
morning or under stressful circumstances. It is, therefore, of interest to assess the 
levels of 7-KC and 7OHC concomitantly with those of corticosterone and 11-
dehydrocorticosterone when attempting to interpret the likely role of 11HSD1 in 
physiology or pathophysiology.  
 
Furthermore, it may be proposed that oxysterol-mediated competitive inhibition of 
reduction of glucocorticoids will be more significant under hyperlipidaemic 
conditions (which are associated with a pathological increase of oxidised lipids in 
tissues and plasma, (Brown and Jessup, 2009)) than in normolipidaemia (Wamil et 
al., 2008). For example, inhibition of this reaction may occur in peripheral tissues, 
such as the aortae and macrophages, in which oxysterols can accumulate and reach 
micromolar concentrations (Brown and Jessup, 1999). Although high levels of 
cholesterol are precursors for increased synthesis of 7-oxysterols via non-enzymatic 
routes, it is clear that generation by 11HSD1 may also affect their local levels 
(Jessup and Brown, 2005). However, all potential interactions that may happen 
between 7-oxysterols and glucocorticoids in vivo are predicated on the assumption 
that 7-oxysterols are transported across the ER membrane (Massey, 2006) to the site 
of 11HSD1 activity.  
4.5.2. Manipulation Of Cellular Cholesterol Levels 
In view of the above findings it is possible that factors influencing synthesis of 7-
oxysterols may alter the kinetics of metabolism by 11HSD1. It seems logical that 
increased cholesterol levels in vivo would contribute to subsequent increases in 




oxysterol levels but this relationship is poorly understood. This concept was explored 
further in the context of variations in cellular concentrations of cholesterol. Methyl-
-cyclodextrin (MCD) was used to acutely deplete cholesterol in cultured cells, 
where it acted as a carrier to bind to and remove cholesterol from the membranes. It 
has been suggested that MCD binds cholesterol in lipid rafts (Christian et al., 1997; 
Gaus et al., 2004; Kilsdonk et al., 1995). Lipid rafts are membrane microdomains 
involved in many cellular functions, including transduction of cellular signals and 
cell entry by pathogens (Zeng et al., 2009). 
 
In addition, incubation of MCD with high concentrations of cholesterol can form a 
saturated complex (Chol:MCD) which is used in vitro to deliver cholesterol to the 
cellular membranes by active transport. This complex has been used at a 1:8 molar 
ratio (i.e. the saturation limit of MCD) (Danthi et al., 2004, Klein et al., 1995), but 
in practice in this work, a 1:6 mix was found most efficient. Using cholesterol 
depletion/loading approaches, the work in this chapter demonstrates that depletion of 
cellular cholesterol levels leads to a subsequent reduction in the 7-oxysterol levels, 
whereas increase of cholesterol leads to an increase in 7-oxysterol levels. Most 
importantly, these findings prove that cholesterol is the primary source of some 7-
oxysterols in the cell-type tested. 
 
The depletion of cholesterol in HEK293 cells showed that, despite a reduction in the 
intra-cellular levels of 7-oxysterols, the rate of 11HSD1-mediated glucocorticoid 
metabolism remained similar to controls. A concern with the experimental model 
was that depletion of cholesterol (which, if prolonged, may potentially lead to 
disruption of cell membranes (Byfield et al., 2004)), might also have disturbed the 
coupling between 11HSD1 and H6PDH (Bujalska et al., 2008; Hewitt et al., 2005). 
However, upon removal of cellular cholesterol the activity of 11HSD1 remained 
unchanged. Therefore this suggests that cholesterol depletion did not affect the 
orientation of 11HSD1 in the membrane. 
 
Loading the cells with cholesterol simulated the scenario in obesity and 
dyslipidaemia, where high concentrations of cholesterol may promote high 




concentrations of oxysterols within the oxLDL. Therefore, based on previous 
findings (section 4.5.1), it was hypothesized that increased levels of 7OHC in 
oxLDL would inhibit dehydrogenation of glucocorticoids by 11HSD1, thus 
promoting reduction of inactive to an active glucocorticoid by 11HSD1. Loading 
cholesterol into HEK293 cells, using a cholesterol:MCD complex, successfully 
increased the levels of 7-oxysterols. However, the effect on enzyme direction was 
opposite to that proposed, in that reduction decreased and dehydrogenation 
increased. It is possible this is a consequence of the increase in cellular cholesterol, 




It is again possible that loading HEK293 cells with cholesterol, might have altered 
distribution of lipids in the cell membrane. This would cause disruption to the cell 
membrane, which could be predicted to alter the stability of 11HSD1 within the ER 
and thus influence its activity. Indeed disruption of the cellular environment has been 
shown to suppress reduction and promote dehydrogenation of glucocorticoids by 
11HSD1 in tissues ex vivo (Bujalska et al., 2005; Bujalska et al., 2002), consistent 
with the data in this chapter. Recent work however, with lipid-rich THP-1 
macrophages or adipocytes (Balázs et al., 2009; Wamil et al., 2008), associated the 
ability of 7-KC to inhibit 11HSD1 reductase activity (dehydrogenase was not 
studied) with the ability of these cells to sequester oxysterols. This suggests therefore 
that the effects of cholesterol loading differ in cells that physiologically accumulate 
lipids (e.g. macrophages and adipocytes) and those that are not (e.g. VSMC). To 
shed further light on this relationship, future experiments could be performed using 
primary macrophages (expressing 11HSD1) from hyperlipidaemic or 
atherosclerotic mice, (Gilmour and et al., 2006), where accumulation of cholesterol 
(Qin et al., 2006) and 7-oxysterols has been demonstrated (Brown and Jessup, 1999; 
Libby, 2002a; Lizard et al., 2006). Although primary macrophages and adipocytes 
are the candidate cells for this work, due to expression of 11HSD1, it is crucial to 
consider that 7-oxysterols may readily be utilised via other enzymes present in these 




cells, such as 27-hydroxylase (Javitt, 2008), making these systems more complex to 
study.  
 
Certainly, all of the findings in this Chapter have implications in obesity and 
hypercholesterolaemia, as they suggest that long-term accumulation of lipids in cells 
will influence activation of glucocorticoids by 11HSD1; this remains to be 
confirmed in vivo. In relation to pathophysiology, pharmacological inhibition of 
11HSD1 in atherosclerosis is beneficial as it reduces the actions of active 
glucocorticoid (Hermanowski-Vosatka et al., 2005). The data in this chapter show 
that beneficial effects of inhibition of 11HSD1 may also be due to further 
interactions with 7-oxysterols. 
 














Chapter 5. Levels Of 7-Oxysterols In Murine Plasma 
And Tissues 





Oxysterols are present in the circulation at far greater concentrations than 
cholesterol. The proportions of different oxysterols can vary between plasma 
lipoprotein fractions (Babiker and Diczfalusy, 1998; Diczfalusy et al., 1996) and in 
tissues (Griffiths et al., 2006; Leoni et al., 2005; Tsai, 1984; Vatassery et al., 1997; 
Yoshida et al., 2003). In healthy humans, 7-oxysterols circulate in low micromolar 
concentrations (0.15 – 0.73 µM), of which ~10% constitutes the un-esterified form 
(Dzeletovic et al., 1995b). Under pathological conditions, the levels of particular 
oxysterols may increase by up to 100 times (Adachi et al., 2000; Katz et al., 1982).  
 
Findings from experiments described in previous chapters of this thesis have 
indicated that cellular levels of 7-KC and 7OHC may be dependent on the activity 
of 11HSD1. The influence of 11HSD1 on circulating and tissue levels of 
oxysterols has not been extensively explored. It has been proposed that 11HSD1 
may play a role in detoxification of accumulated 7-KC by preferentially converting 
7-KC to 7OHC in the liver (Schweizer et al., 2004). The inhibition of this enzyme 
(using carbenoxolone) caused a hepatic accumulation of 7-KC in rats (Schweizer et 
al., 2004). In a more recent study, Larsson et al., (2007) showed a rapid inter-
conversion of circulating, deuterium-labelled 7-KC and 7OHC, in healthy 
volunteers. They speculated that changes in circulatory levels of both  
7-oxysterols could be assigned to the actions of 11HSD1. The results from chapter 
3 proposed a dominant dehydrogenation activity of 11HSD1 (7OHC to 7-KC) in 
cells, which may lead to accumulation of 7-KC. Although, the systems assessed in 
previous chapters may not represent actual in vivo conditions for measuring the 
activity of 11HSD1, it still remains possible that 11HSD1 acts as a reductase in 
vivo (7-KC to 7OHC). Therefore, inhibition of 11HSD1 would lead to 
accumulation of 7-KC and reduction in 7OHC.  
 
Several research groups have reported increased levels of 7-oxysterols in the plasma 
of patients with atherosclerosis and diabetes mellitus type 2 (0.1 - 0.6 µM), in 
comparison with normal subjects (low nM, 10 –30 nM) (Endo et al., 2008). In foam 




cells, atherosclerotic plaques and hyperlipidaemic serum levels of 7-oxysterols can 
reach high micromolar concentrations (Brown et al., 2000a; Brown and Jessup, 1999; 
Hodis et al., 1991; Hodis et al., 2000). The accumulation of 7-KC and 7OHC in the 
plasma of patients with hyperlipidaemia and diabetes mellitus is suggested as a 
biomarker of oxidative stress (Arca et al., 2007; Ferderbar et al., 2007; Katsumi et 
al., 2000; Zwirska-Korczala et al., 2002). 11HSD1 may also be regulating the 
proportion of 7-KC to 7OHC, as the ratio of these compounds seems to be 
important for the final (patho)physiological output (Steffen et al., 2006). Despite 
contributing to an in vivo clearance of 7-oxysterols, it is still not understood if 
11HSD1 is regulating their plasma or cellular concentrations. Given that 7-
oxysterols may have a distinct function in the body and may inhibit glucocorticoid 
metabolism, it is essential to clarify the contribution of 11HSD1 to the levels of 7-
oxysterols in circulation. Further, the regulation of circulatory 7-oxysterols by 
11HSD1 is of importance for understanding the atheroprotective effect of 11HSD1 
inhibition. 
5.2. Hypothesis And Aims 
The hypotheses underlying the work presented in this chapter were that 11HSD1-
mediates the ratios of circulating 7-oxysterols, and that 7-KC would accumulate in 
the plasma and tissues upon inhibition of 11HSD1. 
 
Therefore, the specific aims were to: 
• Determine the levels of 7-oxysterols in normolipidemic mice by adapting current 
methods used in humans; 
• Investigate whether 11HSD1 disruption in mice decreases the ratio of 7OHC to 
7-KC, in that it will reduce the levels of 7OHC and/or increase levels of 7-KC in 
plasma and tissues. 
• Determine whether levels of 7-oxysterols are elevated in plasma and tissues of 
atherosclerotic (ApoE-/-) mice, and  
• Investigate whether 11HSD1 inhibition in ApoE-/- mice decreases the ratio of 
7OHC to 7-KC. 





Method development was performed using plasma from a readily available source 
(5-alpha reductase-1 heterozygous; 5αSRD1+/- mice). The concentrations of 
cholesterol and oxysterols were quantified in plasma, livers and/or aortae from three 
murine models (C57Bl/6, ApoE-/- and 11HSD1-/-). 
5.3.1. Method Development 
In order to establish the conditions for gas chromatography/ mass spectrometry 
(GC/MS), preliminary work was performed to adapt methods from the literature for 
use with murine plasma. For this purpose plasma from surplus, male and female,  
5-alpha reductase-1 heterozygous (5αSRD1+/-) mice (age 1 year, n=12) was used 
(Mahendroo et al., 2001). Initial work aimed to determine the sensitivity of methods 
found in the literature and to establish the minimum volume of murine plasma 
needed for determining the levels of 7-oxysterols. The process of method 
development is described in section 5.4.1. Plasma (400-500 µl) was collected by 
pooling samples to obtain n=6 per gender group. Levels of 7-oxysterols were 
determined following lipid extraction and derivatisation steps (section 2.11.1 and 
2.13.2) and the amount of cholesterol and 7-oxysterols quantified using GC/MS 
(section 2.13.3). 
5.3.2. Does Disruption Of 11HSD1 in Mice Regulate The Levels Of 7-
Oxysterols? 
C57Bl/6 and 11HSD1-/- mice (male, age 20 weeks, n=10) were killed and plasma 
and livers (section 2.4) obtained and processed (section 5.3.4). Plasma (400-500 µl) 
was collected by pooling samples. Further extractions of lipids from plasma and 
hepatic fractions (100-200 µl) were performed as described (see sections 2.11.1 - 3). 
Levels of 7-oxysterols were determined as above (section 5.3.1).What are the Levels 
Of 7-Oxysterol in Atherosclerotic ApoE-/- Mice? 
ApoE-/- mice (male, age 22 weeks, n=6) were fed an atherogenic Western diet 
(D12079B, Research diets, USA; fat 21%, protein 29%, carbohydrate 50%, 
cholesterol 0.21%) for 14 weeks. Plasma (250-400 µl) was collected from individual 




animals. Levels of 7-oxysterols and cholesterol were determined as above (section 
5.3.1) 
5.3.3. Does Inhibition Of 11HSD1 Influence The Levels Of 7-
Oxysterols In Atherosclerotic ApoE-/- Mice? 
ApoE-/- mice (male, age 8 weeks, n=6) were fed an atherogenic Western diet for 6 
weeks and then randomized to receive either Western diet (as in 5.3.3, controls) or an 
11HSD1 inhibitor (10 mg/kg/day, mixed within Western diet) for a further 8 weeks. 
The 11HSD1 inhibitor used was the Merck compound 544 ((3-(1-adamantyl)-
6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine; Enamine Ltd., Ukraine), at a 
dose which has previously been shown to inhibit cholesterol accumulation in the 
aortae of ApoE-/- mice (Hermanowski-Vosatka et al., 2005). Levels of 7-oxysterols 
and cholesterol were determined as above (section 5.3.1).  
5.3.4. Tissue Handling At Cull 
All mice were culled by decapitation, except ApoE-/- mice (section 5.3.4.1), which 
were culled by asphyxiation. Plasma samples were obtained as described (section 
2.4.6). Hepatic microsomal and cytosolic fractions were obtained as in section 2.4.2. 
Aortae were processed (as in section 2.4.5) and protein concentrations were 
determined in hepatic and aortic preparations (section 2.4.7). 7-oxysterols were 
extracted from plasma (300-500 µl), microsomes (100 µl) and cytosols (200 µl) as 
described (section 2.11.1) and levels quantified as before (section 2.13.3). 




5.3.5. Evaluation Of Efficacy Of 11HSD1 Inhibitor  
5.3.5.1. Inhibition Of 11HSD1 Activity In Vitro 
For in vitro studies, HEK293 cells transfected with murine 11HSD1 (m11HSD1) 
were treated with steroids (30 nM) or 7-oxysterols (1 µM) as described (section 2.6). 
The 11HSD1 inhibitor (1 µM) was dissolved in water that contained 2-
hydroxypropyl--cyclodextrin (5%, w/v) and vortexed (400 rpm, 2 min). Cells were 
treated with inhibitor or vehicle (5% w/v, 2-hydroxypropyl--cyclodextrin in water) 
for 2 hours prior to addition of medium containing steroids or oxysterols, and 
incubated for a further 35 min or 16 hours, respectively. All in vitro assays of steroid 
conversion were performed in 12-well plates, whilst all assays of conversion of 7-
oxysterols were performed in 6-well plates. The control wells contained medium 
with vehicle (5%, w/v) and no cells, to which EtOH, 7-oxysterols or steroids were 
added. 
5.3.5.2. Inhibition Of 11HSD1 Activity Ex-Vivo 
Assays of inhibition of inter-conversion of corticosterone (B) to 11-
dehydrocorticosterone (A) by 11HSD1 in hepatic homogenates were performed as 
described (section 2.7.1), except that the concentration of unlabelled B was 25 nM. 
Assays of 11-dehydrocorticosterone (A) conversion to corticosterone (B) by 
11HSD1 in hepatic homogenates were performed as described (section 2.7.3), 
except that the concentration of unlabelled A was 25 nM. The low concentrations 
were employed to enhance the possibility of revealing inhibition ex vivo. Samples 
were processed as described (sections 2.7.1 and 2.7.3), and detection of radiolabelled 
steroids performed (section 2.12.2). 
5.3.6. Extraction Of Oxysterols And Cholesterols From Biological 
Fluids And Tissue 
Cholesterol and oxysterols were extracted from plasma (minimum volume 300 µl) 
and biological tissue together with d7-standards, as described in the final optimized 




method (sections 2.11.1 and 2.11.2). The extraction and processing of sub-cellular 
fractions (200 µl) was performed as described (section 2.11.3). Oxysterols and 
cholesterol were analysed and detected using GC/MS (sections 2.13) and quantified 
as described (section 2.13.4). 
5.3.7. Controls And Quantitation 
Blank controls containing water only (0.5 ml) or water with d7-standards (50 µl) 
were included with each experiment. For quantitation of oxysterols and cholesterol, 
standard curves were constructed from samples prepared in water (0.5 ml) containing 
standards (10 µl each) representing a range of concentrations of cholesterol (0.5, 1, 5, 
10, 20, 50, 100 and 500 	M) and oxysterols (5, 25, 50, 125, 250, 500 nM, 1 µM and 
2 µM). Standards were processed as described for test samples (section 2.11.1). A 
new standard curve was generated during each assay to control for inter-assay 
differences in sample processing and extraction.  
 
To calculate the accuracy and precision (inter-assay from n=6 replicates) of the 
analytical method (GC/MS) used in this chapter the following formulae were used: 
 
• (1) Accuracy (% RME) = ((Mean – Reference value)/Reference value) x100  
• (2) Precision (% CV) = (standard deviation/mean) x100 
5.3.8. Statistical Analysis 
All samples of blood (except from ApoE-/- mice) and aortae were obtained by 
pooling the tissue from two animals, as single aliquots, whereas microsomes and 
cytosols were analysed in duplicate. Statistical significance was determined using a 
non-parametric Mann-Whitney test for all data relating plasma/tissue analysis, and  
1-way ANOVA for multiple comparisons, with a Tukey’s posthoc test. In cases of 
normally distributed data, an unpaired Student’s t-test was used for comparisons. 
Pearson correlations were performed to investigate associations between plasma 
concentrations of 7-oxysterols and those of cholesterol. 





5.4.1. Development Of A Method To Quantify The Levels Of 7-
Oxysterols by GC/MS 
An extensive literature search (summarized in Table 5 - 1) on use of mass 
spectrometry for detection of oxysterols in murine plasma and tissues was performed 
(Griffiths et al., 2006; Murakami et al., 2000; Volin, 2001). Notable parts of method 
development pertaining to each stage are given below. Minor adaptations of these 
methods are described with each type of biological sample used.  
 
a) Solvent extraction (Step A, Figure 5.4.3) 
Comparison of two different mixes of solvents used for initial extraction of 
oxysterols from plasma samples showed that these produced similar overall recovery 
of 7OHC and 7-KC (Table 5 - 2). Centrifugation of samples was effective in 
breaking the emulsion between solvent mixture and plasma, and this was achieved 
more quickly with the diethylether:hexane mix (5 min, as opposed to 15 min with 
CHCl3:MeOH). Therefore for reasons of stability, subsequent lipid extractions from 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Oxysterols were extracted into two different mixes of solvents (CHCl3:MeOH, 2:1 and 
diethylether:hexane, 2:3), in duplicate. 7-Oxysterols were quantified by GC/MS and recovery 
was calculated as a percentage of the peak area of standards following extraction compared 
to those without extraction. Data represent mean of duplicates, n=2. 
 
 
b) Solid phase extraction (SPE) (Step B, Figure 5.4.3) 
Following lipid extraction, the recovery of analytes was tested after elution from the 
diol columns. The highest achieved percentages of recovery were ~80 % (7-KC) and 
~52 % (7OHC).  
 
c) Hydrolysis (Saponification) (Step C, Figure 5.4.3) 
Tests were performed to check the effect of temperature on the recovery of 7OHC 
and 7-KC following hydrolysis of plasma lipids (see Table 5 - 3). By performing 
cold hydrolysis, at 4°C, maximal recovery of both 7-KC and 7OHC (and their 
deuterium-labelled isotopomers) was obtained (~100%), compared with warm 
(37°C) or RT-hydrolysis. Subsequently cold saponification was performed on ice 
using KOH (1 ml, 20% in methanol) and in the dark. 
Percentage Recovery (%) 
 
  CHCl3 : MeOH   
(2:1) 
Diethylether : Hexane  
(2:3) 
   H2O   59 74 
7OHC 
 Plasma   40 41 
   H2O 100 84 
7-KC 
 Plasma   68 61 









The recovery of 7-oxysterols (5 µg) from water was tested following the procedure described 
in Figure 5.4 – 1. Hydrolysis (Step C) was performed at different temperatures (cold (4°C), 
RT (22 – 24°C) or Warm (37°C)) by incubating the samples with methanolic KOH (20 %, 0.5 
ml, 2h). Analytes were detected by GC/MS and percentage recovery of 7-oxysterols from 
hydrolysed samples was calculated relevant to the peak areas of non-hydrolysed samples 
subjected to the same conditions (methanol, without KOH). The results show similar 
recoveries of oxysterols when hydrolysis is performed at cold or RT, compared to warm, 
although, greater efficiency is ensured if low temperature is maintained as low as possible 
during the hydrolysis. Data represent mean of duplicates, n=2. 
Hydrolysis 
Cold RT Warm Step C  
 7OHC 7-KC 7OHC 7-KC 7OHC 7-KC 
Percentage         
Recovery  (%) 
100 100 84 99 64 83 




d) Solvent extraction (Step D, Figure 5.4.3) 
Following hydrolysis, 7OHC and 7-KC were extracted into solvents; chloroform or 
diethyl ether (with 50 µg/ml BHT). Use of either solvent resulted in reasonable and 
similar recoveries of 7OHC and 7-KC (Table 5 - 4), but diethyl ether was ultimately 
used to achieve quicker phase separation. 
 
 








Samples were processed for extraction in steps outlined in Figure 5.4 – 1. Efficiency of 
extraction (Step D) was compared using two solvents, chloroform (CHCl3) or diethyl ether. 
The percentage recovery was calculated by expressing the peak areas as a ratio to those of 
non-extracted samples. The results show similar percentage recovery with either solvent. 
However diethyl ether was selected as it allowed a quicker phase separation. Data represent 
mean of duplicates, n=2. 
 
 
5.4.1.1. Detection Of Oxysterols In Biological Fluids And Tissue 
Based on the method development, a final protocol was adopted and used for 
subsequent analyses and detection of oxysterols in murine biological fluids and 
tissues. The full method is outlined in Figure 5.4 – 1.  
Chloroform Diethyl ether 
Step D  
7OHC  7-KC 7OHC  7-KC 
Percentage 
Recovery  (%) 
55 78 58 79 








Figure 5.4-1 Optimized method for the extraction of oxysterols from biological 
fluids and tissues. 
Detection of oxysterols in samples (0.4 - 1ml) of murine biological fluids and tissues includes 
Step A - Solvent extraction; Step B - Solid phase extraction, SPE; Step C – Hydrolysis; Step 
D - Solvent extraction. Subsequent detection of oxysterols was performed by GC/MS 
(section 2.13.3) with the ions selected for analysis as listed in Table 2 - 1.  Toluene : EthylAc 
(1:1), Toluene:Ethylacetate; KOH, Potassium hydroxide; MeOH, Methanol; NaCl, Sodium 
chloride; RT, Room temperature. 




5.4.1.2. Precision And Accuracy Of The Method Developed For 
Detection Of Oxysterols 
The reproducibility of the preferred assay was investigated by analyzing the same 
biological fluids and tissues from mice enriched with known amounts of oxysterols 
(0.5-50 ng) or cholesterol (0.19 – 20 µg) in a 0.2 ml aliquot of sample. To account 
for endogenous concentrations of these compounds, baseline levels were always 
subtracted from those in the enriched samples. Standard curves with known amounts 
of 7KC, 7OHC, 7αOHC or cholesterol were prepared and the linearity of the 
response assessed and reported in Table 5 - 5 as the correlation coefficient (r). The 
inter-assay coefficient of variation for precision was ± 12 %, and the RME of 
accuracy:  3.8 – 15%.  
 
 
Table 5-5 Calibration curves for 7-oxysterols and cholesterol 
 
 
Calibration curves were constructed for the amount of each 7-oxysterol (X) against the 
corresponding ratio of peak-area ratio (Y) of derivatised oxysterol(s) to that of a derivatised-
deuterated internal standard. For detection of 7α-hydroxycholesterol (7αOHC), [2H7]-7-
hydroxycholesterol (7OHC) was used as an internal standard. Linearities were checked by 
linear regression, and the equation for the line of best fit given as in the table. Correlation 
coefficients of r >0.97 were achieved. 7-KC, 7-ketocholesterol. 




  coefficient (r) 
7OHC 1.0 – 20 ng 4 Y = 0.0006X + 0.0043  0.978 
7OHC 0.5 – 50 ng 6 Y = 0.0023X – 0.0254  0.999 
7-KC 0.9 – 50 ng 6 Y = 0.0023X – 0.0255  0.986 
Cholesterol 0.19 – 20 µg 5 Y = 0.0922X + 0.0226   0.987 




5.4.2. Quantitation Of Plasma Lipids In Experimental Animals 
5.4.2.1. Lipid Levels In Murine Plasma – Method Development 
Cholesterol and oxysterols were detected in plasma from transgenic 5αSRD1+/- male 
and female mice, which were available for use, in order to verify the utility of the 
optimized extraction method and refine the calibration range. The nature of this 
genetic background will not be discussed further, however, phenotypically their lipid 
profiles are not different from those of control (C57Bl/6) mice (unpublished, 
Livingstone et al.). Consistent levels of cholesterol (µg/ml) and  
7-oxysterols (ng/ml) were determined in all samples tested (Table 5 - 6). Levels of 
cholesterol were higher than those of 7-oxysterols by three orders of magnitude. The 
order of abundance of 7-oxysterols in murine plasma was 7-KC > 7αOHC > 
7OHC; all present at ng/ml concentrations. 
 
In both genders plasma 7-KC levels were higher than those of 7OHC. The levels of 
7-KC and the ratio of 7-KC to 7OHC (7-KC/7OHC) were higher in females 
compared with male mice. In addition, when levels of 7-KC and 7OHC were 
related to the total plasma cholesterol, both ratios of 7-KC/Chol and 7OHC/Chol 
were significantly higher in females compared with male mice.  




Table 5-6 Comparison of lipid levels in plasma from male and female 
















Mean plasma cholesterol and 7-oxysterol concentrations were compared between male and 
female 5Reductase1+/- mice (5SRD1+/-). Cholesterol levels were higher in males than in 
females. Levels of 7-ketocholesterol (7-KC) and all plasma ratios were significantly higher in 
female than in male mice. In addition, levels of 7-KC appeared higher than 7-
hydroxycholesterol (7OHC). 7OHC, 7-hydroxy-cholesterol. All data are mean ± SEM, 
compared by non-parametric Mann-Whitney test (levels), unpaired Student t-test (ratios), 
n=6, p<0.05, p<0.01. 
Plasma Male Female p-value 
Cholesterol (µg/ml) 
66.5 ± 3.6 
(172 µM) 
42.5 ± 3.5 
(109.6 µM) 0.001 
  7-Oxysterols (ng/ml) 
7OHC 
38.8 ± 8.2 
(0.097 µM) 
21.3 ± 1.4 
(0.053 µM) 0.062 
7OHC 
21.6 ± 1.4 
(0.054 µM) 
28.2 ± 1.9 
(0.071µM) 0.074 
7-KC 
34.5 ± 8.8 
(0.086 µM) 
64.8 ± 10.6 
(0.162 µM) 0.026 
 Ratios 
7-KC/7OHC 1.527 ± 0.278 2.221 ± 0.205 0.050 
7-KC/Chol x100 0.055 ± 0.017 0.158 ± 0.029 0.012 
7-OHC/Chol x100 0.034 ± 0.004 0.069 ± 0.098 0.007 




5.4.2.2. Does Disruption Of 11HSD1 In Mice Alter The Levels Of 
Plasma 7-Oxysterols? 
Plasma concentrations of 7-oxysterols and cholesterol were measured in C57Bl/6 
(control) and 11HSD1-/- mice. Cholesterol levels in control mice were higher than 
in the previous genotype (5αSRD1+/-), (see Tables 5 - 6 and 5 - 7), despite having 
similar body weights (data not shown). Cholesterol levels were significantly lower in 
the 11HSD1-/- than in control mice (Table 5 - 7). 
 
In both control and 11HSD1-/- mice, 7-oxysterols were present in the range of 5-60 
ng/ml. Levels of 7-KC in the control mice were higher than those of 7OHC, in 
agreement with the findings from pilot work (Section 5.4.2). In mice lacking 
11HSD1 activity, there was a trend for increased concentrations of 7-KC (p=0.08) 
compared with C57Bl/6 (see Table 5 - 7), but the levels of 7αOHC or 7OHC were 
similar in these strains. Accordingly, genetic disruption of 11HSD1 resulted in a 
significant increase in the ratios of 7-KC/7OHC compared with controls. 
 
In C57Bl/6 normolipidemic mice, total circulating 7-KC, 7OHC and 7αOHC levels 
were 10,000 times lower than total cholesterol. The ratio of 7-KC to total cholesterol 
(7-KC/Chol) was significantly higher in the plasma of 11HSD1-/- mice compared 
with control, as was the ratio of 7OHC/Chol (Table 5 - 7). When levels of 7-
oxysterol were correlated with the total cholesterol levels, a positive association was 
observed in control plasma samples for 7OHC (p=0.026 r=0.814, n=8) and 7-KC 
(p=0.029 r=0.806; n=7) but not for (7αOHC p=0.39 r=0.38, n=8). In the plasma 
samples from 11HSD1-/- mice there a significant correlation was not observed 
between the concentrations of any of the 7-oxysterols detected and total cholesterol 
levels (7αOHC p=0.95 r= -0.02, n=8; 7OHC p=0.51 r=0.27, n=8; 7-KC, p=0.31 
r=0.45, n=7). 




Table 5-7 Disruption of 11HSD1 in mice alters plasma levels of cholesterol 






















Levels of cholesterol (µg/ml) and 7-oxysterols (ng/ml) were determined in plasma from 
11HSD1-/- and control C57Bl/6 mice. Cholesterol levels were reduced upon disruption of 
11HSD1. In both genotypes 7-oxysterols were present in the range of 5-60 ng/ml. Levels of 
7-ketocholesterol (7-KC) were higher than 7-hydroxycholesterol (7OHC) or 7-
hydroxycholesterol (7OHC). A trend was revealed for increased 7-KC levels, with an 
associated increase in the ratio of 7-KC/7OHC, upon disruption of 11HSD1. Similarly, the 
ratios of 7-oxysterols to the total cholesterol were significantly increased in plasma of 
11HSD1-/- mice. All data are mean ± SEM, compared by non-parametric Mann-Whitney test 
(levels) or unpaired Student t-test (ratios), n=8, p<0.05. 
Plasma C57Bl/6 11HSD1-/- p-value 
Cholesterol (µg/ml) 
398.4 ± 74.4 
(1.03 mM) 
174.6 ± 54.6 
(0.451 µM) 0.02 
  7-Oxysterols (ng/ml) 
7OHC 
22.9 ± 2.8 
(0.057 µM) 
20.5 ± 1.6 
(0.051 µM) 0.89 
7OHC 
9.1 ± 2.3 
(0.023 µM) 
9.5 ± 0.9 
(0.024 µM) 0.72 
7-KC 
36.5 ± 8.9 
(0.091 µM) 
53.5 ± 6.7 
(0.133 µM) 0.08 
Ratios 
7-KC/7OHC 4.142 ± 0.373 5.445 ± 0.471 0.04 
7-KC/Chol x100 0.014 ± 0.005 0.039 ± 0.009 0.01 
7OHC/Chol x100 0.003 ± 0.001 0.007 ± 0.002 0.03 




5.4.3. Quantitation Of Tissue Lipid In Experimental Animals 
5.4.3.1. Does Disruption Of 11HSD1 Alter The Levels Of 7-
Oxysterols In Hepatic Fractions In Mice? 
7OHC and 7-KC were readily detected in hepatic sub-cellular fractions from 
C57Bl/6 and 11HSD1-/- mice (Table 5 - 8). In livers from C57Bl/6 mice, both  
7-oxysterols were equally abundant in the microsomal and cytosolic fractions. As in 
plasma, the levels of 7-KC in the microsomal preparations, were significantly higher 
than those of 7OHC (p=0.01), although this was not the case in the cytosolic 
fraction in which 7OHC and 7-KC were present with similar abundance. Disruption 
of 11HSD1 resulted in significantly lower levels of both 7OHC and 7-KC levels 
inside the microsomes compared with control. The ratios of 7-KC/7OHC were 
significantly reduced in 11HSD1-/- mice compared with C57Bl/6. The levels of  
7-oxysterols in the cytosols of 11HSD1-/- mice were almost undetectable (Limit of 
detection L.O.D. = 0.01 – 0.03 ng/mg). 
5.4.4. What Are The Plasma Levels Of 7-Oxysterols In Atherosclerotic 
ApoE-/- Mice? 
Plasma concentrations of 7-oxysterols and cholesterol were measured in ApoE-/- 
mice (Table 5 - 9). Cholesterol levels were higher than in the previous genotypes 
(5αSRD1+/- and 11HSD1-/-), (see Tables 5 - 6 & 5 - 8).  7-Oxysterols were present 
in the range of 120 – 560 ng/ml. Levels of 7-KC were higher than those of 7OHC, 
in agreement with previous findings and as seen by comparison of the ratios of 7-
KC/7OHC. Total circulating 7-KC, 7OHC and 7αOHC levels were 10,000 times 
lower than total cholesterol. The ratios of 7-KC/Chol were higher than those of 
7OHC/Chol. 

























The levels of 7-ketocholesterol (7-KC) and 7-hydroxycholesterol (7OHC) were quantified 
in hepatic microsomal (100 µl) and cytosolic (200 µl) fractions from 11HSD1-/- and C57Bl/6 
mice. Levels of 7-KC were higher than those of 7OHC in microsomes from control mice 
(p<0.01), and this difference was reversed in microsomes from 11HSD1-/- mice. Disruption 
of 11HSD1 caused significant reduction in microsomal levels of 7-KC and 7OHC. 7-KC 
and 7OHC were present at a similar level in the hepatic cytosolic fraction of C57Bl/6 mice. 
Levels of both 7-oxysterols in hepatic cytosols from 11HSD1-/- mice were 0.02-0.04 ng/mg 
(LOD 0-0.03 ng/mg), and detected in only 3 out of 8 samples. Peaks for 7-
hydroxycholesterol were not quantified. All data are corrected for protein concentration (~20 
mg/ml) and represent mean ± SEM, compared by a non-parametric Mann-Whitney test, n=8, 
p<0.05, p<0.01. n/d, not detected; n/c, not calculated. 
7-Oxysterols  
 (ng/mg protein) 
   C57Bl/6   11HSD1-/-    p-value 
 Microsomes 
7OHC   16.1 ± 11.4    7.8 ± 0.7    0.03 
7-KC   51.3 ± 28.3    3.0 ± 1.1    0.01 
7-KC/7OHC   1.9 ± 0.1    0.3 ± 0.1    0.001 
Cytosols 
7OHC   25.3 ± 13.4  0.03 ± 0.01    0.40 
7-KC   39.8 ± 19.2  0.02 ± 0.01    0.27 
7-KC/7OHC   2.5 ± 0.7 n/d n/c 




























The levels of 7-ketocholesterol (7-KC) and 7-hydroxycholesterol (7OHC) were quantified 
in plasma (250-300 µl) from ApoE-/- mice fed chow diet. Levels of 7-KC were higher than 
7OHC or 7-hydroxycholesterol (7OHC). Levels of 7-KC and 7OHC in plasma of ApoE-/- 
mice were higher compared to those detected in plasma of C57Bl/6 mice. All data represent 
mean ± SEM, n=6. 
Plasma ApoE-/- 
Cholesterol (mg/ml) 
4.4 ± 0.4 
(12.0 mM) 
  7-Oxysterols (ng/ml) 
7OHC 
171.7 ± 42.1 
  (0.427 µM) 
7OHC 
163.2 ± 15.5 
 (0.406 µM) 
7-KC 
493.6 ± 88.7 
 (1.227 µM) 
Ratios 
7-KC/7OHC     3.112 ± 0.651 
7-KC/Chol x100     0.012 ± 0.003 
7OHC/Chol x100     0.004 ± 0.001 




5.4.5. Does Inhibition Of 11HSD1 Influence The Levels Of 7-
Oxysterols in ApoE-/- Mice? 
5.4.5.1. Determination Of 11HSD1 Inhibition In Vitro  
The ability of compound 544 (11HSD1 inhibitor) to inhibit 11HSD1 activity was 
tested in vitro. Measurements of the reaction rate of glucocorticoid inter-conversion 
by 11HSD (reductase and dehydrogenase) were assessed in the presence of vehicle 
or compound 544 (1 µM). In the presence of inhibitor reaction velocities of reduction 
of 11-dehydrocorticosterone were lower than in controls (Figure 5.4 – 2). 
 
In addition, the ability of compound 544 to inhibit the metabolism of 7-oxysterols by 
11HSD1 was tested in vitro. The reaction rates of conversion of 7-KC to 7OHC 
(reductase) as well as those of 7OHC to 7-KC (dehydrogenase) were assessed in the 
presence of vehicle or compound 544 (1 µM). In the control cells both reactions 
proceeded (as reported in Chapter 3, Figure 3.4 – 3) and dehydrogenation of 7OHC 
occurred at a faster rate. Addition of compound 544 did not inhibit dehydrogenation 
of 7OHC to 7-KC nor reduction of 7-KC to 7OHC (Figure 5.4 – 3).  
 
The amounts of 7-oxysterols distributed between the medium and cells was 
calculated as a percentage of total amount of oxysterols recovered (7-KC+7OHC) 
from both compartments, and are shown in Figure 5.4 – 4. On average total of  
70 - 82 % of oxysterols were recovered. In the assay of reduction, 7-KC (expressed 
as a percentage of total oxysterol recovered) remained mostly in the medium (> 
40%) and about half this amount was detected in the cells (<20%). In the same assay, 
7OHC was generated and detected in cells (~5%) and in the medium (~12%). Upon 
measuring the reductase activity in the presence of compound 544, there was no 
obvious change in proportions of distributed 7-oxysterols compared to control. 
 









Figure 5.4-2 Selective inhibition of 11HSD1 in vitro reduces both reduction 
and dehydrogenation of glucocorticoids.  
HEK293 cells stably-transfected to generate murine 11HSD1 recombinant enzyme were 
used to assess inhibition of reduction of [3H]4-11-dehydrocorticosterone (green bars) and 
inhibition of dehydrogenation (blue bars) of [3H]4-corticosterone. Substrate (30 nM in DMEM) 
was added to the cells to assess the reaction rates in the presence of vehicle (5% w/v 2-
hydroxypropyl--cyclodextrin), or 11HSD1 inhibitor (1 µM, compound 544 in 5% w/v 2-
hydroxypropyl--cyclodextrin, 3h). The data show that compound 544 non-selectively inhibits 
the activity of 11HSD1, in both reduction and dehydrogenation of glucocorticoids. All data 
represent mean ± SEM compared by an unpaired Student’s t-test, n=6, *p<0.05, **p<0.01. 










Figure 5.4-3 Inhibition of 7-oxysterol metabolism by 11HSD1 in vitro. 
HEK293 cells stably transfected to generate murine recombinant 11HSD1 were used to 
assess inter-conversion of alternative substrates. The velocities of reduction of 7-
ketocholesterol (7-KC, red bars) and dehydrogenation of 7-hydroxycholesterol (7OHC, 
purple bars) by m11HSD1 were assessed. Substrates (1 µM in DMEM) were added to the 
cells and reaction rates were assessed in the presence of vehicle control (5% w/v, 2-
hydroxypropyl--cyclodextrin), or 11HSD1 inhibitor (Compound 544, 1 µM, 16h). The data 
show that compound 544 does not inhibit the 11HSD1-mediated reduction of 7-KC or 
dehydrogenation of 7OHC. All data represent mean ± SEM; compared using unpaired 
Student’s t-test, n=6. 









Figure 5.4-4 Substrate distribution between the cells and medium upon 
inhibition of 11HSD1-mediated 7-oxysterol conversion in vitro. 
The distribution of substrates (7-ketocholesteorl (7-KC) and 7-hydroxycholesterol (7OHC); 
1 µM) across the cellular and extracellular compartments was expressed as a percentage 
(%) of a total amount of oxysterols recovered. Reactions were performed in both reductase 
and dehydrogenase directions in the absence (vehicle) and in the presence of inhibitor (I, 
compound 544, 1 µM). For each reaction, % formed product or % remaining substrate was 
determined: 7-KC in the cell (full red), 7OHC in the cell (full purple), 7-KC in the medium 
(pale red), 7OHC in the medium (pale purple). On average total of 70 - 82 % of oxysterols 
was recovered. The addition of inhibitor in the reduction direction did not change the 
proportions of distributed 7-oxysterols compared to control. A noticeable shift in proportions 
of distributed 7-oxysterols was seen with inhibitor in the dehydrogenation direction compared 
to control. The inhibitor facilitated export of 7-oxysterols from cells and majority was 
recovered from the medium. 




During the assay of dehydrogenation, the majority (>50%) of 7OHC (expressed as 
a percentage of total oxysterol recovered) was converted to 7-KC and between 15-
20% of 7OHC was left in the medium and cells. Most of 7-KC that was formed 
remained in the cells (~50%) although some (~12%) was found in the medium. Upon 
measuring the dehydrogenase activity in the presence of compound 544, there seem 
to be a noticeable shift in proportions of distributed 7-oxysterols, such that  
7-oxysterols were exported from cells and majority was recovered from the medium. 
 
5.4.5.2. Determination Of Lipid Levels In ApoE-/- Mice Following 
Inhibition Of 11HSD1 
7-Oxysterols and cholesterol were quantified in the hepatic fractions from ApoE-/- 
mice. Lipid levels in hepatic microsomes (Table 5 - 10) and cytosols (Table 5 - 11) 
from ApoE-/- mice treated with an inhibitor of 11HSD1 (compound 544) and 
matched control (5%, 2-hydroxypropyl--cyclodextrin) are given in Tables 5 - 10 
and 5 - 11, respectively. The levels of hepatic lipids in the ApoE-/- mice were 
between 5 to 9 times higher compared to those determined in the control mice, 
reported in Table 5 - 8.  
 
Levels of cholesterol or 7-KC and 7OHC in hepatic microsomal fractions were not 
different between control and 11HSD1 inhibitor-treated ApoE-/- groups. The ratio of 
7-KC/7OHC also remained unchanged between the two groups. Normalisation of 7-
oxysterols to the total cholesterol levels in the microsomes, did not reveal difference 
in either the ratio of 7-KC to total cholesterol (7-KC/Chol) or 7OHC/Chol (see 
Table 5 - 10). 
 
Cholesterol levels in the hepatic cytosolic fractions were present in the similar range 
(150 – 250 µg/mg) to those in hepatic microsomal fractions from ApoE-/- mice 
(Tables 5 - 10 and 5 - 11). The levels of 7-KC and 7OHC in control cytosolic 
fractions were similar, and did not change upon treatment of ApoE-/- mice with 
11HSD1 inhibitor. 




The ratios of 7KC/7OHC in the hepatic cytosols of ApoE-/- control mice (Table  
5 - 11) were not different (p>0.1) from those in the hepatic microsomes of the same 
animals (see Table 5 - 10). Normalisation of 7-oxysterols to the total cholesterol 
levels in the cytosols did not reveal differences in either the ratio of 7-KC/Chol or 
7OHC/Chol (see Table 5 - 11). 
 
 


















Levels of 7-oxysterols (ng/mg) and cholesterol (µg/mg) were not different in hepatic 
microsomes from ApoE-/- mice treated with an 11HSD1 inhibitor (compound 544, 10 
mg/kg/day, in food, 8 weeks) and matched ApoE-/- mice treated with vehicle (5% w/v, 2-
hydroxypropyl--cyclodextrin in food). The ratios of 7-ketocholesterol (7-KC)/7-
hydroxycholesterol (7OHC) as well as the ratio of each 7-oxysterol to cholesterol were also 
unchanged. Data are corrected for protein concentration and represent mean ± SEM, all 
compared by unpaired Student’s t-test, n=6, p>0.05. 
Microsomes 





Cholesterol (µg/mg) 242.5 ± 68.5 149.9 ± 44.4 0.28 
  7-Oxysterols (ng/mg protein) 
7OHC  137.8 ± 73.5   85.6 ± 12.2 0.49 
7-KC  185.5 ± 77.8 106.6 ± 21.3 0.35 
Ratios 
7-KC/7OHC  1.67 ± 0.22  1.39 ± 0.27 0.44 
7-KC/Chol x100  0.85 ± 0.26  1.44 ± 0.74 0.69 
7-OHC/Chol x100  0.59 ± 0.24  0.99 ± 0.45 0.45 






















Levels of 7-oxysterols (ng/ml) and cholesterol (µg/ml) were not different in hepatic cytosols 
from ApoE-/- mice treated with an 11HSD1 inhibitor (compound 544, 10 mg/kg/day, in food, 
8 weeks) and matched ApoE-/- mice treated with vehicle (5% w/v, 2-hydroxypropyl--
cyclodextrin in food). The ratios of 7-ketocholesterol (7-KC)/7-hydroxycholesterol (7OHC) 
as well as the ratio of each 7-oxysterol to cholesterol were also unchanged. All data are 
corrected for protein concentration and represent mean ± SEM, all compared by unpaired 
Student’s t-test, n=6, p>0.05. 
 
5.4.5.3. Levels Of 7-Oxysterols In Aortae Of C57Bl/6 Mice 
Attempts were made to determine the levels of 7-oxysterols in whole aortae, 
assuming that some of the circulating 7-oxysterols may be sequestered by cells in the 
vessel wall. For this purpose intact aortae from C57Bl/6 mice were used in which 
levels of 7-oxysterols were found to be close to the detection limit (4-5 times 
background). Levels were measured after pooling two aortae (n=5-6), and higher 
levels (p=0.05) of 7-KC (1.41 ± 0.81 ng/mg tissue) were detected compared to those 
of 7OHC (0.16 ± 0.06 ng/mg tissue). The ratio of 7-KC/7OHC (12.69 ± 3.40) was 
higher in the aortic samples (p<0.01, 1-way ANOVA, Tukey’s post hoc test) 
compared to that in plasma (p<0.01) (Table 5 - 7) or hepatic subcellular fractions 
(p<0.01) of C57Bl/6 mice (Tables 5 - 8). 
Cytosols 





Cholesterol (µg/mg) 272.1 ± 76.9 262.8 ± 67.7 0.92 
  7-Oxysterols (ng/mg protein) 
7OHC  154.8 ± 39.0   102.6 ± 19.5 0.25 
7-KC 285.5 ± 117   160.7 ± 27.0 0.32 
 Ratios 
7-KC/7OHC   1.60 ± 0.19     1.62 ± 0.09 0.94 
7-KC/Chol x100   1.66 ± 0.89     0.89 ± 0.24 0.42 
7-OHC/Chol x100   0.87 ± 0.34     0.53 ± 0.11 0.35 





The work presented in this chapter tested the hypothesis that 7-KC would accumulate 
in the plasma and tissues upon inhibition of 11HSD1. The initial aim of this work 
was to develop a sufficiently sensitive method (i.e. GC/MS) to measure circulatory 
levels of 7-oxysterols and cholesterol in the mouse. In brief, the data in this chapter 
show that levels of 7-oxysterols in plasma of chow-fed C57Bl/6 mice, are in a range 
between 10-100 ng/ml (0.03-0.25 µM); similar to the levels reported in human 
plasma or other murine models previously studied (for references see Table 5 - 1). 
Hepatic sterols were equally distributed between microsomes and cytosol, whereas 
very low amounts of oxysterols were detected in healthy aortae. Consistently, the 
levels of 7-KC were higher than those of 7OHC in all model systems studied. 
Genetic disruption of 11HSD1 caused a lowering of total circulating cholesterol, 
but produced only subtle changes in the plasma levels of 7-oxysterols. In the liver of 
11HSD1-/- mice, both 7OHC and 7-KC were substantially reduced compared to 
C57Bl/6 mice. An 11HSD1 inhibitor (compound 544) inhibited metabolism of 
glucocorticoids but not 7-oxysterols by this enzyme, and did not alter tissue levels of 
7-oxysterols. This important finding reflects on the specificity of compound 544 for 
11HSD1-mediated metabolism of glucocorticoids, indicating that inhibition of this 
pathway accounts for the main effects induced by this compound. These findings are 
important for improving the understanding of therapeutic benefits of 11HSD1 
inhibition in diseases such as atherosclerosis and hyperlipidaemia (Hermanowski-
Vosatka et al., 2005). 
5.5.1. Method Development - Detection Of Oxysterols In Murine 
Biological Fluids And Tissues 
The initial aim for this chapter was to develop a method that allowed efficient 
recovery of oxysterols from murine plasma. The detection of oxysterols in various 
murine tissues, cells and fluids from experimental animals required a sensitive, 
reproducible and accurate analytical method with minimal interference from other 
peaks in the mass chromatographic trace. Early investigations in the field of 




oxysterols were severely hampered by the lack of such an analytical method and, as a 
consequence, studies often arrived at vastly different conclusions (Brown and Jessup, 
1999). Although there are many GC/MS-based methods for detection of oxysterols 
levels in plasma and tissues (see Table 5 - 1), several research groups have reported 
difficulties associated with stability during sample preparation (Dzeletovic et al., 
1995a; Kritharides et al., 1993). For the findings presented in this chapter, it was 
important to adapt a single method from the literature for determination of low 
concentrations of 7-oxysterols in murine models due to limited volume of materials 
available. Therefore, the GC/MS method using deuterium-labelled internal standards 
was developed, yielding high sensitivity analysis of 7-oxysterols and cholesterol and 
detecting concentrations in the mouse of a similar magnitude to those in previous 
literature reports from humans (Table 5 - 1). The method developed was suitable for 
measuring oxysterols in murine tissues and plasma and follows four key sample 
preparation steps: 
  a) Solvent extraction 
  b) Solid-phase extraction (SPE) 
  c) Hydrolysis, and 
  d) 2
nd
 Solvent extraction. 
 
a) Solvent extraction 
Chloroform:methanol (2:1, v/v) (Sevanian et al., 1994; Siems et al., 2005) and 
diethylether:hexane (2:3, v/v) (Endo et al., 2008) solvent extraction systems were 
utilized and recoveries compared as given in Table 5 - 2. Initial studies were carried 
out to investigate recovery of oxysterols from water and human plasma (300 – 1000 
µl), allowing large volumes to be analysed in duplicate. Overall greater efficiency 
and minimum inter-assay variation of extraction was achieved using the mixture of 
diethylether in hexane. 




b) Solid phase extraction (SPE) 
The next stage involved solid phase extraction (SPE), which often uses silica (Si)- or 
diol (2-OH)-based columns in combination with different solvents (Simpson, 1992). 
Diol columns are suitable for processing of lipophilic biological materials and were 
suggested by Varian technical support. Diol columns were prepared with 
toluene:ethyl acetate (1:1, 2 ml), under vacuum as described (Endo et al., 2008; 
Sevanian et al.,  994) and used successfully before further detection of 7-oxysterols. 
Use of Si columns was abandoned, 7-oxysterols could not be detected in the eluate. 
c) Hydrolysis (Saponification) 
Saponification is an important step for isolation of sterols and oxysterols, which in 
biological tissues are usually present at much lower levels than triglycerides. This 
step is, therefore, employed prior to GC/MS to remove triglycerides, free fatty acids 
and water-soluble impurities during extraction of oxysterols. During this process, 
abundant lipids are hydrolyzed to form water-soluble components using NaOH or 
KOH (in methanol or ethanol). To avoid degradation of cholesterol and sterol oxides, 
a modification of previously reported methods (Brown et al., 1997; Hodis et al., 
1991; Maerker and Unruh, 1986) was applied, involving very mild, ice-cold 
saponification (20 % KOH in methanol). Our findings agreed with previous studies, 
showing that higher saponification temperatures produce greater degradation of 7-
KC (Park et al., 1996; Schroepfer, 2000). For example Brown et al., (1997) and Park 
et al., (1996) achieved higher recovery of 7-KC (97%) with practically negligible 
loss after 18h of acid hydrolysis at RT, than after 30 min of heating (37°C, 45%; 
75°C, 31%). Previously, data were not available concerning the recovery of 7OHC, 
so tests were performed to check the effect of different temperature on hydrolysis. 
The highest abundance of both 7OHC and 7-KC was achieved by performing the 
hydrolysis at 4 °C whereas at RT, 7OHC had degraded more than 7-KC. These 
studies established that this step should be performed at 4°C. 






 Solvent extraction. 
The second solvent extraction allowed recovery of 7-oxysterols after hydrolysis. Use 
of chloroform or diethylether resulted in reasonable and similar recoveries, however, 
diethyl ether solvent allowed quicker phase separation. 
 
Based on the data given in the method development section, the reproducibility 
between the experiments was within acceptable limits of precision and accuracy, as 
particular care was taken to minimize the sample exposure to the air and pro-
oxidative environment. To minimize this variation and prevent auto-oxidation, 
EDTA and argon were always used, as previously reported (Schroepfer, 2000). Since 
EDTA is able to quench metal ions that might contribute to auto-oxidation, EDTA 
coated onto vials and the collecting funnel, was used as the anti-coagulant for blood 
collection. 
 
Levels of 7-oxysterols were consistently more readily detected in plasma and hepatic 
cytosol, than in aortic tissue, whilst an even greater abundance of 7-oxysterols was 
found in the hepatic microsomal preparations. For the chow-fed C57Bl/6 mice, it 
became apparent that plasma (~ 300 µl) and aortic samples from two animals had to 
be pooled for the robust detection of oxysterols. This was not the case for plasma 
used from ApoE-/- mice, in which cholesterol and oxysterols could be measured in a 
plasma volume between 150-250 µl. The method developed here can be applied 
successfully for detection of 7-oxysterols in 300 µl of plasma from normolipidaemic 
mice. New methods are constantly emerging for the detection of oxysterols in 
biological samples by liquid chromatography mass spectrometry (LC/MS) and novel 
derivatives are being developed to improve the sensitivity of detection. Comparisons 
of LC/MS with GC/MS have been assessed to compare sensitivity of these two 
approaches (Griffiths et al., 2008; Honda et al., 2008). Although the newly-
developed method presented in this chapter provides sensitivity greater than HPLC-
UV detection, the latest method for LC/MS detection by Honda et al., (2008), to 
form picolinyl esters, may provide even greater sensitivity. These studies suggest 
using 100-300 µl of mouse plasma from normolipidemic mice for LC/MS detection 




of 7-KC (DuSell et al., 2008; Umetani et al., 2007) as opposed to the 500 µl volume 
previously recommended by others. 
 
The analytical method developed was tested in pilot work using plasma from the 
normolipidemic 5αSRD1+/- mice. These mice were used simply because they were 
being culled and, therefore, provided a ready supply of plasma. The concentrations 
of 7-oxysterols were established and in order of abundance were: 7-KC > 7OHC 
>7αOHC. This pattern is consistent with previous studies measuring 7-oxysterols in 
human plasma (Iuliano et al., 2003; Zieden et al., 1999). In murine plasma, the levels 
of 7-oxysterols can vary between animals with different genetic backgrounds 
(Schroepfer, 2000; Terasaka et al., 2007). Here, similar levels were detected in 
plasma from C57Bl/6 and 5αSRD1+/- mice of a mixed (C57BL/6J//129Sv/Ev) 
background, while 5 to 9 times higher levels of 7-oxysterols were detected in plasma 
from ApoE-/- mice. Differences existed between the circulating levels of cholesterol 
and 7-KC between male and female mice. 7-KC levels were higher in female mice, 
whereas total cholesterol levels were higher in male mice. Gender differences have 
been reported for cholesterol (higher in females) or HDL cholesterol levels (higher in 
males), in murine models such as LDLR+/- or ApoE-/- (Bruell et al., 1962; Lie et al., 
2006). Similar data have not always been clear for 7-oxysterols in human plasma 
(Dzeletovic et al., 1995b; Schroepfer, 2000), although the differences may simply be 
expected due to a different hormonal regulation of lipid metabolism between genders 
(Vitale et al., 2009). 
 
These preliminary experiments provided information on the range of concentrations 
of 7-oxysterols and un-esterified cholesterol in murine plasma. These concentrations 
were used to design further experiments testing the biological functions of  
7-oxysterols on the vasculature. The ratio of 7-KC to 7OHC was calculated in all 
further assays as a measure of net inter-conversion of the two 7-oxysterols. Gender 
differences were not considered in further work as only male mice were used for 
subsequent analysis.  




5.5.2. Determination Of Lipid Levels In Animal Models 
There are various factors that determine the levels of 7-oxysterol in the body, all of 
which may be subject to sexual dimorphism. Oxysterols are predominantly derived 
from the diet directly and/or by auto-oxidation of, or enzymatic synthesis (such as 
synthesis via 7α-hydroxylase or 11HSD1 (Brown and Jessup, 2009)), from 
cholesterol. To establish whether cholesterol is the major determinant of the levels of 
7-oxysterols in biological fluids and plasma of mice, a correlation between 7-
oxysterol levels with cholesterol levels was sought. There were positive correlations 
between 7-oxysterol and cholesterol levels in the plasma of C57Bl6 mice. However, 
in plasma of 11HSD1-/- mice similar correlations were not observed. The 
explanation of this strain difference is not entirely clear although some explanations 
can be suggested. Previously, strong correlations were reported between total 
cholesterol concentrations and oxidized lipids (mainly 7-oxysterols) (Schroepfer, 
2000). Katsumi et al., (2000) reported a positive association between 7-KC and 
serum cholesterol concentrations in patients with poorly controlled type II diabetes 
vs. control patients. More recent work in adolescent girls indicates that serum 
oxysterol levels increase with LDL cholesterol, ApoB, insulin and obesity; all 
indicators of early stage metabolic syndrome (Alkazemi et al., 2008). In contrast, 
there is also contradictory evidence in the literature (Schroepfer, 2000), including a 
study in healthy Italian volunteers, which demonstrated that neither 7-KC nor 
7OHC concentrations correlated with the total cholesterol concentrations, and 
suggested that production of oxysterols is not necessarily related to increased total 
cholesterol (Iuliano et al., 2003). More recent study by the same research group 
speculated that the concentrations of circulating 7-oxysterol are influenced by 
enzymatic reactions, such as those investigated here, involving 11HSD1 (Larsson et 
al., 2007). The work in this chapter reports that upon disruption of 11HSD1 in 
mice, 7-oxysterols do not correlate with cholesterol in plasma. There is not yet a 
plausible explanation as to why is this the case, although, possibly the reduction in 
cholesterol levels, but not oxysterols in these mice, might be the explanation. In 
addition, disruption of 11HSD1 leads to an increase in circulating 7-KC despite the 
reduction in cholesterol.  




It is however, possible that other metabolic routes of oxysterols may have changed in 
11HSD1-/- mice. This is likely given the changes in lipid-signalling pathways in the 
liver following over-expression of 11HSD (Paterson et al., 2004). This may disrupt 
the balance between the 7-oxysterol and cholesterol pools. The most obvious 
alternative route of 7-oxysterol metabolism in 11HSD1-/- mice is via CYP27 (Figure 
5.5 – 1), which could utilize 7-KC from plasma and liver (Li et al., 2007). Extensive 
work by Freeman et al., (2005) showed that formation of 7-ketocholesteryl esters as 
well as 7-KC-arachidonate accumulates in the macrophages and may represent a 
significant pool in these cells, leading to activation of cleaved caspase-3 (Freeman, 
2005). Another widespread mechanism for metabolism of 7-oxysterols is sulphation 
of the 3-hydroxyl group, thus in the absence of 11HSD1, 7-KC is metabolized to 
7KC-3-sulphate (Song et al., 2001). Neither of these alternative metabolites were 
quantified in the assays used. Therefore, measurement of additional metabolites of 
oxysterols may be necessary to fully understand the relationship between cholesterol 
and oxysterols.  
5.5.2.1. 11HSD1 Regulates The Levels Of 7-Oxysterols In Murine 
Plasma 
Although the levels of 7-oxysterols have been related to those of cholesterol in mice 
(Terasaka et al., 2008), the significance of changes in ratios of individual oxysterols 
(7-KC and 7OHC) in plasma has not been addressed. The proportions of 7-KC  
to 7OHC were not considered in relation to the activity of 11HSD1 before.  
Steffen et al., (2006) have investigated the proportions of 7OHC to 7-KC in 
oxidized LDL (oxLDL). Their work showed that the ratio of 7OHC to 7-KC in a 
mixture of oxysterols, is a crucial determinant of the cytotoxicity of oxLDL to 
endothelial cells. The importance of the balance between individual 7-oxysterols has 
also been alluded to in a study by Breuer et al., (1993) who measured 7-KC and 
7OHC in rat liver, proposing that reduced levels of 7-KC may be associated with a  
rise in the levels of 7OHC. This finding suggested that formation of 7OHC  
occurs from 7-KC, although they were not aware of the 11HSD1-mediated 
metabolism of these species at the time. 









Figure 5.5-1 Routes of metabolism of 7-ketocholesterol (7-KC) 
Possible routes of metabolism of 7-KC in rodents and primates. Reaction with 7-KC can take 
place on the A or B rings or on the side-chain of the cholesterol backbone. CYP27, 
Cytochrome P450 27-hydroxylase; LCAT, Lecithin : cholesterol acyl-transferase; ACAT, 
Acyl-coenzyme A : cholesterol acyltransferase. 




Therefore from the perspective of Breuer et al., inhibition of 11HSD1 could 
contribute towards accumulation of 7-KC and reduction in 7OHC levels in the 
plasma and peripheral tissues. In this chapter, two models were used to examine the 
effect of inhibition of 11HSD1 on the abundance of 7-oxysterols: 11HSD1 
knockout mice and administration of a pharmacological inhibitor of 11HSD1. In the 
plasma of 11HSD1-/- mice there was a trend towards higher concentrations of 7-KC, 
and the ratio of 7-KC/7OHC was higher compared to C57Bl/6 mice. The 
pronounced increase in 7-KC would be expected upon disruption of 11HSD1 if 
reduction of 7-KC to 7OHC was the predominant route of metabolism in vivo. The 
data from this work suggest this may still be the case, although the in vitro findings 
in Chapter 3 of this thesis showed that 11HSD1 was a predominant dehydrogenase 
for 7-oxysterols. The disruption of 11HSD1 led to reduced levels of 7-oxysterols in 
hepatic microsomes and cytosols, thus demonstrating that 11HSD1 determines the 
cellular levels of these compounds. If this is the case in vivo, an increase in plasma 
levels of 7OHC should be anticipated following disruption of 11HSD1. 
 
When levels of 7-oxysterols were normalized to the total cholesterol the effect of 
11HSD1 disruption became evident, in that both 7-KC/Chol and 7OHC/Chol were 
increased. Since this finding was established for both 7-KC and 7OHC, it is not 
possible to hypothesize that 11HSD1 only catalyses initial step of the detoxification 
of 7-KC, reducing it stereospecifically to 7OHC. Perhaps, the oxidation of 7OHC 
to 7-KC by 11HSD1 occurs simultaneously in the body, or there are other sources 
of 7OHC in the 11HSD1-/- mice, like reactive oxygen species (ROS) production 
and lipid oxidation (Rimner et al., 2005).
 
Levels of 7-oxysterols in hyperlipidaemic mice are within the same order of 
magnitude (µM) as the Km of 7OHC. Therefore, changes in the balance of 7-
oxysterols are perhaps of low significance for metabolism of glucocorticoids by 
11HSD1 in the animals fed chow diet, but may be of greater importance in mice fed 
a high fat diet, and power the metabolism of 7-oxysterols by 11HSD1. It is assumed 
that increased circulatory levels of 7-oxysterols may also be delivered into tissues 
where, through nuclear signalling or direct molecular interaction, they may impair 




tissue function (Deckert et al., 2002; Deckert et al., 1997). Translated into 
hyperlipidaemic (e.g. ApoE-/- or LDLR-/-) mice, where increased levels of 7-
oxysterols are observed (Brown and Jessup, 1999), 11HSD1 may be balancing the 
ratio of 7-KC to 7OHC and thus influence the magnitude of their proatherogenic 
actions. 
5.5.2.2. 11HSD1 Regulates The Levels of 7-Oxysterols In Murine 
Hepatic Fractions 
In contrast to plasma ratios of 7-KC/7OHC, this ratio was reduced (compared with 
C57Bl/6 controls) in hepatic microsomes from 11HSD1-/- mice. This is consistent 
with a predominant dehydrogenation of 7-oxysterols by 11HSD1. The reason for 
different profiles of 7-oxysterols between plasma and liver is not clear, as 
mechanisms for packaging 7-oxysterols into plasma lipoproteins or delivery of 7-
oxysterols to the ER lumen are not well understood. However, the microsomal 
compartment is intimately linked to 11HSD1 expression and it is perhaps not 
surprising that more profound differences are observed here. Similar amounts of 7-
oxysterols were seen in microsomes and cytosols from C57Bl/6 mice, but became 
almost undetectable in the cytosols of 11HSD1-/- mice, suggesting the 7-oxysterols 
are anchored in some way within this compartment. Overall, reduced levels of 7-
oxysterols in the microsomes of 11HSD1-/- mice are accompanied by lowered total 
cholesterol levels. The microsomal ratio of 7-KC/7OHC was significantly reduced 
due to disruption of 11HSD1, whereas this ratio could not be established for 
cytosols from 11HSD1-/- mice. It is, thus, likely that expression of 11HSD1 
influences the cellular distribution of hepatic 7-oxysterols. 




5.5.2.3. Pharmacological Inhibition of 11HSD1 Does Not Inhibit 
Metabolism of 7-Oxysterols 
The role of 11HSD1 in metabolism of 7-oxysterols was also explored 
pharmacologically. The activity of the 11HSD1 inhibitor (compound 544) was 
confirmed by the demonstration that it inhibited the conversion of glucocorticoids in 
cultured cells and reduced lesion size in atherosclerotic mice (Iqbal et al., 2009), 
similar to reports by Hermanowski-Vosatka et al., (2005). However, compound 544 
did not inhibit the metabolism of 7-oxysterols by 11HSD1 in cultured cells. Hepatic 
levels or proportions of 7-oxysterols were not altered in the hyperlipidaemic ApoE-/- 
mice and ApoE-/- mice administered the 11HSD1 inhibitor (compound 544) (Iqbal 
et al., 2009), suggesting either low efficacy of drug delivery to liver compartments, 
or selective inhibition of glucocorticoid metabolism. The levels of 7-oxysterols and 
cholesterol show variation within the same group but the difference between 
treatments was not seen, even after normalizing the levels of 7-oxysterol to the total 
cholesterol. A possible explanation may lie in time of sampling, since expression of 
various genes for the enzymes in hepatic metabolic pathways are under the circadian 
expression and a control of multiple mechanisms including the CLOCK molecule 
(Noshiro et al., 2007). Thus the levels of circulating 7-oxysterols might have varied 
within treated and control groups depending on the time of blood collection (am or 
pm) due to diurnal variation in peripheral tissues (Reilly et al., 2007).  
 
More likely elucidation for the lack of inhibitory effects on metabolism of 7-
oxysterols, may lie in the design of compound 544. Since metabolism of 
glucocorticoids by 11HSD1 was still dimly observed in the presence of the 
inhibitor, it would appear that compound 544 does not mask enzyme’s active site or 
completely abolish binding of substrates. This latter finding concurs with the data 
established in this chapter, using the inhibitor with HEK293 cells in vitro, in which 
glucocorticoid (but not 7-oxysterol) metabolism by 11HSD1 was altered. Indeed, 
this inhibitor acts to specifically prevent glucocorticoids from accessing the active 
site, while inadvertently favouring the binding of 7-oxysterols. Therefore, clear 
differences have been established in this chapter, between the interactions of 




11HSD1 inhibitor (compound 544) with glucocorticoid versus 7-oxysterol 
substrates in the active site of 11HSD1 to inhibit the activity of this enzyme.  
 
5.5.2.4. Levels Of 7-Oxysterols In Aortae Of C57Bl/6 Mice 
Assessment of 7-oxysterols in the peripheral tissue, namely the aorta, was performed 
using C57BL/6 mice. In the aorta of C57Bl/6 mice fed chow diet, levels of 
oxysterols were relatively low but were, nevertheless, detectable and 7-KC levels 
were greater than 7OHC. In a recent study, Umetani et al., (2007) detected similar 
levels of 7-KC and 27-OHC in murine aorta to those reported here, but found that the 
levels increased three times when mice were placed on a high cholesterol high fat 
(HCF) diet. Previous reports in humans show that levels of 7-KC and 7OHC in 
atherosclerotic plaque increase with progression of atherosclerosis (Brown et al., 
1997; Vaya et al., 2001) and this has also been reported for ApoE-/- mice (Brown and 
Jessup, 1999). It may be expected for both 7-KC and 7OHC to accumulate in the 
vessels, in atherosclerosis (Thomas et al., 2001). Only one other study reported on 
oxysterol levels in the vessel wall. Findings by Terasaka et al., (2008) reported that 
7-KC levels were undetectable in the aortae of chow fed mice, but could be 
measured in the aortae of mice fed high cholesterol diet. This is certainly in line with 
results presented in this chapter. 
  
Consistent with results obtained using plasma, levels of 7-KC were higher than 
7OHC in the aorta, perhaps suggesting that the main source of vascular oxysterols 
is from the plasma pool. However, levels of 7-KC were ten fold higher than those of 
7OHC in vessels as opposed to two fold higher in plasma. As such, the ratio of 7-
KC/7OHC was higher in the vessels than in microsomes, cytosols or plasma. The 
mechanisms of oxysterol inactivation and clearance in the vessel are not known. 
Accumulation of 7-KC via 11HSD1-mediated dehydrogenation of 7OHC may 
subsequently result in the 7-KC being sequestered more readily by the endothelium, 
smooth muscle cells and other surrounding cells (macrophages), as reported before 
(Kritharides, 1995; Santillan et al., 1982; Tall et al., 2008). The macrophages within 
the vessel wall may also contain a set of enzymes for further processing of oxysterols 




prior to or after their storage. It is possible that 7OHC is metabolised or exported at 
a much faster rate than 7-KC by the vasculature. Differences in storage of 7-KC 
versus metabolism of 7OHC, may therefore contribute to an increase in the ratio of 
7-KC/7OHC in the vessels. Therefore, the balance of export and metabolism of 7-
oxysterols is clearly different between the aortae and the liver. 
 
The metabolism of 7-oxysterols has so far been best described in the liver, where 
clearance of 7-KC occurs relatively quickly (Erickson et al., 1977; Lyons et al., 
1999), by a rapid transfer from chylomicrons to other lipoprotein and/or plasma 
fraction (Emanuel et al., 1991). 7-KC can be converted into bile acids for excretion 
out of the body (for review see Brown et al., (1999) and Carpenter (2002)) or be 
metabolised by various aldo-keto reductases specific to the liver (e.g. 3α-
hydroxysteroid dehydrogenase (3α-HSD) or CYP450s, which are not present on the 
peripheries (Jin and Pennings, 2007; Qin and Cheng, 1994)). The evidence for other 
route of metabolism of 7-oxysterols outside of liver comes from a study in patients 
with cerebrotendinous xanthomatosis (CTX), who lack 27-hydroxylase (CYP27), 
(Cali et al., 1991; Fujiyama et al., 1991). Patients with CTX accumulate 7-KC in the 
macrophages and in plasma due to their inability to further metabolise 7-KC. In the 
macrophages from normal patients, CYP27 reduces 7-KC to 27-hydroxy-7-
ketocholesterol (27OH-7-KC) (Figure 5.5 – 1). However, it is suggested by Jessup et 
al., (2005) that high levels of 7-KC in patients with CTX are actually lower than 
expected, because in the macrophages 11HSD1 also contributes to the clearance of 
7-KC. It is not clear from the literature whether 7OHC can also undergo this type of 
metabolism. It is however tempting to speculate that the formation of 27-hydroxy-
7OHC can occur via CYP27 route too. This would suggest that efficient 
metabolism of 7-KC includes reduction to 7OHC by 11HSD1, then formation of 
27-hydroxy-7OHC by CYP27 and further metabolism to bile acids. Being that 
7OHC is relatively short-lived (1.5h) (Larsson et al., 2007), it may more readily be 
inactivated by auto-oxidation (Santillan et al., 1980). Thus, high levels of 7-KC and 
ratio of 7-KC/7OHC observed in the normolipidaemic aortae in this chapter may 
indeed be cleared out via 11HSD1 and CYP27 enzymes. However, the activity of 
11HSD1 (not tested for CYP27 here) is much slower in the vessels compared to the 




liver, and thus clearance of 7-KC in this tissue occurred at a slower rate, measuring 
high 7-KC. 
 
In summary, the work in this chapter provides evidence that 11HSD1 controls 
aortic, hepatic and plasma level of 7-oxysterol in normolipidemic mice. Levels of 7-
oxysterols are elevated in plasma and tissues with development of atherosclerosis, 
but current available 11HSD1 inhibitor is not designed to reduce the metabolism of 
7-oxysterols, or their levels and proportions in murine tissues. Increased 7-
oxysterols, may thus compete with glucocorticoids and inhibit dehydrogenation by 
murine 11HSD1, to foster the formation of active glucocorticoid in atherosclerosis. 














Chapter 6. Impact Of 7-Oxysterols On Function Of 
Murine Aortae 





Previous studies of 11HSD1-mediated metabolism of glucocorticoids in vascular 
tissue have demonstrated the presence of both isozymes of 11-hydroxysteroid 
dehydrogenase (11HSD1 and 11HSD2) in vascular cells (Christy et al., 2003; 
Krozowski and Chai, 2003; Walker et al., 1991). Controversy still exists concerning 
the localisation and directionality of these enzymes in the vascular wall (Morris et 
al., 2003). It is generally accepted, however, that (in murine aorta, at least) 11HSD1 
is localized predominantly to infiltrated macrophages and vascular smooth muscle 
cells (VSMC) (Cai et al., 2001; Hatakeyama et al., 2001). In contrast, 11HSD2 is 
restricted to the endothelial cells (Christy et al., 2003). In the vascular wall both 
isozymes of 11HSD actively interconvert glucocorticoids (Dover et al., 2006). 
 
The work in Chapter 5 presented evidence that 7-ketocholesterol (7-KC) may be 
present in relatively high levels compared with 7-hydroxycholesterol (7OHC) in 
the vessel wall. This may have important implications for vascular function as an 
increase in the oxidized lipid content of endothelial cells has previously been shown 
to inhibit the endothelium-dependent relaxation of aortic segments from 
hyperlipidaemic mice (Deckert et al., 1999). 7-Hydroxycholesterol and 7-
ketocholesterol can mimic the ability of oxidized lipids (oxLDL) to inhibit the 
relaxation response to acetylcholine, as shown in rabbit aortic segments in vitro 
(Deckert et al., 1997). The molecular mechanism of these inhibitory effects on 
arterial relaxation is, as yet, unknown and indeed differences between the vascular 
effects of these two oxysterols poorly characterised. Alterations in endothelium-
dependent relaxation by 7-oxysterols have been found to be independent of their 
known cytotoxic effects (Lizard et al., 1997), but in HUVECs 7OHC and 7-KC 
reduced the histamine-activated release of nitric oxide (Deckert et al., 1998).  
 
The work described in Chapter 3 would predict that 11HSD1 in the vessel wall can 
interconvert 7-oxysterols. Thus, it has been proposed that 11HSD1 may regulate the 
concentrations of 7-KC and 7OHC in the arterial wall. Whether 11HSD1-mediated 
metabolism of 7-oxysterols in vascular cells influences the functional consequences 




of exposure of vessels to these compounds, has not yet been determined. This 
chapter investigates the direct influence of 7-KC and 7OHC on the function of 
murine aortae and assesses the ability of vascular 11HSD1 to interconvert these 7-
oxysterols. 
6.2. Research Hypothesis And Aims 
This chapter explores the hypothesis that 7-oxysterols generated by 11HSD1 in the 
vascular wall impair functional responses of the murine aortae ex vivo.  
 
• The specific aims for this chapter were to: 
• Develop a method to allow investigation of the effects of 7-oxysterols on vascular 
function, and; 
• Determine whether incubation with 7-KC or 7OHC ex vivo alters the function of 
isolated murine thoracic aortae. 
6.3. Methods 
6.3.1. Method Development 
The experiments described in this chapter were designed to test the functional effects 
of exposure to 7-oxysterols on murine thoracic aortae ex vivo. This required extended 
incubation of isolated vessels, raising concerns over preservation of vascular 
function and prompting pilot experiments to determine whether use of tissue culture 
medium (DMEM) was preferable to physiological saline solution (PSS). Previous 
work by Christy et al.,  (2003) of ex vivo incubations of aorta suggested that DMEM 
preserves vascular function after extended periods of incubation, but certain 
constituents of DMEM (such as L-arginine) have unwanted vasoactive properties 
(Christy et al., 2003). Therefore, for the purpose of work presented in this thesis 
DMEM without L-Arg was used, and outcomes were described further in method 
development, section 6.4.1. To determine whether functional experiments could be 
performed in arteries bathed in culture medium, contractile and relaxant responses 




were compared in aortic rings (male C57Bl/6 mice, age 8-12 weeks, n=4) in DMEM 
without L-arginine (DMEM-L-Arg) or in PSS. 
6.3.1.1. Preparation of Solution of 7-Oxysterols 
Stock solutions of 7-oxysterols (30 mg/ml in ethanol) were freshly prepared as 
described (section 2.2.2), including butylated hydroxytoluene (BHT; 250 µg/ml) as 
an antioxidant (Schroepfer, 2000). Working solutions were prepared by adding 7-
oxysterol stock (60 µl) to culture medium (DMEM-L-Arg; 30 ml, containing 1% v/v 
stripped FBS, as in section 2.6.1.1) to achieve working concentrations of 7-KC (25 
µM) or 7OHC (20 µM) (Lizard et al., 1999; Seye et al., 2004). Samples were 
vortexed (400 rpm, RT, 10 min) then sonicated (10 min, RT). The final concentration 
of vehicle (ethanol with 250 µg/ ml BHT) in DMEM was   < 0.2%. 
6.3.1.2. Does Culture Medium Alter The Functional Responses Of 
Aortic Rings From C57Bl/6 Mice? 
Thoracic aortae from C57Bl/6 mice (male, age 8 - 12 weeks, n=12) were collected in 
PSS or culture medium (DMEM) and dissected into four rings (section 2.4.5), which 
were mounted in a small vessel wire myograph (section 2.10.1). Endothelium was 
removed from the aortic rings by rubbing with a wire probe (section 2.10.2). The 
rings were incubated under optimal resting tension (7.36 mN) (Bagnall et al., 2006) 
in either PSS or DMEM-L-Arg at 37°C with 95%O2/ 5% CO2. The aortic rings were 
then subjected to the standard experimental protocol and vasorelaxation and 
vasocontraction were measured as described (section 2.10). 
6.3.1.3. Functional Responses Of Aortae From 11HSD1-/- Mice: 
Effect Of Endothelium 
To determine whether aortic rings from 11HSD1-/- mice on a C57Bl/6 background 
produced the expected responses when assayed in culture medium, the effect of 
endothelial removal from these vessels was assessed using DMEM-L-Arg rather than 
PSS. Thoracic aortae from 11HSD1-/- mice (male, age 8-12 weeks, n=6) were 
collected and dissected in sterile DMEM-L-Arg, and divided into four rings of which 




two had the endothelium removed. The standard experimental protocol (section 
2.10.3) was performed to confirm the pattern of functional responses of aortic rings 
with and without the endothelium. 
6.3.2. Effect Of 7-Oxysterols On Vascular Function In Vitro 
To determine whether exposure to 7-oxysterols altered aortic contraction or 
relaxation, arteries from C57Bl/6 mice were subjected to short (4h) or long (24h) 
exposure to 7-oxysterols (7-KC or 7OHC) or vehicle in DMEM-L-Arg prior to 
functional analysis. The possibility that 11HSD1 in the isolated aorta could 
metabolise 7-oxysterols in the incubation mixture was assessed by measuring 
concentrations of both 7-KC and 7OHC at the end of the incubation period. 
6.3.2.1. Short-Term Exposure Of Aortic Rings 7-Keto-cholesterol 
And 7-Hydroxycholesterol 
Thoracic aortae from C57Bl/6 mice (male, age 8 - 12 weeks, n=8) were divided into 
four rings and submitted to the standard experimental protocol (section 2.10.3). The 
vessels were equilibrated in oxygenated DMEM-L-Arg (95% O2 and 5% CO2, 37°C) 
containing stripped FBS (1% v/v). Cumulative concentration-response curves were 
then obtained using the vasoconstrictors noradrenaline (10-9 – 10-5 M), serotonin 
(5HT; 10-9 – 10-4 M) and potassium chloride (10 – 125 mM). Aortic rings were 
further equilibrated (30 min), then incubated with 7-KC (25 µM, one ring) or 7OHC 
(20 µM, one ring) in DMEM-L-Arg and two rings in vehicle only (EtOH, 50 µg/ml 
BHT) for 4 hours (incubation medium was refreshed every 2h) and further functional 
responses were measured, as in section 6.3.2.4. 
6.3.2.2. Long-Term Exposure Of Aortic Rings To 7-Keto-
cholesterol And 7-Hydroxycholesterol 
To further assess the effects of 7-oxysterols on vascular function, aortic rings were 
prepared from aortae of C57Bl/6 mice (male, age 8-12 weeks, n=6) as in section 
6.3.2.1, for an overnight incubation (24 h) in a humidified atmosphere (95% O2 / 5% 
CO2, 37°C, 24 h). Single aortic rings were immersed in DMEM-L-Arg containing 7-




KC (25 µM), 7OHC (20 µM), or vehicle (EtOH, 50 µg/ml BHT) in a 12-well plate. 
Following incubation, vessels were mounted onto the myograph and subsequent 
functional responses were measured (section 6.3.3.4). 
6.3.2.3. Does Vascular 11HSD1 Metabolise 7-Oxysterols in 
Isolated Aortic Rings? 
To determine whether 11HSD1 in the aortic ring metabolises 7-oxysterols during 
the incubation period, samples (2 ml) of incubating solutions were collected after the 
incubation procedure (4 h and 24 h). Oxysterols were extracted from the medium 
(section 2.6.3.1) and detected using GC/MS analysis (section 2.13) to assess both 
stability and the extent of conversion by 11HSD1 (section 6.4.2.3). 
6.3.2.4. Measurement Of Vascular Responses 
At the end of the prescribed incubation period, and in the continued presence of the 
7-oxysterol or control solution, cumulative concentration-response curves were 
constructed for 5HT (10-9 – 10-4 M) and NA (10-9 – 10-4 M). In addition, cumulative 
concentration-response curves were performed for the vasodilators, ACh (10-9 – 10-2 
M, endothelium-dependent) and SNP (10-9 – 10-4 M; endothelium-independent), 
following contraction with a sub-maximal concentration (EC80, 3x10
-7 – 10-6 M) of 
5HT. 
6.3.3. Data Analysis 
Mac Lab Chart version 3.3 was used to record all myography data recording at a 
speed of 20 or 10 divisions/s. All analyses were performed using Graph Pad Prism 
v5.0 software by fitting Hill curves. Contractile responses are expressed as force per 
unit length (mN/mm) and as a percentage of the maximum contraction in response to 
KPSS (% KPSS). Relaxations were expressed as a percentage of the contraction in 
response to the EC80 of 5HT (% 5HT). 





Sensitivity is a negative logarithm of the molar concentration producing a half-
maximal relaxation (IC50) or contraction effects (EC50) and is hence expressed as 
-LogIC50 for vasorelaxants, and pD2 (-LogEC50) for vasoconstrictors. Sensitivity 
values were obtained after applying the sigmoid dose-response equation:  
Y=Bottom + (Top-Bottom)/(1+10^(LogEC50-X)); where X is logarithm of 
concentration, Y is the response. Emax is the maximal response to a drug. All maximal 
relaxations (Emax), induced either by ACh or by SNP, were expressed as a percentage 
to 5HT (0.3 µM) from experimental data.  
6.3.4. Statistical Analysis 
For all experiments using animal tissues, individual experiments were carried out 
using aortae from 4 - 14 mice. Where two denuded and two intact rings were used 
from individual aortae, data were calculated by obtaining an average result from the 
two comparable (i.e. with endothelium or without endothelium) aortic rings from 
each animal. All data are mean ± standard error of the mean (SEM) and were 
compared using unpaired Student’s t-test or 1-way ANOVA with Tukey’s multiple 
comparison post-test as appropriate. P values were accepted as statistically 
significant when <0.05; n represents the number of different animals used. 





The experiments described in this chapter were designed to test the effects of 7-KC 
and 7OHC on the function of mouse aorta. Prior to these experiments, preliminary 
work was performed to establish suitable conditions for incubation of vessels with 7-
oxysterols. Endothelium-intact and -denuded aortic rings were compared to 
demonstrate the functional consequences of severe endothelial dysfunction. 
Myography experiments were subsequently performed to test whether 7-oxysterols 
inhibit vascular contraction in response to 5HT, NA and KPSS, or endothelium-
dependent/-independent relaxation, in response to ACh/SNP. Levels of 7-KC and 
7OHC were measured in the medium following vessel incubation, to determine 
whether metabolism of 7-oxysterols by 11HSD1 has occurred. 
6.4.1. Method Development 
6.4.1.1. Preparation of Solutions of 7-Oxysterols 
The highest concentrations of 7-oxysterols that could be maintained in solution in 
DMEM were 25 µM (7-KC) and 20 µM (7OHC). Preparation of higher 
concentrations (Deckert et al., 2002) led to precipitation of the oxysterols. 
6.4.1.2. Incubation Of Vessels In PSS And DMEM 
To determine whether functional investigations could be performed using culture 
medium in the myograph bath, cumulative concentration-response curves were 
produced for 5HT, NA, ACh and SNP in vessels bathed in PSS or DMEM-L-Arg. 
No difference in maximal response was observed during the general experimental 
protocol (section 2.10.3) with KPSS but contractions appeared slower to develop in 
arteries bathed in DMEM-L-Arg. As expected, mechanical removal of the 
endothelium was associated with a smaller response to KPSS (Table 6 - 1A) and 
virtual abolition of acetylcholine-mediated relaxation. 
 




Both 5HT and NA produced concentration-dependent contractions in intact and 
denuded aortic rings. Bathing the vessels in DMEM-L-Arg had no significant effect 
on the size (Emax, Table 6 - 1A) or sensitivity (pD2, Table 6 - 1B) of the responses 
produced. A trend towards reduced maximal response to NA for vessels bathed in 
DMEM-L-Arg did not achieve significance (p=0.05). In arteries bathed in  
DMEM-L-Arg, calculation of contractile response as a percentage of the maximum 
response to KPSS indicated that removal of the endothelium produced an increased 
Emax to NA but not to 5HT (Figure 6.4-1). 
 
Maximum response (Emax) and sensitivity (-logIC50) to ACh or SNP were not 
different if aortic rings were bathed in DMEM-L-Arg rather than PSS (Table 6 - 1 A 
& B). As expected, ACh-induced relaxation was attenuated but SNP-mediated 
relaxation unaffected by removal of the endothelium whether the aortic rings were 
bathed in PSS (Table 6 - 1) or in DMEM-L-Arg (Figure 6.4 – 1). 




Table 6-1A Maximal contraction and relaxation of isolated mouse aorta are not 
altered if myography is performed using culture medium rather than PSS. 
 
Maximal (Emax) relaxation (%) and contraction (mN/mm) responses evoked by 
vasoconstrictors (5HT, NA) and vasodilators (ACh, SNP) in the vessels bathed in either 
physiological salt solution (PSS) or culture medium (DMEM-L-Arg). Data were obtained 
using intact and denuded rings of thoracic aortae isolated from adult, male, C57Bl/6 mice. 
The use of DMEM-L-Arg did not significantly alter the maximum functional responses 
produced by mouse aortae. All values represent mean ± SEM, compared by an unpaired 
Student’s t-test, n=4, p<0.05. NA, noradrenaline; 5HT, 5-hydroxytryptamine; ACh, 
acetylcholine; SNP, sodium nitroprusside; p-values are obtained upon comparison between 
vessels bathed in culture medium and PSS. 
Table 6-1 A  Emax 
 
Drug Endothelium PSS DMEM-L-Arg 
p-value 
  
   
5HT Intact 2.63 ± 0.22 2.40 ± 0.43 0.69 
 Denuded 2.25 ± 0.69 2.22 ± 0.22 0.88 
     
ACh Intact 79.90 ± 5.66 64.20 ± 6.34 0.11 
 Denuded not calculated not calculated  
     
NA Intact 1.21 ± 0.18 0.96 ± 0.15 0.05 
 Denuded 1.99 ± 0.74 1.44 ± 0.19 0.48 
     
SNP Intact 100.53 ± 0.41 102.80 ± 2.68 0.34 
 Denuded 108.71 ± 3.70 113.54 ± 3.04 0.48 




Table 6-1B Sensitivity of isolated mouse aortic rings to vasoactive factors is 
not altered if myography is performed using culture medium rather than PSS. 
 
Sensitivity (pD2 or -logIC50) of functional responses evoked by vasoconstrictors (5HT, NA) 
and vasodilators (ACh, SNP) in vessels bathed in either physiological salt solution (PSS) or 
culture medium (DMEM-L-Arg). Data were obtained using intact and denuded rings of 
thoracic aortae isolated from adult, male, C57Bl/6 mice. The use of DMEM-L-Arg did not 
significantly alter the sensitivity of responses to any of the compounds. All values represent 
mean ± SEM, compared by unpaired Student’s t-test, n=4, p<0.05. NA, noradrenaline; 5HT, 
5-hydroxytryptamine; ACh, acetylcholine; SNP, sodium nitroprusside; p-values are obtained 
upon comparison between vessels bathed in culture medium and PSS. 
Table 6-1 B  Sensitivity      
Drug Endothelium PSS DMEM-L-Arg 
p-value 
  
   
5HT Intact 6.93 ± 0.12 6.60 ± 0.09 0.07 
 Denuded 7.01 ± 0.22 6.54 ± 0.10 0.11 
     
ACh Intact 6.84 ± 0.37 8.17 ± 0.83 0.19 
 Denuded not calculated not calculated  
     
NA Intact 6.41 ± 1.19 7.85 ± 0.25 0.16 
 Denuded 8.04 ± 0.24 6.98 ± 0.32 0.81 
     
SNP Intact 7.61 ± 0.17 8.23 ± 0.16 0.15 
 Denuded 8.30 ± 0.17 7.71 ± 0.22 0.08 






Figure 6.4-1 Cumulative concentration-response curves obtained from aortic 
rings bathed in DMEM without L-arginine. 
In the endothelium intact aortic rings (black squares) from male C57Bl/6 mice bathed in 
culture medium (DMEM-L-Arg) the removal of the endothelium (open circles) had no effect 
on 5-hydroxytryptamine (5HT)-mediated contraction, but it has enhanced contraction to 




noradrenaline (NA). Presentation of the data as a percentage of the response to 
physiological salt solution with potassium (KPSS) corrects for damage to the medial smooth 
muscle in denuded arteries. Acetylcholine (ACh)-mediated relaxation, but not the response 
to sodium nitroprusside (SNP), was virtually abolished by removal of the endothelium. These 
results are consistent with the effects of denudation obtained in arteries bathed in PSS. All 
points represent mean ± SEM, compared by 1-way ANOVA with Tukey’s post hoc test, n=4. 




6.4.1.3. Effect Of Endothelium On Aortae From 11HSD1-/- Mice 
Vascular reactivity was measured in intact and denuded aortic rings from 11HSD1-/- 
mice in bathed DMEM-L-Arg. As anticipated, removal of the endothelium had a 
tendency to reduce the contractile response to 125 mM K+ (KPSS; Table 6 - 2). The 
maximal response (Emax), but not the sensitivity (pD2), to 5HT was reduced in 
endothelium-denuded, compared with endothelium-intact, aortic rings (p0.02). 
However, when the Emax was expressed as a percentage of the response to KPSS (to 
correct for mechanical injury to the vessel wall), it was shown that denudation 
resulted in an enhanced response to 5HT (Table 6 - 2). A similar effect of endothelial 
cell removal was seen with the response to NA. 
 
Removal of the endothelium virtually abolished the relaxant response to ACh but 
caused a significant (p=0.02) increase in the relaxant response to SNP (Table 6 - 2). 
The sensitivity of the tissue to SNP, however, was unchanged. 





Table 6-2 The impact of removal of endothelial cell on functional responses of 























Maximal relaxation (%) and contraction (Emax) responses and sensitivity (expressed as –
logIC50 or pD2) for 125mM K
+ (KPSS), 5-hydroxytryptamine (5HT), acetylcholine (ACh), 
sodium nitroprusside (SNP) and noradrenaline (NA). Responses were obtained using rings 
of thoracic aortae isolated from 11HSD1-/- mice. Values for each concentration-response 
curve were produced in Dulbecco’s modified essential media without L-arginine (DMEM-L-
Arg buffer). Removal of endothelium produced an alteration in responses broadly similar to 
those observed with rings from C57Bl/6 mice. All data represent mean ± SEM, n=6, 
compared by unpaired Student’s t-test, *indicates a significant difference between intact and 
denuded arteries, p<0.05. 
11HSD1-/- (n) 
 Intact (6) Denuded (6) p-values 
KPSS 
Emax, mN/mm 1.4 ± 0.2 0.56 ± 0.1 0.19 
5HT 
Emax, mN/mm 3.28 ± 0.6 1.41 ± 0.2  0.02* 
Emax, %KPSS 238.6 ± 22.5 295.9 ± 39.4  0.01* 
pD2 6.74 ± 0.1 6.53 ± 0.1 0.18  
NA 
Emax, mN/mm 1.59 ± 0.4 0.84 ± 0.2 0.09 
Emax, %KPSS 120.3 ± 9.4 175.7 ± 35.9  0.01* 
pD2 7.64 ± 0.3 7.13 ± 0.2 0.16 
ACh 
Emax, %5HT 1.59 ± 0.4 0.84 ± 0.2 0.09 
-LogIC50 7.8 ± 0.1 not calculated  
SNP 
Emax, %5HT 73.6 ± 26.6 87.1 ± 30.7  0.02* 
-LogIC50 8.14 ± 0.2 7.69 ± 0.5 0.57 






6.4.2. Effect Of 7-Oxysterols On Vascular Function In Vitro 
The purpose of these experiments was to establish the effect of 7-oxysterols on 
functional response of mouse aortae ex vivo. The effects of 7-KC (25 µM) or 7OHC 
(20 µM) on the function of mouse thoracic aorta were monitored after short (4h) and 
prolonged (overnight) incubation. 
6.4.2.1. Short-Term Exposure Of Aortic Rings to 7-Keto-
cholesterol And 7-Hydroxycholesterol 
Exposure of aortae from C57Bl/6 mice to high physiological concentrations of 7-
oxysterols (25 µM 7KC or 20 µM 7OHC), for 4h did not attenuate the maximal 
contractile response to high concentration potassium solution (KPSS, during the 
standard start procedure). Exposure of mouse aorta to 7-KC, but not 7OHC 
produced a small reduction (p=0.049) in NA-induced maximum contraction (Emax), 
but had no effect on the sensitivity (pD2), see Table 6 – 3 and Figure 6.4 – 2.  
 
Pre-treatment of vessels with either 7-KC or 7OHC did not alter the maximal 
relaxation responses or the sensitivity to the endothelium-dependent vasodilator 
ACh. There was a suggestion that the maximal response to endothelium-independent, 
SNP-mediated vasorelaxation was increased after incubation with either 7-KC 
(p=0.05) or 7OHC (p=0.08) but this did not achieve significance. 





Table 6-3 Effect of 7-ketocholesterol (7-KC) and 7-hydroxycholesterol 
(7OHC) on relaxation and contraction of mouse aorta – short incubation.  
 
 





(A) Responses of endothelium-intact aortic rings to 7-ketocholesterol (7-KC, 25 µM) or 
vehicle (ethanol containing 50 µg/ml butylated hydroxytoluene, BHT): i) Maximal relaxation 
(Emax %5HT) and contraction (mN/mm), ii) Sensitivity (expressed as  
-LogIC50 for relaxants or pD2 for vasoconstrictors. (B) Responses of endothelium-intact aortic 
rings to 7-hydroxycholesterol (7OHC, 20 µM) and vehicle (ethanol, containing 50 µg/ml 
BHT): i) Maximal relaxation (Emax, %5HT) and contraction (mN/mm), ii) Sensitivity 
(expressed as –LogIC50 or pD2). Comparisons were made between vehicle-treated and 7-
KC-treated rings, and between vehicle-treated and 7OHC-treated rings for responses to 
each drug. 7-KC, but not 7OHC produced a small reduction (p=0.049) in Na-induced 
maximum contraction, but had no effect on the sensitivity. All values represent mean ± SEM, 
compared by unpaired Student’s t-test (vehicle vs. 7-KC, vehicle vs. 7OHC), n=6-8, 
*p<0.05, t trend. NA, noradrenaline; 5HT, 5-hydroxytryptamine; ACh, acetylcholine; SNP, 
sodium nitroprusside.  







Figure 6.4-2 Influence of 7-oxysterols on vascular reactivity of mouse aorta – 
short incubation.  




Aortae from C57Bl/6 mice were incubated (4 hours) with 7-KC (25 µM, red), 7OHC (20 µM, 
purple) or vehicle (black squares). Responses to noradrenaline (NA), acetylcholine (ACh) 
and sodium nitroprusside (SNP) were tested in endothelium-intact vessels. Relaxations were 
expressed on a scale where the response to 5HT represented 100% and return to baseline 
was expressed as 0%. Incubation with 7-KC, but not 7OHC, produced a small reduction of 
NA-mediated contraction (p=0.04). Incubations had no effect on ACh-mediated relaxation 
but 7-KC produced a trend towards increased SNP-mediated relaxation (p=0.054). All points 
represent mean ± SEM, compared by 1-way ANOVA with Tukey’s post hoc test, n=6-8. 
 
 
6.4.2.2. Long-Term Exposure Of Aortic Rings to 7-Keto-
cholesterol And 7-Hydroxycholesterol 
Exposure of aortae from C57Bl/6 mice to 7-KC (25 µM) or 7OHC (20 µM) for 24 h 
did not attenuate the maximum contractile response to potassium solution (KPSS, 
during the start of general procedure) (Table 6 - 4). Furthermore, prolonged 
incubation with 7-oxysterols did not alter aortic contraction in response to 5HT or 
KPSS (Table 6 - 4); Figure 6.4 – 3). 
 
Exposure of mouse aorta to 7-KC produced a trend (p=0.05) for reduction of 
maximum contraction (Emax) compared with vehicle control, whereas sensitivity 
(pD2) remained unchanged. There was not a significant difference observed between 
contractile responses of aortic rings to NA, after prolonged treatment with 
7OHC/vehicle (Table 6 - 4, Figure 6.4 – 3). 
 
Prolonged treatment of aortic rings with either 7-oxysterol did not alter maximal 
relaxation responses to the endothelium-dependent vasodilator ACh. Similarly, there 
was no difference between the relaxation responses to the endothelium-independent 
vasodilator SNP after prolonged incubation of aortic rings with either 7-KC or 
7OHC (Table 6 - 4, Figure 6.4 – 3). 





Table 6-4 Effect of 7-ketocholesterol and 7-hydroxycholesterol on relaxation 
and contraction of mouse aorta – long incubation. 
 






Responses of endothelium-intact aortic rings were measured following 24h incubation with 
(A) 7-ketocholesterol (7-KC, 25 µM) or (B) 7-hydroxycholesterol (7OHC, 20 µM) and 
compared with vehicle (ethanol containing 50 µg/ml butylated hydroxytoluene, BHT)-treated 
controls: i) Maximal relaxation (Emax %5HT) and contraction (mN/mm), ii) Sensitivity 
(expressed as –logIC50 for relaxants or pD2 for vasoconstrictors. All values represent mean ± 
SEM, compared by unpaired Student’s t-test (vehicle vs. 7-KC; vehicle vs. 7OHC), n=4-6, 
*p<0.05. NA, noradrenaline; 5HT, 5-hydroxytryptamine; ACh, acetylcholine; SNP, sodium 
nitroprusside. 







Figure 6.4-3 Influence of 7-oxysterols on vascular reactivity of mouse aorta – 
long incubation.  
Endothelium-intact aortae from C57Bl/6 mice (n=4) were incubated (24h) with 7-KC (25 µM, 
red), 7OHC (20 µM, purple) or vehicle (black squares) Responses to noradrenaline (NA), 
acetylcholine (ACh) and sodium nitroprusside (SNP) were tested. Relaxations were 
expressed on a scale where the response to 5HT represented 100% and return to baseline 
was expressed as 0%. Incubation of aortic rings with 7-KC, but not 7OHC, produced a 
trend for reduction of NA-mediated contractions (p=0.05) but neither oxysterol had any effect 
on ACh-mediated or SNP-mediated relaxations compared with vehicle control. All points 
represent mean ± SEM, compared by 1-way ANOVA with Tukey’s post hoc test, n=4-6. 





6.4.2.3. Are 7-Oxysterols Metabolised by 11HSD1 in the Aortic 
Wall? 
Of particular interest for this thesis was metabolism of 7-oxysterols by 11HSD1 in 
the vessel wall. Formation of products from both 7-KC and 7OHC was monitored 
by GC/MS after the short and long incubations with 7-oxysterols (Figure 6.4 – 4 A). 
The individual substrates were successfully recovered from the medium after both 
incubations as shown by single peaks of 7-KC or 7OHC on the GC/MS 
chromatograms (Figure 6.4 – 4 B and C). After short (4h) incubation, 7-KC was not 
detected in medium from vessels exposed to 7OHC. Similarly, 7OHC was not 
detected in medium from vessels exposed to 7-KC. After prolonged (24h) exposure, 
7OHC was detected in two (of eight) incubations with 7-KC whilst 7-KC was 
detected in two (of six) incubations with 7OHC. 










Figure 6.4-4 GC/MS chromatogram of derivatised 7-oxysterols detected in the 
medium upon incubation of vessels.  
A) Separation by GC/MS of derivatised standards: 7-hydroxycholesterol (7OHC); 7-
hydroxycholesterol (7OHC); cholesterol and 7-ketocholesterol (7-KC). Metabolism of 7-
oxysterols by B) reduction (7-KC7OHC) and C) dehydrogenation (7OHC7-KC) of 
substrates (20 - 25 µM) by 11HSD1 were assessed in the aortic rings (1 - 2 mm) from 
C57Bl/6 mice following a long (24 h) incubation. Only substrates (7-KC and 7OHC, 
respectively) were detected in each reaction, suggesting that conversion to respective 
products (7OHC and 7-KC) did not occur. GC/MS, Gas chromatography/Mass 
spectrometry. 





The work presented in this chapter tested the hypothesis that metabolism of 7-
oxysterols by 11HSD1 in the vascular wall may impair functional responses of 
murine aortae ex vivo. The initial aim was to determine whether 7-oxysterols alter 
vascular function in aortic rings from C57Bl/6 mice. In order to achieve this it was 
necessary to develop a method to allow sustained incubation, and functional 
assessment, in arterial sections bathed in culture medium, rather than PSS. It was 
demonstrated that performing functional investigations in L-arginine deplete DMEM 
did not dramatically alter responses to vasoconstrictor or vasodilators. Subsequent 
experiments also confirmed that the impact of endothelial cell removal could also be 
demonstrated in aortic rings from 11HSD1 knockout mice, using DMEM-L-Arg 
rather than PSS. Using this approach, it was demonstrated that exposure to 7-KC or 
7-OHC for up to 24 hours did not alter functional responses of the mouse aorta. 
Furthermore, analysis of culture medium found very little evidence of metabolism of 
these 7-oxysterols by aortic 11HSD1 ex vivo. 
 
6.5.1. Use of culture medium for functional investigations and 
prolonged incubation with 7-oxysterols 
In order to assess the impact of exposure to 7-oxysterols on vascular function, it was 
desirable to perform extended incubations of aortic rings with these compounds; 
particularly given the potential for oxysterols to interaction with nuclear hormone 
receptors. This was not possible if PSS was used as the incubating medium as this 
only maintains arterial function for several hours (Christy, 2003). Previous work has 
demonstrated that arterial function can be maintained for up to ~24hours if vessels 
are incubated in DMEM (Christy et al., 2003)). It was valuable, therefore, to 
determine whether the actual functional analyses could also be performed in culture 
medium (rather than PSS). This approach has been used successfully by others 
(Brem et al., 1997; Christy et al., 2003). Initial difficulties encountered with 
excessive foaming from bovine serum albumin (BSA) in the myograph were 




countered by using charcoal-stripped FBS (which also ensured that no steroids were 
present in the culture medium). The absence of L-arginine was important for these 
experiments, being that L-arginine is a precursor for the synthesis of NO by nitric 
oxide (NO) synthase, therefore use of DMEM without L-arginine assured no 
exogenous supply of substrate for the production of NO by the aortic rings in vitro. 
Indeed, previous work by Christy et al., (2003) has demonstrated that DMEM 
containing high concentrations of L-arginine ameliorated the functional 
abnormalities associated with endothelial cell dysfunction in 11HSD2 deficient 
mice. Nevertheless, the use of DMEM deprived of L-arginine has allowed to 
maintain the viability and vascular function of aortic rings. Overall, performing 
myographic investigations in arteries bathed in DMEM-L-Arg produced responses 
similar to those obtained in PSS. Responses to vasoconstrictors were initially slower 
to develop in DMEM-L-Arg, but the maximal responses achieved were very similar 
to those in PSS and were therefore predicted to be the same in normal DMEM. The 
demonstration that vasoconstrictor and (endothelium-dependent and -independent) 
vasorelaxant responses were similar whether obtained in DMEM-L-Arg or PSS, 
confirmed that myographic experiments could be performed in culture medium. This 
was important as it allowed continued exposure to 7-oxysterols during functional 
investigations. 
 
In addition to assessing the affect of 7-oxysterols on function of aorta isolated from 
control (C57Bl/6), it was originally intended that similar experiments would be 
performed in vessels from 11HSD1 knockout mice. This would clarify the influence 
of aortic 11HSD1 activity on modulating the functional effects of the 7-oxysterols. 
It was necessary, therefore, to confirm that functional responses could be obtained 
when aortae isolated from mice of both genotypes were bathed in DMEM-L-Arg. 
The data obtained demonstrated that removal of the endothelium abolished ACh-
mediated relaxation and enhanced the maximum response to SNP. This is consistent 
with the effect of removing a fully functional endothelium (Hadoke et al., 2001). 
Furthermore, endothelial denudation provoked enhanced contraction to 5HT and, 
particularly, to NA; consistent with the observation that denudation removes the 
physiological antagonism of contraction produced by basal and stimulated release of 




NO from the endothelium (Bullock et al., 1986; Martin et al., 1986). If anything, the 
effects of endothelial cell removal were more apparent in aortae from 11HSD1 
knockout mice than in C57Bl/6; perhaps due to the greater number of vessels used 
and improved myographic technique. The data obtained in aortae from 11HSD1 
knockout mice suggest normal contractile and relaxant function in these animals. 
This is consistent with data obtained from similar knockout mice on an MF1 
background (Hadoke et al., 2001). It is an important observation as pharmacological 
inhibition of 11HSD1 dehydrogenase activity has been associated with an enhanced 
response to vasoconstrictors, whereas inhibition of the reductase reaction produces 
attenuated constriction (Morris et al., 2003). 
 
6.5.2. Functional Responses Of Mouse Thoracic Aorta To  
7-Oxysterols 
Hyperlipidaemia and atherosclerosis are associated with abnormalities of vascular 
function (Crauwels et al., 2003; Jiang et al., 2001). Components of an atherosclerotic 
plaque, such as oxidized low-density lipoproteins (oxLDL), have cytotoxic 
properties and may impair vascular function. A large part of oxidized LDL (40%) 
contains 7-oxysterols, ~30% of which is 7-KC. There is a good body of work 
showing that accumulation of oxysterols into endothelial and aortic smooth muscle 
cells leads to apoptotic cell death (Rho et al., 2005). Further deposition of oxidized 
cholesterol and cholesterol oxidation products (such as 7-oxysterols) may contribute 
to vascular toxicity (Vine et al., 1998). Such a high-lipid environment may not only 
impair vascular function but influence the stability of atherosclerotic plaque in 
human and mice (Gaut and Heinecke, 2001; Libby, 2002a). Furthermore increased 
levels of oxidized-LDL in atherosclerosis and hyperlipidamia are known cause of 
foam-cell formation. The build-up of these hormones in the vessel may also 
influence contractility and thus alter vascular tone and function as explored here.  
 
The ex vivo culture of aortic rings, as used for the myography studies, has not 
previously been applied to assess inter-conversion of 7-oxysterols. This approach 
was able to demonstrate that it is possible to preserve stability of 7-oxysterols upon 




incubation, as both 7-KC and 7OHC were successfully recovered from DMEM. It 
had been postulated that 7-oxysterols may be taken up by the vessels during 
incubation but the recovery of 7-oxysterols indicates that this did not happen. Under 
conditions used, the measurement of 11HSD1 activity was not always achieved 
during the incubation of aortic rings, possibly due to the small amount of tissue used. 
It was subsequently established that the use of whole aortae was needed to obtain 
measurable conversion of 7-oxysterols by 11HSD1 as reported in Chapter 3. 
 
Despite previous reports detailing adverse effects of exposure of vascular rings to 7-
oxysterols ex vivo (Deckert et al., 1998), preparing solutions in the concentration 
range described in the literature proved surprisingly difficult (as the oxysterols came 
out of solution at high concentrations). The approach ultimately adopted was 
involved preparing 7-oxysterol solutions in DMEM containing FCS (Built, H. et al, 
personal communication). In addition, an antioxidant (BHT) was included in the 
solution to prevent oxidative degradation of the lipid during prolonged incubation (as 
described by Deckert et al., 1998). BHT is not known to affect NO production and 
endothelium-dependent relaxation ex vivo. Indeed, BHT did not alter histamine-
induced NO production in cultured HUVECs (Deckert et al., 2002). 
 
Unexpectedly, given published experience with these compounds, incubation of 
murine aortae with 7-oxysterols did not cause major functional impairment. The 
small reduction in NA-mediated contractions after short-term incubation with 7-KC 
is unlikely to be due to changes in endothelial cell function as responses to ACh and 
SNP were unaltered. Furthermore, the lack of effect on 5HT and KPSS-mediated 
contraction suggest that this alteration was specific to the α-adrenoceptor-mediated 
responses. The mechanism underlying this change, and the reason why it was not 
evident after 24h incubation, are unclear. Deckert et al. previously aimed to dissect 
out the mechanism of 7-KC action on vascular function, demonstrating that 7-KC 
inhibits endothelium-dependent relaxations to ACh (Deckert et al., 1998; Deckert et 
al., 2002; Deckert et al., 1997). The current studies performed using murine aortae 
have produced conflicting findings to those obtained by Deckert and colleagues in 
rabbit aorta. This may be due to species differences (although this seems unlikely) 




but several concerns became evident during the work in mice. As stated (above), it 
was difficult to achieve the high concentrations of oxysterols (50 µM) achieved in 
these previous studies, without sample precipitation. Hence the experiments reported 
here used lower (although physiologically high) concentrations of 7-oxysterols  
(20 – 25 µM). It is also possible that the use of DMEM-L-Arg, rather than the PSS 
buffer used by Deckert et al., (1998) accounts for the different results. It is possible 
that the use of DMEM without L-arginine has depleted the substrate for the 
endogenous NO production after an overnight incubation of the vessels. If the effects 
of 7-oxysterols have been on NO synthesis, then those might have been masked by 
the given experimental conditions. Alternatively, the use of nitric oxide synthase 
inhibitor (L-NAME) may be considered to investigate the NO status of the vessels 
after an overnight incubation in DMEM. Indeed, these experiments might have been 
conducted if the changes in function were seen in response to either of 7-oxysterols 
when incubating the vessels in DMEM without L-arginine or PSS. Therefore the 
endothelial dysfunction seen in the previous work by Deckert et al., may have been 
(at least partly) the result of extended incubation in PSS, although why this was 
differentially affected by the presence of 7-oxysterols is unclear. 
 
One other study, published during the course of this thesis, demonstrated a lack of 
inhibition of endothelium-dependent relaxation to acetylcholine either after 
incubation of murine aortic rings with physiologically high levels of 7-KC (205 µM), 
or after subcutaneous treatment of mice with 7-KC (10 mg/kg/day, 1week) (Kiss et 
al., 2006). In vitro, 7-KC induced oxidative stress in endothelial cells and further 
activated nuclear poly(ADP-ribose) polymerase (PARP) but these effects were 
attenuated upon inhibition of NOS activity. Thus 7-KC may impair NO-production 
in vascular endothelium and impair dimerisation of eNOS (Terasaka et al., 2008). 
Adding to the plethora of published work, it is established that 7-KC, like oxLDL 
induces oxidative stress via formation of O2
– in the vascular endothelium, which 
inactivates NO and forms peroxynitrate (ONOO–), thus consequently leading to 
oxidation of eNOS (Deckert, 1999; Fransen et al., 2008; Leonarduzzi et al., 2004; 
Lizard et al., 2006). 
 




Given the cytotoxic properties of oxysterols (Hughes et al., 1994), their effects may 
be exerted through various other signalling events, influencing molecular 
interactions, like hedgehog signalling (Hh) pathway, (Christensen and Ott, 2007; 
King et al., 2008). Moreover, the ability of 7-KC/7OHC to induce apoptosis (by 
activating Fas ligand (FasL) to interact with the its receptor (FasR)) is now being 
elucidated (Lordan et al., 2008). It remains possible that formation of these species, 
their accumulation within the vessel wall and pro-apoptotic actions on vascular cells 
over a prolonged period of time may indeed impair endothelial function and eNOS 
activity. Alternatively, accumulation of 7-KC or 7OHC (at high nM concentrations) 
may influence GC metabolism (see chapter 4). Therefore the main consequence of 
accumulation of 7-oxysterols may be perhaps to influence 11HSD1-mediated 
glucocorticoid metabolism and the effects of glucocorticoids on the vasculature. 














Chapter 7. General Discussion And Future Work 




7.1. General Overview 
This thesis explored the role of 11HSD1 in regulating the concentrations and 
actions of 7-oxysterols. The latter substrates are recognised as alternative substrates 
to glucocorticoids for metabolism by 11HSD1. This work was prompted by the 
increasing interest in 11HSD1 as a therapeutic target in atherosclerosis, a disease 
associated with an increased circulating and tissue burden of these oxidised lipids 
(Prunet et al., 2006). To date there is a lack of understanding of how inhibition of 
11HSD1 can reduce plaque size and lipid accumulation (Hermanowski-Vosatka et 
al., 2005; Iqbal et al., 2009; Nuotio-Antar et al., 2007), although mechanisms to 
reduce cardiovascular risk factors (e.g. insulin resistance, weight gain, angiogenesis 
(Small et al., 2005; Wamil and Seckl, 2007)) may easily be explained by suppression 
of the actions of glucocorticoids. 
 
Oxysterols (of which 7-oxysterols are a significant proportion Dzeletovic et al., 
1995) increase in abundance in hyperlipidaemia (Arca et al., 2007; Vaya et al., 2001) 
and their concentrations have been suggested as biomarkers of oxidative stress 
(Ferderbar et al., 2007; Larsson et al., 2007) and indices of susceptibility to 
atherosclerosis and cardiovascular disease (Alkazemi et al., 2008). They are formed 
from cholesterol by various routes (Antonchick, 2007) but whether measurement of 
concentrations of oxysterols, as opposed to just those of cholesterol, to assess 
cardiovascular risk will provide added value is unknown. The main barrier to 
understanding their diagnostic potential is the lack of a defined molecular target. 
More recently 27-hydroxycholesterol has been demonstrated as a ligand for the 
estrogen receptpr- (ER) (DuSell et al., 2008; Umetani et al., 2007), but as yet a 
receptor has not been defined for 7-oxysterols (the possibility of activation of LXR 
has been investigated (Janowski et al., 1999; Wang et al., 2008) but largely 
dismissed (Olkkonen, 2008; Wamil et al., 2008)). Nonetheless, it is clear that these 
compounds are readily subject to oxidation and may form free radicals in tissues and, 
therefore, if the burden of 7-oxysterols is increased within tissues (such as 
macrophages, plaques and vessels) oxidative damage may ensue. The question, then, 
may be posed as to whether the distinct 7-oxysterols (i.e. 7-KC, 7OHC, 7αOHC) 




differ in their toxic actions. If this were true then the proportions of these compounds 
may influence disease progression and, hence, an understanding of factors 
controlling this balance (including 11HSD1) would be of value. 
 
Previous literature proposes a number of mechanisms of actions of 7-oxysterols in 
tissues, including: free radical production (Chisolm and Steinberg, 2000; 
Lukyanenko and Lukyanenko, 2009); altered vascular relaxation and contractility 
(Deckert et al., 2002; Kiss et al., 2006); induction of apoptosis (Li et al., 2001; 
Vejux et al., 2008). However, the actions of the distinct 7-oxysterols have not been 
explored systematically and the potential role of 11HSD1 has been largely ignored. 
In this thesis, 7-oxysterols were not able to alter vascular contractility significantly, 
although a weak effect to reduce noradrenaline-mediated contraction was observed. 
Preliminary data (not presented) also implied that these agents do not promote 
apoptosis or induce free radical generation; therefore arguing against a direct 
molecular target, at least in vessels. If 7-KC and 7OHC had produced different 
effects in the systems tested, one might have inferred a role for 11HSD1 in gating 
these actions, and this may still be the case in other tissues where oxysterols 
accumulate and 11HSD1 is expressed (e.g. macrophages, foam cells (Gilmour and 
et al., 2006)); or via mechanisms as yet undefined. Whether, subsequent actions of 7-
oxysterols on glucocorticoid production manipulate maintenance of normal 
endothelial function and atherosclerotic plaque stabilisation (Libby, 2002b), is a 
separate research question, which may follow beyond this thesis. Also, the question 
that remains is “does 11HSD1 in the macrophages contribute to a local clearance of 
7-KC?”. In spite of a lack of clear differences the actions of 7-KC versus 7OHC, a 
beneficial effect of disruption of 11HSD1 may lie in a suppression of total 7-
oxysterol concentrations in tissues (as in the reduction of 7-oxysterols in hepatic 
microsomes from 11HSD1-/- mice), thereby reducing the overall propensity to 
oxidative stress. Indeed transgenic disruption of 11HSD1 substantially reduced the 
total amount of 7-oxysterols in tissues (as well as affecting the proportions). 
 
Metabolism of 7-oxysterols by murine 11HSD1 could be easily demonstrated in 
vitro, in cultured cells and in ex vivo explants. The in vitro data presented here 




confirmed reports in other species that 7-oxysterols were metabolised by 11HSD1. 
However, some interesting differences were identified. Firstly, 7-oxysterols were 
metabolised at a slower and less efficient rate than glucocorticoids, rendering them 
poorer substrates for the enzyme. Secondly, the equilibrium of the inter-conversion 
between 7OHC and 7-KC differed from that of glucocorticoids, in that the balance 
of the reaction favoured dehydrogenation of oxysterols, even in the presence of 
excess H6PDH. This contrasted with the characteristics of the reaction catalysed 
using glucocorticoids as substrates, in which reduction dominates (Bujalska et al., 
2005; Hewitt et al., 2005; Lavery et al., 2006). The cause of this distinction was not 
clear as in silico modelling suggested favourable binding of both 7OHC and 7-KC 
for the active site of 11HSD1. The difference may relate to transport and 
availability of 7-oxysterols within different subcellular compartments. 
 
Experiments performed using in vitro cell culture suggested that cells preferentially 
excluded 7-KC, although both 7OHC and 7-KC could penetrate the cell membrane. 
Little is known about active transport of 7-oxyserols within cells, although it is well 
recognised that membrane transporters exist for other species of oxysterol (Babiker 
and Diczfalusy, 1998; Baldan et al., 2009). Thus it remains possible that 7-KC was 
unable to efficiently access the lumen of ER, where the active site of 11HSD1 is 
located (Frick et al., 2004; Odermatt et al., 1999), in the models used. Assessment of 
metabolism within primary hepatocytes, which retain more comprehensive 
characteristics of the intact liver, may provide further insight into 11HSD1 substrate 
preference. In mice with transgenic disruption of 11HSD1, at least in hepatic 
microsomes, the balance of 7-oxysterols was changed in favour of 7OHC, 
corroborating the predominant dehydrogenation activity. This difference was not, 
however, evident in plasma where an increase in 7-KC was observed upon disruption 
of 11HSD1, potentially contributing towards storage of 7-KC in the vasculature for 
metabolism via other more dominant routes (Jessup et al., 2005). However, the 
difference between levels of 7-oxysterols in tissues vs. plasma may reflect the fact 
that circulating pools of esters of 7-oxysterols (Freeman et al., 2005) were not 
quantified. 
 




Whilst the change in balance in 7-oxysterols following 11HSD1 inhibition may not 
influence physiological processes directly, an indirect role for 7-oxysterols was 
revealed. Competitive inhibition of metabolism of conventional glucocorticoid 
substrates by 7-oxysterols (Figure 7.1 – 1) was demonstrated, mainly for 7OHC to 
prevent dehydrogenation of active glucocorticoid. Importantly this effect was limited 
to 7-oxysterols and to some extent to cholesterol, thus presenting them with a 
function distinct from other side-chain oxidised sterols. Therefore, the concentrations 
of 7-oxysterols may regulate the balance between active and inactive 
glucocorticoids, beyond the actions of H6PDH (Figure 7.1 – 2). 
 
The concentrations of oxysterols found within the body are of central importance 
when considering the likelihood of their inhibitory effect on glucocorticoid 
metabolism in vivo. The Ki values of inhibition of GC metabolism were in a range of 
1 - 8 µM, and the circulating concentrations of 7-oxysterols (although they increase 
with age) are only in the nM range in normolipidaemia, but in dyslipidaemia may 
rise to ~100µM. Their concentrations under normal conditions demonstrate a 
circadian pattern (Noshiro et al., 2007; Reilly et al., 2007) but even then the 
maximum achieved in healthy individuals is unlikely to influence glucocorticoid 
actions. This suggests, therefore, that concentrations of 7-oxysterols may only 
influence the balance of active and inactive glucocorticoid (favouring production of 
the active species) during disease pathogenesis. Again, this effect will be most 
marked in tissues where oxysterols accumulate and 11HSD1 is expressed. Indeed 
sites such as the liver, macrophages, foam cells and atherosclerotic plaques meet 
these criteria. These tissues may, therefore, be exposed to increased active 
glucocorticoids under atherosclerotic conditions, as well as suffering from increased 
oxidative stress induced by excess oxysterols. Excess glucocorticoid production, like 
that displayed in patients with Cushing’s syndrome is also associated with 
dyslipidaemia and metabolic syndrome. The decreasing glucocorticoid action in 
specific tissues (such as adipose, liver and the vasculature) might protect against the  









Figure 7.1-1 The cross-talk between metabolism of glucocorticoids and 7-
oxysterols by 11HSD1. 
11-Hydroxysteroid dehydrogenase type 1 (11HSD1) catalyses the metabolism both of 
both 7-oxysterols and glucocorticoids. Conversion of 7-ketocholesterol (7-KC) to 7-
hydroxycholesterol (7OHC). may occur alongside the metabolism of 11-
dehydrocorticosterone (A) to corticosterone (B) in rodents. The two pathways compete for 
the metabolism by their mutual enzyme target. 










Figure 7.1-2 7-Oxysterols regulate the balance between active and inactive 
glucocorticoids, beyond the actions of H6PDH. 
11-Hydroxysteroid dehydrogenase type 1 (11HSD1) cataylses the metabolism of 
glucocorticoids (inactive 11-dehydrocorticosterone to active corticosterone) and  
7-oxysterols (interconversion of 7-ketocholesterol (7-KC) and 7-hydroxycholesterol 
(7OHC)) in the cell. Hexose-6-phosphate dehydrogenase (H6PDH) converts glucose-
phosphate (G6P) to 6-phospho gluconolactone (G6P=O) thus generating NADPH for the 
11HSD1 reactions within the endoplasmic reticulum (ER).  
7-Oxysterols can compete with glucocorticoids for metabolism by 11HSD1 and thereby 
regulate the balance between the active and inactive glucocorticoid. 




detrimental metabolic consequences of obesity, diabetes and atherosclerosis (Hale 
and Wang, 2008).  
 
It may, therefore, be postulated that inhibition of 11HSD1 therapeutically will have 
the combined action of impairing activation of glucocorticoids directly but also in 
lowering the harmful actions, and inducing a change in the balance, of 7-oxysterols. 
Whether the ensuing increase in cellular and circulating 7OHC will be sufficient to 
alter 11HSD1 activity and thus influence the concentrations of active glucocorticoid 
will depend on the relative concentrations of these two classes of substrate.  
 
The recent use of 11HSD1 inhibitors for treatment of atherosclerosis 
(Hermanowski-Vosatka et al., 2005) has extended the possible clinical application of 
these compounds. However, this potential role suffers form the fact that there have 
been no clinical trials with 11HSD1 inhibitors in patients with cardiovascular 
disease. Furthermore, the mechanism through which these compounds reduce lesion 
size has not been identified. It is conceivable that the beneficial effects of 11HSD1 
inhibition occur through prevention of 7-oxysterol inter-conversion rather than (or as 
well as) glucocorticoid metabolism. To determine which of these is most important 
development of atherosclerotic plaques could be studied in 11HSD1 knockout 
mice (e.g. ApoE-/-,11HSD1-/-, (Hadoke et al., 2008)) following adrenalectomy (to 
remove endogenous glucocorticoids). In addition, the influence of selective 
11HSD1 inhibitors on 7-oxysterol metabolism could be ascertained in clinical trials 
if measurements of plasma oxysterols (in particular 7-KC and 7OHC and 
calculation of the ratio of these two species) were performed (Courtney et al., 2007)  
 
In Chapter 5 of this thesis, a study was performed using an 11HSD1 inhibitor 
(Compound 544) but in spite of reducing plaque size (Hermanowski-Vosatka et al., 
2005; Iqbal et al., 2009), tissue concentrations of 7-oxysterols were not altered. Of 
interest, this compound also failed to inhibit 7-oxysterol metabolism in vitro, 
whereas it efficiently prevented reduction of glucocorticoids. This suggests that the 
presence of the drug in the active site of the enzyme is able to induce allosteric 
modifications in the binding of glucocorticoid but not of 7-oxysterols. The nature of 




interactions between Compound 544 and the active site have not been modelled; 
such an approach might elucidate why conversion of these different substrates is not 
affected in the same way by the inhibitor. It is, as yet, hard to predict whether it will 
beneficial to design the ability to inhibit 7-oxysterol metabolism into potential new 
11HSD1 inhibitors. Although, arguably, a total reduction in oxidised lipids due to 
lowering of the levels of cholesterol (as reported in chapter 5), would be 
advantageous. In any case it will be important to measure circulating glucocorticoids, 
7-oxysterols and cholesterol when interpreting the effects and efficacy of these 
drugs. These measurements would have complemented the inhibitor study presented 
by Hermanowski-Vosatka et al., (2005) and would have given a coherent 
mechanistic understanding into atheroprotective effect of inhibition of 11HSD1. It 
is possible that upon inhibition of 11HSD1 in the vascular cells, other cell types, 
such as macrophages, may take over the clearance of 7-KC. In particular, the 27-
hydroxylase (CYP27A1) route (Brown et al., 2000a) may compensate for the 
inhibition of 11HSD1 by clearing 7-KC via formation of 27-hydroxyl-7-KC-
cholesterol (Lee et al., 2006). 
 
 
In summary the work from this thesis has established that:  1) murine 11HSD1-
mediates the metabolism of 7-oxysterols (7-KC and 7OHC).  2) These alternative 
substrates (7-oxysterols) compete with the glucocorticoids for metabolism by 
11HSD1 and, therefore, may control the production of active glucocorticoid 
(corticosterone) by the cell.  3) Cellular cholesterol levels in vitro determine 7-
oxysterol levels and, thus, may have further inhibitor actions on glucocorticoid 
metabolism by 11HSD1.  4) Genetic deletion (or inhibition) of 11HSD1 in mice 
has confirmed that 11HSD1 and cholesterol, regulate the plasma and tissue levels of 
7-oxysterols.  5) Individual 7-oxysterols do not cause impairment in endothelium-
dependent vascular reactivity in vitro. 
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